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ABSTRACT 
 
 
White adipose plays a major role in the regulation of whole body metabolism 
through the storage and hydrolysis of triglycerides and by secretion of adipokines. The 
function of endocrine cells is highly dependent on the unfolded protein response (UPR), a 
homeostatic signaling mechanism that balances the protein folding capacity of the 
endoplasmic reticulum (ER) with the cell's secretory protein load. Here we demonstrate 
that the adipocyte UPR pathway is necessary for its secretory functions, and can thus play 
a crucial role in the control of whole body energy homeostasis. ER protein folding 
capacity is dependent both on the number of available chaperones as well as on their 
activity, which requires a sufficient ATP supply. In 3T3-L1 adipocytes, mitochondrial 
biogenesis occurred in parallel with induction of the UPR; therefore, we tested whether it 
was necessary for efficient ER function. Inhibition of mitochondrial ATP synthesis 
through depletion of Tfam, a mitochondrial transcription factor, or treatment with 
inhibitors of oxidative phosphorylation, demonstrate that ER function is sensitive to acute 
changes in adenine nucleotide levels. In addition, adenylate kinase 2 (AK2), which 
regulates mitochondrial adenine nucleotide interconversion, is markedly induced during 
adipocyte and B cell differentiation. AK2 depletion impairs induction of the UPR and 
secretion in both cell types. Interestingly, cytosolic adenylate kinase 1 (AK1) does not 
have the same effect upon UPR induction. We show that adenine nucleotides promote 
proper ER function and alterations in specific aspects of ATP synthesis can impair UPR 
signaling. Understanding the complex energetic regulation of the UPR may provide 
insight into the relationship between UPR and disease. 
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CHAPTER I 
INTRODUCTION 
  
Metabolism is a tightly controlled system involving cross-regulation and signaling 
between multiple tissues. Each tissue has a distinct role in the system and can alter the 
activities of the other tissues through chemical and protein factors secreted into the blood 
stream. Energetic homeostasis is maintained principally through the functions of insulin 
sensitive tissues, such as the brain, muscle, liver, pancreas, and white adipose tissue (1). 
If the function of any of these tissues is compromised, it leads to a breakdown in 
energetic homeostasis. Persistent dysregulation results in a pathology termed the 
metabolic syndrome. The metabolic syndrome is a cluster of conditions, including 
obesity, insulin resistance, dyslipidema, hypertension, and Diabetes Mellitus (2). 
Additionally, studies show that this syndrome is associated with twice the risk of 
developing cardiovascular disease (1). The prevalence of the metabolic syndrome has 
reached epidemic proportions throughout the world. Originally only a problem in 
industrialized nations, there are now increasing incidences of these metabolic diseases 
even in developing nations. Studies have identified overnutrition and inactivity as two of 
the major contributing factors to the development of the metabolic syndrome. However, 
molecular causes also need to be investigated as potential targets for prevention or 
treatment. 
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Obesity and Diabetes Mellitus 
  
 Two of the main pathologies of the metabolic syndrome, obesity and Diabetes 
Mellitus (hereafter referred to as diabetes), are often discussed as one condition. Though 
these are two distinct pathologies, they are believed to have common molecular origins. 
The body mass index (BMI) is a calculation used to estimate a healthy body weight 
respective to height. BMI equals the mass of a person in kilograms divided by the square 
of their height in meters. While a healthy BMI is between 18.5 and 25, human obesity is 
defined medically as having a BMI equal to or greater than 30. Due to the increased 
adiposity, obese individuals often suffer from insulin resistance, where the body does not 
respond properly to insulin signaling, and diabetes. Diabetes is a condition where there is 
insufficient insulin necessary to maintain glucose homeostasis resulting in high blood 
glucose levels. The dramatic increase in the number of cases of diabetes worldwide in 
recent years has promoted interest in determining the cause(s) of this disease to find 
preventative measures and new treatments. Diabetes is a condition with three distinct 
pathologies. Gestational diabetes results from an increase in blood glucose levels that 
occurs in some mothers during pregnancy (3). Glucose homeostasis often returns to 
normal after birth. Type 1 diabetes (T1DM), or juvenile diabetes, is an autoimmune 
disease that attacks the insulin-producing β cells of the pancreas (4). Due to the lack of β 
cells, T1DM patients are dependant on exogenous sources of insulin to maintain glucose 
homeostasis. There is no cure for T1DM as of now, but there is promising research being 
conducted on β cell transplantation. Type 2 diabetes (T2DM) was previously referred to 
as adult-onset, but this is no longer applicable due to increased incidences in children and 
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adolescents (5). T2DM occurs when the body does not produce sufficient amounts of 
insulin for proper glucose metabolism, typically due to excessive body weight. The 
patients may require glucose lowering drugs, exogenous insulin, or both, and can make a 
full recovery with effective treatment, including diet and exercise. 
 With increased weight gain, the body is often unable to produce enough insulin to 
compensate, resulting in T2DM (5). Increased adiposity alone, however, is not the sole 
cause for the development of diabetes. In fact, it appears that other factors must also 
occur to promote this pathology, including increased free fatty acids in the blood stream 
and impaired cellular metabolism. Recent data supports the hypothesis that failure of the 
adipose tissue to sufficiently expand is more a cause for the disease rather than the 
general expansion of the tissue itself (2). To further that concept, more work is being 
done on understanding the function of the adipose organ. 
White adipose tissue, traditionally thought to be an inert lipid storage depot, 
regulates whole body metabolism by monitoring nutrient levels (6,7). It can then act on 
the central nervous system and peripheral tissues to control caloric intake and utilization 
through the secretion of adipokines. These hormones and cytokines, including leptin, 
adiponectin, resistin, retinol binding protein 4, and tumor necrosis factor alpha (TNFα), 
can also affect blood pressure, lipid and glucose metabolism, inflammation, and 
atherosclerosis (8-10). The importance of these secreted factors have led to the 
reclassification of the adipose tissue as an endocrine organ. Given the importance of 
adipokines to whole body homeostasis, understanding the molecular mechanisms that 
regulate adipocyte secretion is highly relevant.  
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 Eukaryotic cells have two sources of protein synthesis, the cytosol and the 
endoplasmic reticulum (11). The majority of cellular proteins are translated and folded 
within the cytosol. However, a subset of proteins destined for either secretion, such as the 
adipokines, or insertion into the plasma membrane are synthesized and processed within 
the endoplasmic reticulum. The endoplasmic reticulum (ER) is composed of a 
phospholipid bilayer surrounding a lumen to form a network of tubules and vesicles 
adjacent to the cell’s nucleus. There are three types of endoplasmic reticulum, defined by 
their major function: The rough ER (RER), so named by the presence of ribosomes on the 
membrane surface, is the location of ER protein synthesis. Smooth ER (SER), lacks 
ribosomes and therefore has a “smooth” membrane, functions in the synthesis of lipids 
and steroids, carbohydrate metabolism, and regulation of calcium. The sarcoplasmic 
reticulum, a specialized form of SER found in smooth and striated muscle cells, regulates 
the calcium stores necessary for contraction. While the SER and sarcoplasmic reticulum 
play important and necessary roles in cellular homeostasis, the ER as an organelle is 
commonly associated with protein folding. 
Proteins destined for transport through the secretory pathway require the aid of 
luminal ER chaperones to achieve their final functional conformation. Importantly, unlike 
proteins folded in the cytosol, those folded in the ER also have the potential to undergo 
post-translational modification, such as glycosylation or proteolytic cleavage (12). 
Adiponectin, a major adipocyte factor, is synthesized as a 247 amino acid polypeptide 
that undergoes extensive folding to form a trimer stabilized through disulfide bond 
formation (8,9). It is further processed into higher molecular weight complexes prior to 
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secretion by adipocytes. Resistin, another adipokine, also undergoes multimeric assembly 
dependant on disulfide bonds for stabilization (13). The volume of factors synthesized 
and secreted, along with the complex folding required for some of these proteins, suggest 
that there is a considerable load on the endoplasmic reticulum of the adipocyte. 
Perturbations in folding caused by either physiological or pharmacological insult can 
cause the ER to become overloaded with unfolded proteins. Eukaryotic cells have 
evolved a system of responses to deal with this stress, termed the “unfolded protein 
response”. 
 
The Unfolded Protein Response 
 
 The unfolded protein response (UPR) is a mechanism by which cells can recover 
from an overburdened ER (14). Most components of the mammalian UPR can be found 
conserved in eukaryotic systems, from yeast to higher order mammals. Originally 
discovered as a stress response to low glucose levels in cultured cells (15,16), further 
studies elucidated its important role in ER homeostasis. The UPR involves a three-
pronged approach to allow the cell to recover from ER stress: 1) translational repression 
to reduce proteins entering the ER, 2) increased chaperone expression to improve ER 
folding efficiency and capacity, 3) and degradation of misfolded proteins in the ER to 
lower the ER load. These processes allow cells to respond to a variety of stresses from 
the physiological burden caused by cellular differentiation or a high volume of secretion, 
and pharmacological stress, such as from chemically induced impairments or heat shock. 
Importantly, an impaired UPR, when the cell is unable to respond properly, has been 
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shown to cause or exacerbate a variety of human ailments, including neurodegeneration, 
viral infection, and Diabetes Mellitus (17-19). 
 
Key Players in the UPR 
 There are three major sensors on the ER membrane that monitor when the protein 
folding capacity is exceeded, IRE1 (inositol requiring enzyme 1), ATF6 (activating 
transcription factor 6), and PERK (eukaryotic translation initiation factor 2 alpha kinase 
3). Each responds by initiating independent branches of the UPR to restore ER 
homeostasis (Figure 1.1). They each exist in an inactive state as monomers bound to 
immuonglobulin heavy chain-binding protein (BiP/GRP78) (20,21). BiP, an ER resident 
chaperone, dissociates upon increased levels of unfolded proteins to aid in protein 
folding. This allows activation of the sensors through homodimerization of IRE1 and 
PERK and proteolytic cleavage of ATF6. The universal function of these distinct 
signaling cascades is to reduce general translation while increasing the expression of 
select ER chaperones. ER associated protein degredation (ERAD) is also increased upon 
UPR activation. If these methods fail, and the stress upon the ER remains, all three 
branches will initiate an apoptotic response. 
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Figure 1.1: Three Main UPR Branches. 
The UPR has three major ER resident sensors, IRE1, ATF6, and PERK, which are 
inactive while bound to BiP. During increased levels of unfolded proteins, BiP releases 
the sensors in order to aid in protein folding. This allows activation of the sensors and 
induction of downstream responses to improve the capacity and efficiency of ER folding 
through upregulation of chaperones, decreased general translation, and degradation of 
unfolded proteins through ER associated protein degradation (ERAD). If the stress on the 
ER is not relieved, all three branches of the UPR will initiate apoptosis. 
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Key Players in the UPR: IRE1/XBP1 Branch 
 IRE1 is a transmembrane serine/threonine kinase localized to the ER (Figure 1.2). 
A highly conserved branch of the UPR, yeast IRE1p has two mammalian homologs, 
IRE1α and IRE1β (22,23). Both isofoms can activate the UPR, however more studies 
have been completed on the function of IRE1α. The luminal domain of IRE1 acts as a 
sensor for the ER folding capacity while the cytoplasmic region is required for its kinase 
and endoribonuclease functions (20,24-26). Upon dimerization after BiP release, IRE1 
auto-transphosphorylates, inducing a conformational change and subsequent activation 
(27). The resulting downstream responses include splicing of X-box binding protein 1 
(XBP1) mRNA, which is a transcription factor that increases chaperones and elements of 
ERAD. A late stage response is the induction of apoptosis via a TNF receptor-associated 
factor 2 (TRAF2) and caspase 12 pathway.  
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Figure 1.2: The IRE1/XBP1 branch of the UPR. 
Upon increased ER stress, BiP dissociates from IRE1 allowing homodimerizaiton and 
activation. Activated IRE1 splices XBP1 mRNA to form a stable XBP1 mRNA product. 
Upon its translation, sXBP1 promotes the transcription of ER chaperones. ER 
degradation is also upregulated. Under conditions of unrelieved stress, IRE1 induces 
apoptosis via Traf2 mediated caspase 12 cleavage.  
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 IRE1’s activation is due specifically to auto-phosphorylation, which opens up an 
active site allowing nucleotide binding (28). Upon binding, a conformation change is 
induced allowing for activation of the ribonuclease (RNase) domain of IRE1. The 
conformational change may involve the binding of either adenine triphosphate (ATP) or 
adenine diphosphate (ADP) to the kinase domain. ADP has been shown to be a more 
effective activator in vitro, though ATP also is capable of initiating phosphorylation (25). 
IRE’s ability to activate through binding of adenine nucleotides may also serve as a 
nutritional sensor, regulating protein synthesis and UPR activation based on the energetic 
state of the cell (29).  
 IRE1α knockout mice embryos, which die by embryonic day 13, are smaller than 
their wild type littermates and have severe liver hypoplasia (30). The cause of death 
appears to be due to dysfunction of the placenta rather than embryonic growth (31). To 
bypass the lethality, studies on immune function were performed by reconstituting the 
immune system of recombination activating gene 2 (Rag2) deficient mice with IRE1α-/- 
hematopoietic stem cells. IRE1α was then shown to be required for two distinct steps in 
B cell lymphopoiesis: first in the rearrangement of the Ig genes and production of B cell 
receptors, and second during plasma cell differentiation (30). These murine defects 
indicate that IRE1α expression and activity plays an important role in cellular health and 
function.  
 Acting as an unconventional endoribonuclease, active IRE1 can remove a 26-
nucleotide intron from XBP1, creating a stable mRNA product (25). Spliced XBP1 
(sXBP1) mRNA can then be translated into XBP1, a transcription factor. XBP1 is a 
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member of the cAMP response element-binding/activating transcription factor 
(CREB/ATF) basic region-leucine zipper (bZIP) family (32). It was originally identified 
in a screen for proteins that bound the X-box, a sequence that regulates transcription of 
the human major histocompatibility complex (MHC) (33). Subsequently, XBP1 has been 
shown to be able to regulate the expression of several ER chaperones including BiP, ER-
localized DnaJ homologues 3 and 4 (ERdj3 and ERdj4) and other UPR effectors 
including ATF4, CCAAT/enhancer-binding protein epsilon/DNA damage-inducible 
transcript 3 (CHOP), PERK, protein disulfide isomerase (PDI), ER degradation-
enhancing alpha-mannosidase-like protein (EDEM), as well as its own expression in a 
cell type specific manner (34-36). XBP1 is not only a key player in promoting the 
induction of the UPR, but it also is physiologically necessary for mouse development and 
cell differentiation.  
 Similar to IRE1α, XBP1 knockout mice also exhibit severe liver hypoplasia 
resulting in embryonic death (37). Rescue experiments have shown that in addition to 
functional liver formation, XBP1 is required for proper development of other secretory 
tissues, including the salivary gland and exocrine pancreas (36). Other studies show that 
XBP1 is not only required for the secretory capacity of plasma cells but also the 
differentiation of B cells into antibody secreting plasma cells (38). Interestingly, forced 
XBP1 expression can increase the secretory capacity of primary B cells (36). These data 
show that the IRE1 branch of the UPR not only affects cellular activity but also has a 
great impact on whole body function. 
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Key Players in the UPR: ATF6 Branch 
 Another branch of the UPR is the ATF6 regulated induction of chaperone mRNA 
transcription (Figure 1.3). In addition, ATF6 also may regulate the PERK branch of the 
UPR by inhibiting growth arrest and DNA damage-inducible protein 34 (GADD34), 
which dephosphorylates eukaryotic translation initiation factor 2 alpha (eIF2α), a 
modulator of protein translation. Upon prolonged ER stress, ATF6 will induce apoptosis 
through activating transcription factor 4 (ATF4) regulation of CHOP. 
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Figure 1.3: The ATF6 branch of the UPR. 
BiP dissociates upon increased ER stress allowing ATF6 to translocate to the Golgi and 
undergo proteolytic cleavage. Activated ATF6 promotes the transcription of ER 
chaperones. Under conditions of unrelieved stress, ATF6 via ATF4 induces apoptosis 
through upregulation of CHOP. It can also mediate translational regulation by inhibiting 
GADD34, which dephosphorylates eIF2α. 
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 The two bZIP-type transcription factors, ATF6α and ATF6β, are constitutively 
expressed transmembrane proteins located in the ER (39). Upon activation, ATF6 is 
translocated to the Golgi where it is cleaved by Site-1 and Site-2 proteases (39-41). 
p50ATF6, the soluble N-terminal portion containing the bZIP domain, is transported to 
the nucleus where it directly binds the ER stress response element (ERSE) to induce 
transcription of key UPR effectors including XBP1, BiP, and PDI (42,43). 
 ATF6α knock out mice show no overt phenotype; they are vital, fertile, and 
healthy (44). However, upon acute tunicamycin treatment in vivo, these mice are unable 
to protect against ER stress and exhibit increased toxicity and organ failure. The lack of a 
strong phenotype may be due to the overlap between the ATF6 and PERK/eIF2α 
branches. During chronic ER stress, ATF6 may prolong the block on translation through 
suppression of growth arrest and DNA damage-inducible protein 34 (GADD34), which 
dephosphorylates eIF2α (44). Additionally, if the stress on the ER is not relieved, both 
ATF6 and PERK are able to activate CHOP mediated apoptosis through upregulation of 
ATF4 (42). 
 
Key Players in the UPR: PERK/eIF2α Branch 
 The final ER stress sensor, PERK, is a conserved protein with a luminal domain 
similar to IRE1 and a kinase domain related to double-stranded RNA-dependent protein 
kinase (PKR) (Figure 1.4) (45). Once freed from BiP, PERK is auto-phosphorylated, 
leading to dimerization and trans-phosphorylation (20,46). Both ER stress as well as 
ischemia can activate PERK, which in turn phosphorylates eIF2α on serine 51 
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(45,47,48). Phosphorylation of eIF2α inhibits its ability to initiate protein translation 
causing a decrease in general protein synthesis (49). Upon unrelieved ER stress, PERK, 
in the same manner as ATF6 can induce apoptosis through the ATF4/CHOP pathway.  
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Figure 1.4: The PERK/eIF2α  branch of the UPR. 
Upon increased ER stress, BiP dissociates from PERK allowing homodimerization and 
activation. Activated PERK phosphorylates eIF2α, which decreases general translation. 
Under these conditions, ATF4 is specifically upregulated, which can then induce CHOP 
and apoptosis. 
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 Although PERK knockout mice are viable, about 30% die prenatally and less than 
40% live past the first week of birth (50). At birth they appear healthy and similar to wild 
type littermates but noticeable changes occur within the first few weeks. They experience 
severe growth retardation and by the end of the first week they are already about 50% 
smaller than wild type mice. PERK-/- pancreatic β cells quickly degenerate and the mice 
develop Diabetes Mellitus. The cause of these effects is believed to be due to 
dysregulation of eIF2α and protein synthesis (50), although this has not been confirmed 
and could be due to a different, currently unknown substrate. 
 In addition to PERK, eIF2α can also be phosphorylated by general control non-
derepressible 2 (GCN2), heme-regulated inhibitor (HRI), and PKR (51,52). Though the 
kinase domains are similar, their regulatory domains differ and therefore they can be 
activated by various stimuli. In fact, under various stress conditions they can be activated 
either singly or in combination (53). To determine the physiological role of eIF2α 
phosphorylation, mice were generated containing an alanine replacement of serine 51 
(54). Similar to the PERK-/- mice, eIF2αS51A mice were indistinguishable from wild 
type mice at birth. Although born at a Mendelian ratio, indicating no prenatal lethality, 
almost all the homozygous eIF2αS51A mice died within 18 hours. Death was due to 
hypoglycemia caused by impaired gluconeogenesis in the liver. In addition, similar to 
what was seen in the PERK-/- mice, these mice had decreased β cell populations and 
serum insulin levels. These two mice models indicate that the PERK/eIF2α pathway of 
protein synthesis regulation is necessary for glucose metabolism. Additionally, it 
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strengthens the hypothesis of ER stress as a monitor and/or regulator of nutritional and 
energetic status (29). 
 In addition to its potential function in glucose metabolism, eIF2α phosphorylation 
has a key role in ER stress due to its regulation of protein synthesis. By decreasing 
general translation, the load on the ER is reduced allowing recovery and a return to 
normal folding homeostasis (45,49). Paradoxically, the state of enhanced eIF2α 
phosphorylation promotes translational upregulation of ATF4 (54,55). Select mRNAs 
that contain either a secondary open reading frame or an internal ribosome entry site 
(IRES) can be transcribed upon eIF2α phosphorylation (56). ATF4 has two short open 
reading frames in its 5’ untranslated region (UTR) that prevent initiation at the start 
codon during unstressed conditions (57). Upon eIF2α phosphorylation, reinitiating 
ribosomes are able to promote translation of ATF4 (58). Once translated, ATF4 aids in 
transcription of several members of the UPR including CHOP and GADD34 (59,60). 
ATF4 and its targets are part of the integrated stress response (ISR), a pro-survival gene 
expression program (61). Besides ER stress, several different cellular functions are also 
regulated by ATF4 and the ISR, including amino acid import and protection from 
oxidative stress.  
 The ultimate aim of the three branches of the UPR is to increase the folding 
capacity of the ER to restore homeostasis. A major mechanism for restoring capacity is 
the upregulation of key ER chaperones, including BiP and glucose regulated protein of 94 
kDa (GRP94), as well as enzymes involved in the reduction-oxidation (redox) 
mechanisms of disulfide bond formation, such as BiP and ERO1α. In conjunction with 
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that, the amount of unfolded proteins in the ER is reduced through translational 
attenuation by eIF2α phosphorylation as well as increased proteolysis through ER-
associated degradation (ERAD) (62). ERAD involves a series of checkpoints to separate 
folded from misfolded proteins. Upon prolonged retention in the ER due to problematic 
folding, ER degradation-enhancing α-mannosidase-like 1 (EDEM) acts to separate 
misfolded proteins from their chaperone (63). This improves folding capacity in two 
ways. It makes the chaperones available for further protein folding while allowing the 
misfolded protein to proceed through ERAD. Once a protein is identified as misfolded, it 
is ubiquitinated and degraded by the proteosome (64). EDEM is upregulated during the 
UPR to promote the clearance of misfolded proteins and relieve pressure on the ER 
during this stressed state (65). 
 If the mechanisms employed by the ER are unable to restore homeostasis, the 
final stage of the UPR is the initiation of apoptosis. All three signaling branches have 
pro-apoptotic targets. IRE1, via TRAF2, can induce caspase 12 cleavage and the caspase 
signaling cascade (66). PERK and ATF6, potentially through regulation of ATF4, can 
work synergistically to upregulate CHOP (42). CHOP is a bZIP containing transcription 
factor that is a member of the CCAAT/enhancer binding protein (C/EBP) family (67). 
While it promotes proper cellular function by its role in the differentiation of several cell 
types, it can also induce apoptosis through p38 dependent and independent mechanisms 
(67-71). Upon unresolved UPR, a release of calcium from the ER triggers the canonical 
mitochondrial initiated apoptotic pathway (72-74). Importantly, the switch between 
cytoprotective to cytotoxic activity is due to the duration of ER stress and variations in 
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signaling kinetics (75). Upon prolonged ER stress, the signaling pathways are attenuated 
and apoptosis begins. Artificially sustaining IRE1 activity can prevent UPR initiated 
apoptosis; a potential mechanism to promote cell survival and recovery during UPR 
driven disease states.  
 
UPR and Disease 
 While the role of the UPR is to promote the proper function of the ER, it has been 
shown to play a key role in human health and disease. Several conditions, including 
neurodegeneration, tumor growth, the immune response, and diabetes, have been linked 
to improper or impaired UPR activation. A major focus has been on the pro-apoptotic 
feature of the UPR and its relationship to disease. Recently, direct links between UPR 
signaling and function/dysfunction has been shown to play a role in these maladies. 
 Many unrelated neurodegenerative diseases are caused by an accumulation of 
unfolded proteins that aggregate into deposits, termed lewy bodies (76). Brains afflicted 
with Alzheimer’s disease, characterized by aggregates of amyloid β protein, have been 
shown to display increased UPR activity, leading to cellular toxicity (77,78). 
Interestingly, chaperones are not upregulated indicating that even with increases in 
activation, the UPR is not functioning properly (79). Notably, one chaperone, BiP, has 
been shown to bind to and promote proper folding of the amyloid precursor proteins 
thereby decreasing their plaque-forming potential (80). The UPR is similarly activated in 
Parkinson’s disease, which has aggregation of α-synuclein (81). In a mouse model 
generated by treatment with a neurotoxin, XBP1 overexpression has been shown be 
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cytoprotective (82). Therefore, improving UPR efficiency could serve as a preventative 
and/or therapeutic treatment for these and possibly other neurological diseases. 
 Similar to Alzheimer’s and Parkinson’s diseases, increased UPR activation has 
also been seen in solid tumors (83). In these tumors, the PERK branch is activated by 
hypoxia in an apparent hypoxia inducible factor 1 (HIF1)-independent manner (84). 
Notably, optimal tumor growth is prevented upon depletion of either PERK or XBP1 
(85,86). Under these conditions, tumors are more sensitive to hypoxia and cell death 
thereby signifying the UPR as a potential therapeutic target. Unlike how enhanced UPR 
could improve neurodegeneration, cancer researchers are looking to inhibit the UPR as a 
potential treatment. 
 Upon viral infection, membrane proteins and lipids are usurped for viral 
packaging leading to increased stress on the host cell’s ER (18). The role of the UPR 
during infection is varied dependant on viral stain. It can promote viral activity by 
increasing ER efficiency and thereby aiding in viral replication. Hepatitis B has a 
promoter that is indirectly activated by IRE1 and sXBP1 activity (87). Additionally, in 
order to block the host immune response, the cytomegalovirus US11 protein induces 
degradation of MHCs via UPR activation (88). Conversely, the increased burden on the 
cell by uninhibited viral replication can induce the UPR leading to decreased translation, 
an antiviral response. In fact, PERK and eIF2α depleted cells have been shown to support 
higher viral titers (89,90). It has been discovered that several other viruses manipulate the 
UPR either to promote infection or impair the host’s antiviral response (18). Thus, both 
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stimulatory or inhibitory compounds of the UPR should be developed as either type could 
be useful antiviral treatments, dependant on the infecting viral strain. 
 As indicated earlier, the UPR has been linked to several metabolic conditions, 
including obesity and diabetes. As more data portrays the UPR as a molecular cause of 
the metabolic syndrome, it has become a potential therapeutic target. While T1DM often 
results from an autoimmune attack on the pancreatic β cells, some cases have been shown 
to be due to genetic defects. The Wollcott-Rallison syndrome is a form of T1DM caused 
by a mutation in PERK resulting in pancreatic β cell death (91). Additionally Wolfram 
Syndrome, another T1DM condition, is triggered by mutations in WFS1 (92). WFS1, a 
UPR responsive gene, helps maintain ER homeostasis and its inactivity may lead to the β 
cell dysfunction seen in these patients (93). The Akita mouse, a model of T1DM, has a 
missense mutation in the insulin 2 gene (94). This mutation causes the protein to be 
misfolded and retained in the ER, resulting in ER stress and apoptosis (95). Therefore, 
UPR activity in β cell function and survival is an important consideration for the 
treatment or prevention of some forms of T1DM. 
 Obesity and T2DM have also been linked to altered UPR activity in several 
tissues. Obesity causes increased UPR activation in the liver and adipose tissues (96). 
This activation has been linked to decreased insulin signaling in the liver. Chronic ER 
stress has been seen in both the db/db T2DM mouse model and patients with T2DM (97). 
Hyperglycemia during diabetes leads to increased proinsulin production; this added strain 
on the ER can trigger the UPR and if not released can result in the β cell death seen in 
uncontrolled T2DM (98). Interestingly, treatment of ob/ob mice with chemical 
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chaperones relieves ER stress in the liver and adipose tissue and restores glucose 
homeostasis and insulin sensitivity (99). This indicates that impaired protein folding may 
be a cause of T2DM, and improving UPR efficiency rather than blocking the activation 
of the UPR might be a potential treatment. These data indicate that alterations in the 
adipocyte UPR could directly influence adipokine secretion and thereby whole body 
energy homeostasis. 
Mitochondria  
 
The ER protein folding and the UPR are not the only cellular functions being 
examined as potential causes of the metabolic syndrome. As energetics are often 
dysregulated in obesity and diabetes, numerous studies have been done on the role of 
mitochondria in these diseases. Mitochondria fulfill the energetic needs of the cell, as 
well as numerous other roles required for important cellular functions. This multiplicity 
of roles is reflected in the variation in the mitochondrial proteome seen among different 
tissues (100,101) and during differentiation (102).  
The major function of mitochondria is the generation of ATP through oxidative 
phosphorylation. It however performs other roles including signaling, apoptosis, and 
regulation of cell growth (103). Mitochondria have four compartments each with distinct 
functions: the outer and inner membranes, the intermembrane space, and the matrix 
(104). Their membrane structure is constantly changing through fission and fusion 
events, and the dynamics have been correlated with mitochondrial activity (103). 
Mitochondria are the only organelles with their own genome, which encodes for 37 
genes, including 13 proteins involved in oxidative phosphorylation, 22 transfer RNAs 
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(tRNAs), and 2 ribosomal RNAs (rRNAs). Mitochondrial DNA (mtDNA) transcription 
requires nuclear encoded proteins, Transcription factor A and B, mitochondrial (Tfam 
and Tfbm), and mitochondrial RNA polymerase (105). Tfam has also been shown to 
promote the replication and maintenance of mtDNA. Mutations or malfunctions in 
mtDNA have been implicated in several human diseases including diabetes mellitus, 
anemia, pancreatic dysfunction, and several neurological diseases, including Alzheimer’s 
and Parkinson’s diseases (106). Although some of these have a non-metabolic cause, 
such as an autoimmune response, the majority is often due to impaired oxidative 
phosphorylation leading to decreased ATP production. 
In most cells, oxidative phosphorylation is the major source of energy production, 
in the form of ATP (104). In eukaryotes, the proteins involved in this metabolic pathway 
are located in the mitochondria, while similar protein complexes in prokaryotes are 
located in the inner membrane. In mitochondria, these protein complexes form the 
electron transport chain, which transfers electrons via reduction-oxidation reactions to 
provide energy for the movement of protons from the matrix to the intermembrane space. 
This influx of protons generates an electrochemical gradient across the inner membrane. 
The final complex involved in oxidative phosphorylation is ATP synthase, which uses the 
force of protons crossing the inner membrane back into the matrix to phosphorylate ADP, 
generating ATP. Mitochondrial oxidative phosphylation can be impaired through 
inhibition of any of the protein complexes within the electron transport chain, including 
oligomycin, which blocks ATP synthase. In addition, the proton gradient can be disrupted 
by addition of chemical ionophores, such as FCCP or 2,4-Dinitrophenol, or the 
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uncoupling protein family, all of which transport protons across the inner membrane 
thereby “uncoupling” proton transfer from ATP synthesis. Regulation of ATP synthesis is 
critical as maintenance of a sufficient ATP supply is necessary for cellular function and 
survival. 
ATP synthesis is tightly controlled based upon the energetic needs of the cell. The 
cell has several mechanisms by which it regulates energy levels. AMP activated protein 
kinase (AMPK), is a key regulator of cellular energetics (107). Under conditions of 
reduced energy levels, signaling by AMPK decreases ATP consuming pathways, 
including protein synthesis, and increases ATP generating ones, such as fatty acid 
oxidation. These mechanisms of energy conservation continue until homeostatic adenine 
nucleotide levels are restored. 
Adenylate Kinase 
 
The concentrations of ATP and other adenine nucleotides within the cell are also 
regulated by an ancient family of proteins, the adenylate kinases (EC. 2.7.4.3). Members 
of this family are present throughout the phylogenic tree, from plants to bacteria and 
humans. Adenylate kinase (AK) catalyzes the reversible phosphoryl transfer reaction 
AMP + ATP ⇔ 2ADP. It is necessary for the survival of bacteria and lower eukaryotes 
(108-110). AK has been thought to provide the principal homeostatic mechanism to 
maintain adenine nucleotide ratios under different conditions of ATP production and 
utilization. It has also been proposed that AK provides a mechanism to channel the high 
energy phosphate of ATP from sites of ATP production to sites of utilization through the 
operation of phosphotransfer networks (111). Higher eukaryotes have genes coding for 
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up to 9 enzymes bearing similarity to AK. They differ in cellular and subcellular 
distribution as well as even substrate affinity indicating that each has a specific cellular 
function.  
The most well characterized isoform is AK1, a cytosolic enzyme found in the 
skeletal muscle, brain, and erythrocytes (112,113). AK1, along with creatine kinase and 
nucleoside diphosphokinase, help maintain stable intracellular ATP concentrations (114). 
They are thought to promote energy transfer from ATP generating sites to ATP 
consuming regions. In skeletal muscle over 95% of the total adenylate kinase activity 
corresponds to AK1 (115). It has been shown to aid in transferring ATP from the 
mitochondria to myofibrils (116). However, mice lacking AK1 have normal growth and 
contractile ability (114,115,117). Given the importance of AK activity in prokaryotes, 
and the fact that AK1 is by far the predominant AK activity in muscle, it was rather 
surprising that these mice were able to maintain ATP levels. These results suggest that 
compensatory mechanisms are elicited in these mice to adapt to the lack of this enzyme. 
In fact, alterations in creatine kinase flux and increased glycolytic metabolism were 
observed. Interestingly, it was also observed that the rate of ATP synthesis, assessed by 
18O redistribution into high-energy phosphate-containing metabolites, was significantly 
increased in muscles from AK1-/- mice in response to contraction, indicating more ATP 
had to be produced to maintain normal contractility. Therefore, the efficiency of ATP use 
was lower in AK1-/- mice compared to controls, especially under stress (114,115). 
Proteomic analysis has shown an increase in AK1 in the muscle of obese versus lean 
women (118). This increase in AK1 is believed to compensate for the impaired 
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mitochondrial function during obesity. These results are consistent with a proposed role 
of AK in improving the efficiency of ATP utilization in cells through the operation of 
phosphotransfer networks (111), or other yet unknown mechanisms.  
There are three mitochondrial members of the adenylate kinase family, AK2, 
AK3, and AK4. AK2 is found in the mitochondrial intermembrane space of liver, kidney, 
spleen, and heart (112). There are two isoforms, AK2A and AK2B, differentiated only by 
a small sequence variation in the C terminal region and slightly different tissue 
distribution (113,119). Interestingly, there is large discrepancy between the expression of 
the mRNA and of the protein of AK2, indicating a significant post-transcriptional 
regulation (120). AK3 and AK4 are localized to the mitochondrial matrix, where AK3 is 
more ubiquitously expressed while AK4 is in kidney, heart, liver, and brain (121). Unlike 
the other adenylate kinases, AK3 catalyzes the reaction AMP + GTP ⇔ ADP + GDP 
(122). AK4 has shown no enzymatic activity but can interact with the mitochondrial 
adenine transporter (121). It is believed that AK2 and AK3 work together shuttling 
adenine nucleotides within the mitochondria to promote oxidative phosphorylation (123). 
In this way, they work together to enhance the efficiency of mitochondrial ATP 
synthesis.  
Physiologically, AK2 has been shown to be required for Drosophila growth and 
development (124). Maternally derived AK2 is sufficient for embryonic development, 
however growth arrest occurs during the third larval stage followed by death. Recently, 
mutations in AK2 have been identified as the basis for reticular dysgenesis, a rare form of 
severe combined immunodeficiency (SCID) characterized by a complete lack of 
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granulocytes and almost complete deficiency of lymphocytes in the blood (125,126). 
Mechanistic analysis showed that zebrafish lacking AK2 also had impaired leukocyte 
development (126). Cells from the SCID patients showed enhanced apoptosis, abnormal 
levels of reactive oxygen species, and altered mitochondrial membrane potential, 
indicating that mitochondriopathy might be the underlying cause of this disease (126). 
Interestingly, patients with reticular dysgenesis also suffer from sensorineural deafness. It 
was found that AK2 is located in the stria vascularis region of the inner ear and therefore 
is most likely also responsible for this symptom of the disease (125). The effect of this 
enzyme on hematopoiesis illustrates the importance of adenine nucleotide regulation. 
Further studies on the role of adenylate kinases and energetic regulation will help in 
understanding their importance not only within cellular functions but perhaps also in 
human disease. 
 
Mitochondria and the ER 
 
3T3-L1 adipocyte differentiation is accompanied by the induction of the UPR and 
initiation of adiponectin secretion (127). This induction coincides with a robust increase 
in mitochondrial biogenesis (102). Adiponectin secretion by 3T3-L1 adipocytes is 
compromised by mitochondrial poisons and enhanced by increased mitochondrial 
capacity (128), suggesting a high energy requirement for its processing. These findings 
suggest the possibility that these two events are functionally linked, with mitochondrial 
function being required for UPR induction and efficient secretion in differentiated 
adipocytes.  
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Mitochondria and the endoplasmic reticulum are physically joined by junctions 
between their two membranes (129). The regions of ER that co-sediment with the 
mitochondria, termed mitochondrial associated membranes (MAM), have a different 
composition than non-sedimenting ER (130). These regions show enhanced phospholipid 
synthesis and may be the means by which the phospholipids are transferred between the 
two organelles. These junctions may also improve mitochondrial uptake of calcium 
released by the ER (131,132). The specificity of the mitochondrial calcium transporters is 
too low for efficient import. However, the closeness of the two organelles and the higher 
concentration of calcium near the ER membrane would allow more efficient 
mitochondrial import. Other molecules that need to travel between the two organelles are 
adenine nucleotides. ATP is necessary for ER chaperone function and the resulting ADP 
must return to the mitochondria for oxidative phosphorylation. ATP import from the 
cytosol has been shown to occur via a transporter, however the protein has not been 
identified yet (133). A large percentage of cellular ATP is required for protein folding 
and synthesis in both the cytoplasm as well as the ER. Therefore, direct 
ER/mitochondrial exchange via the MAMs would be a more efficient means of 
nucleotide transport. The crosstalk between the mitochondria and ER becomes more 
important as new data emerges. It is already known that these two organelles have roles 
in similar cellular functions, including calcium signaling and apoptosis. Additionally, 
both have been implicated in metabolic diseases and neurodegenerative conditions, such 
as Alzheimer’s and Parkinson’s diseases. Greater understanding of the role of 
mitochondria in the energetics of the ER and the UPR would supply insight not only into 
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basic cellular function, but could also provide information about the root cause of several 
human diseases and potential targets for prevention and treatment.  
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SPECIFIC AIMS 
 
 The goal of this body of work is to examine the role energetics play in protein 
folding and the induction of the unfolded protein response. Previous studies have 
illustrated the relationship between ER and mitochondrial functions within the cells, 
mainly focusing on calcium regulation and signaling. Additionally, both mitochondrial 
biogenesis and induction of the UPR have been shown during 3T3-L1 differentiation. 
Physiologically, numerous studies have linked the UPR to Diabetes Mellitus and several 
neurodegenerative diseases. Separately, mitochondrial dysfunction has also been 
proposed as a cause for these same diseases. These similarities led us to question whether 
it could be a joint breakdown in both organelles resulting in the disease.  
 Although it is known that ER function requires ATP for chaperone function, the 
full extent of the energetics of ER function has not been examined. Therefore we sought 
to look at the role of mitochondrial ATP synthesis on ER function. ATP is not only 
synthesized by mitochondrial oxidative phosphorylation, but can also be produced 
through adenylate kinase activity. Interestingly, both UPR impairment, such as by IRE1 
or XBP1 depletion, and mutations in AK2 result in profound alterations in hematopoiesis. 
Therefore, we also asked whether AK generated ATP would also be required for ER 
function. Thus, the specific aims of this study are: 
1) To examine the induction of the UPR during 3T3-L1 differentiation and its role in 
 adipocyte secretion. 
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2) To determine the effect of ATP generated from mitochondrial oxidative 
 phosphorylation on UPR function. 
3) To ascertain whether adenine nucleotide regulation by AK affects the UPR. 
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CHAPTER II 
 
 
CONCURRENT UPREGULATION OF THE UPR AND 
MITOCHONDRIAL BIOGENESIS DURING 3T3-L1 
DIFFERENTIATION  
 
The following data includes unpublished results as well as data taken from: 
Shi, X., Burkart, A., Nicoloro, S. M., Czech, M. P., Straubhaar, J., and S. Corvera 
(2008) Paradoxical Effect of Mitochondrial Respiratory Chain Impairment on Insulin 
Signaling and Glucose Transport in Adipose Cells. J Biol Chem 283, 30658-30667. 
 
Burkart, A., Shi, X., Chouinard, M., and S. Corvera (2010) Adenylate Kinase 2 Links 
Mitochondrial Energy Metabolism to the Induction of the Unfolded Protein Response. 
Submitted. 
 
 
The analysis of the mitochondrial DNA and some of the Tfam siRNA transfections were 
performed by Xiarong Shi. Microarray experiments on 3T3-L1 differentiation were 
performed by Sarah Nicoloro with Juerg Straubhaar performing statistical analysis on the 
resulting data. I performed the remaining experiments contained within this chapter.  
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Summary 
 
The white adipose cell plays a major role in the regulation of whole body 
metabolism, through the storage and hydrolysis of triglycerides, thereby affecting 
systemic energy levels and insulin sensitivity. The 3T3-L1 cell line undergoes 
mitochondrial biogenesis during adipocyte differentiation to allow for efficient fatty acid 
metabolism; however, the induction of other metabolic pathways besides fatty acid 
catabolism may indicate that the cell has a greater energetic role than solely triglyceride 
storage. Adipocytes are able to control satiety and energy metabolism through the 
secretion of proteins, such as adiponectin, leptin, and resistin. Secretory function in cell 
types such as pancreatic β cells and antibody producing B cells is highly dependent on 
the unfolded protein response (UPR). Other labs, as well as our own, show that 3T3-L1 
differentiation involves upregulation of the UPR, including key proteins such as the 
endoplasmic reticulum chaperone BiP, and the transcription factors XBP1 and CHOP. 
Here we demonstrate that adiponectin secretion is preceded by the induction of the 
unfolded protein response (UPR) in differentiating 3T3-L1 adipocytes. Additionally, 
impairment of XBP1 activation results in a parallel impairment of adiponectin 
expression, indicating that the adipocyte UPR pathway is necessary for its secretory 
functions, and can thus play a crucial role in the control of whole body energy 
homeostasis. Since mitochondrial biogenesis is occurring in parallel to induction of the 
UPR, we tested whether it was necessary for ER function. Depletion of Tfam, a 
mitochondrial transcription factor, and treatment with chemical inhibitors, shows that ER 
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function is sensitive to acute changes in adenine nucleotide levels through mitochondrial 
manipulations. 
Background 
 
White adipocytes play a central role in the regulation of whole body metabolism 
by sensing nutrient levels, and responding with the secretion of peptide factors that act on 
the central nervous system and peripheral tissues to control caloric intake and utilization 
(6,7). These factors include the hormone leptin, as well as the protein adiponectin (8-10). 
The levels and oligomeric structure of serum adiponectin positively correlates with 
insulin sensitivity (134,135). Moreover, insulin sensitizers of the thiazolidinedione family 
stimulate adiponectin secretion and this effect could contribute to the therapeutic actions 
of these drugs (136). Given the importance of adiponectin to whole body homeostasis, 
understanding the molecular mechanisms that regulate its secretion from adipocytes is 
highly relevant.  
Adiponectin is synthesized as a 247 amino acid polypeptide that undergoes 
extensive folding to form a trimer stabilized through disulfide bond formation (8,9). In 
addition to trimeric adiponectin, higher molecular weight complexes are formed and 
secreted by adipocytes, indicating that the process of adiponectin folding in the 
endoplasmic reticulum is likely to be complex. Earlier proteomic analysis of 3T3-L1 
adipocyte differentiation revealed a pronounced increase in the mRNA levels for the ER 
chaperone ERO1α (102), a protein involved in disulfide bond formation during protein 
folding (137). It has also been recently shown that the UPR is upregulated during 3T3-L1 
  
36 
adipocyte differentiation (127). These studies prompted us to investigate whether further 
adaptations of the ER folding machinery would be necessary for the establishment of 
adipocyte secretory functions.  
Protein folding capacity in the endoplasmic reticulum is achieved through a series 
of mechanisms collectively termed the “unfolded protein response” (UPR) (98,138-140). 
These mechanisms can be induced by artificial pressure upon the secretory pathway, such 
as that which occurs when cells express proteins that are difficult to fold or when drugs, 
such as tunicamycin, impair the enzymatic machinery required for folding (19). Under 
these extreme conditions, three branches of the UPR are activated, each initiated through 
activation of the transmembrane endoplasmic reticulum signaling proteins ATF6, IRE1, 
and PERK. ATF6 is cleaved by Golgi membrane endopeptidases to produce a bZIP 
domain that translocates into the nucleus. IRE1, through its intrinsic endoribonuclease 
activity cleaves the mRNA for the transcription factor XBP1, resulting in translation of a 
stable product. These induce transcriptional and translational responses that enhance the 
folding capacity of the ER. The serine/threonine protein kinase PERK phosphorylates and 
inactivates eIF2α, resulting in temporary arrest of general protein translation thus 
transiently limiting protein synthesis. 
Specific branches of the UPR are active in cells that sustain chronically elevated 
protein flux through the ER, such as the pancreatic β cell and the salivary gland, and 
these cells are particularly sensitive to alterations in the UPR pathway (141). Thus, PERK 
knockouts or knock-ins of non-phosphorylatable mutants of the PERK substrate eIF2α 
result in rapid post-natal β cell failure and diabetes (142). The IRE1 branch of the UPR is 
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activated upon differentiation of plasma cells, and is necessary at the latest stages of 
differentiation to enable the secretion of immunoglobulins (30,143). Here we provide 
evidence for the induction of the XBP1 branch of the UPR during the process of 
adipocyte differentiation, and its requirement for adiponectin secretion. These data 
indicate that alterations in the adipocyte UPR could directly influence adipokine secretion 
and thereby whole body energy homeostasis. 
We have previously reported that differentiation of 3T3-L1 preadipocytes is 
accompanied by a robust increase in mitochondrial biogenesis (102), which coincides 
with the induction of the UPR and initiation of adiponectin secretion. Adiponectin 
secretion by 3T3-L1 adipocytes is compromised by mitochondrial poisons and enhanced 
by increased mitochondrial capacity (128), suggesting a high energy requirement for its 
processing. These findings suggest the possibility that these two events are functionally 
linked, with mitochondrial biogenesis being required for UPR induction and to sustain 
adiponectin secretion in differentiated adipocytes.  
Mitochondria play an essential role in fulfilling the energetic needs of the cell, as 
well as numerous other roles required for cell function. This multiplicity of roles is 
reflected in the variation in the mitochondrial proteome seen among different tissues 
(100,101), or during differentiation (102). To investigate the relationship between 
mitochondrial biogenesis and the induction of the UPR, we focused on manipulating 
oxidative phosphorylation through two methods, Tfam depletion and chemical inhibitors. 
Previous work from our laboratory has shown that Tfam, a factor involved in mtDNA 
transcription and replication (144) can be silenced during 3T3-L1 adipocyte 
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differentiation, mitigating the increase in oxidative phosphorylation that accompanies 
normal mitochondrial biogenesis (145). In addition, we used chemical compounds such 
as FCCP, a mitochondrial uncoupler, and oligomycin, which blocks the mitochondrial 
ATP synthase, to induce inhibitory manipulations of oxidative phosphorylation. We find 
that acute impairments of oxidative phosphorylation results in diminished UPR 
activation, however more prolonged alterations through Tfam depletion has little effect 
on ER function, suggesting that the observed changes are due to the differential 
regulation of ER function or compensation through other mechanisms. 
  
Results  
 
The 3T3-L1 cell line is a well-characterized model system for adipocyte 
differentiation and function. Treatment of these cells with a hormone cocktail induces a 
phenotypic change from a fibroblastic pre-adipocyte to a quiescent adipocyte (Figure 
2.1A). Upon differentiation, the 3T3-L1 takes on characteristics of a primary adipocyte 
including lipid accumulation, insulin sensitivity, and the expression of adipocyte specific 
proteins. Previously, our lab has shown that mitochondrial biogenesis occurs during 
differentiation, as demonstrated by the increased protein expression of cytochrome C and 
heat shock protein 60 (HSP60) (Figure 2.1B and (102)). The increased protein expression 
accompanies increased mitochondrial mass and increased function as assessed by oxygen 
consumption (102). Mass spectrometry analysis was performed on proteins increased 
during differentiation purified from a crude mitochondrial isolation; interestingly, 
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ERO1α, an ER resident protein was co-purified and shown to be significantly increased 
(102). We sought to determine whether the increase in ERO1α represented a general 
improvement in the secretory capacity of the cell as a function of adipogenesis.  
The adipocyte, a known secretory cell, regulates whole body metabolism through 
secretion of adipokines and other proteins, such as tumor necrosis factor alpha (TNFα) 
(146,147). Adiponectin is an adipokine found in human serum at concentrations of 10-20 
µg/mL (148). It is also produced and secreted at copious levels by 3T3-L1 adipocytes and 
we used it as a marker of secretory ability throughout differentiation. The cell begins 
expressing adiponectin at low levels on day 3 of differentiation (data not shown). 
However, secretion does not begin until day 4 of differentiation and peaks around day 7 
(Figure 2.1C).  
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Figure 2.1: Differentiation of 3T3-L1 adipocytes. 
A. Bright field image of 3T3-L1 fibroblasts (left) and adipocytes (right). B. 3T3-L1 cells 
were harvested just prior to addition of hormonal cocktail (day 0), and at indicated days 
of differentiation thereafter. Cell extracts were analyzed by western blotting with 
antibodies to the proteins indicated. C. Culture media was analyzed by western blotting 
with anti-adiponectin (Acrp30). All data is representative of three independent 
experiments.  
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The UPR is a combination of responses that work jointly to expand the folding 
efficiency and capability of the ER (43,98,138,139). It is elicited in cells when demand 
for secretory capacity is high, such as during the differentiation of B lymphocytes into 
antibody-secreting plasma cell (38,143). It entails the activation of transcriptional 
mechanisms that increase the levels of ER chaperones, including BiP. Affymetrix chip 
databases of RNA isolated from 3T3-L1 cells at different times of differentiation were 
queried with a list of probe sets for secretory and ER resident proteins. As expected, 
differentiation was accompanied by more than 10-fold increases in RNA expression for 
adiponectin, adipsin, and resistin (Table 1). In addition, other secretory proteins involved 
in extracellular matrix deposition and angiogenesis were also greatly induced. We 
anticipated the ER capacity to expand in order to process this increased secretory load. In 
fact, mRNA levels of resident proteins of the endoplasmic reticulum were also increased 
(Table 1). Enzymes which regulate lipid metabolism were increased, such as stearoyl-
coA desaturase 1 (SCD1) and diacylglycerol O-acyltransferase 1 (DGAT1). As found in 
a previous study (102), ERO1-like, a protein involved in oxidative protein folding, is also 
upregulated. Thus, both the secretory load as well as a transcriptional response for 
endoplasmic reticulum components increase during differentiation.  
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Secretory Proteins Symbol FC 
Adipocyte, C1Q and collagen domain containing Acdc 205.43 
Adipsin Adn 120.26 
Apolipoprotein C-1 Apoc1 34.45 
Resistin Retn 21.95 
Haptoglobin Hp 18.43 
Carboxylesterase 3 Ces3 16.83 
Angiotensinogen Agt 10.31 
Vascular endothelial growth factor A Vegfa 7.89 
Orosomucoid 1 Orm1 7.87 
Retinoic acid receptor responder (tazarotene induced) 2 Rarres2 6.45 
Growth hormone releasing hormone Ghrh 3.56 
ER Resident Proteins Symbol FC 
Stearoyl-Coenzyme A desaturase 1 Scd1 69.96 
Carboxylesterase 3 Ces3 16.83 
Diacylglycerol O-acyltransferase 1 Dgat1 12.80 
Expressed sequence AU018778 AU018778 8.03 
ERO1-like (S. cerevisiae) Ero1l 4.43 
Longevity assurance homolog 4 (S. cerevisiae) Lass4 4.19 
P450 (cytochrome) oxidoreductase Por 3.37 
 
Table 2.1: mRNA expression during 3T3-L1 differentiation. 
 
Databases containing mRNA expression of 3T3-L1 pre-adipocytes and adipocytes were 
generated and analyzed as previously described (102,149). Genes annotated as being 
either extracellular or as residing in the endoplasmic reticulum, and showing a minimum 
of a 3-fold increase during differentiation are listed. The expression levels are an average 
of three independent experiments (p< 0.05). Full gene expression profiles can be obtained 
through www.diabetesgenome.org 
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 The kinetics of induction of these mRNAs during differentiation were then 
analyzed. The most pronounced increase in mRNA for most secreted proteins, including 
adiponectin, adipsin, and resistin, occurred between day 2 and day 4 of differentiation 
(Figure 2.2A). Interestingly, the mRNA for XBP1 began to increase between day 0 and 
day 2, prior to the induction of the secreted proteins, and continued to increase through 
day 4. The active form of XBP1 (sXBP1) is the translation product of an mRNA spliced 
by IRE1, an ER-resident endoribonuclease (43,150). To determine whether increased 
levels of sXBP1 protein parallel the changes in XBP1 mRNA, total extracts of 3T3-L1 
cells obtained during differentiation were analyzed by western blotting (Figure 2.2B). An 
increase in sXBP1 protein was detected at day 2 of differentiation, and this increased to 
maximum level at day 3, after which it decreased moderately and remained present 
throughout differentiation (Figure 2.2B). In this regard, adipocyte differentiation is 
similar to differentiation of B cells into plasma cells, where XBP1 is induced prior to the 
increase in expression of IgM transcripts (143). 
To determine whether downstream targets of XBP1s were induced, we analyzed 
the levels of BiP, a protein chaperone, and ERO1α after the induction of differentiation. 
The levels of both proteins increased during differentiation (compare day 0 and day 2), 
reaching a maximum at day 5 (Figure 2.2B). Notably, increases in both the mRNA and 
protein of XBP1, as well as BiP and ERO1α protein levels, precede the secretion of 
adiponectin that is elicited during 3T3-L1 cell differentiation.  
Together with other forms of cellular stress, ER stress is associated with the 
activation of the transcription factor CHOP/GADD153, a member of the C/EBP family 
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(151). CHOP is induced at least in part through the actions of ATF4 (59), and can 
heterodimerize with other members of the C/EBP family, enhancing or repressing their 
ability to act upon specific promoters (68). In 3T3-L1 cells, CHOP has been reported to 
be induced early in differentiation, and to act to suppress the action of C/EBPα (67). 
CHOP mRNA also becomes elevated later in differentiation, to an extent influenced by 
glucose availability (152,153). Western blotting with antibody to CHOP (Figure 2.2B) 
revealed a detectable increase in CHOP protein levels as cells reach post-confluency (day 
–2 to day 0). This is followed by a decrease in CHOP protein levels at early stages of 
differentiation (day 0 to day 2). CHOP levels then gradually increased through day 7. 
These results confirm those reported by others (67,152,153), and are consistent with the 
induction of the UPR during adipogenesis. 
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Figure 2.2: UPR induction during 3T3-L1 differentiation. 
 A. RNA was isolated from 3T3-L1 cells at days 0, 2, 4, and 6 during differentiation. 
Databases containing this mRNA expression data were generated and analyzed as 
previously described (102,149). The expression levels of secretory proteins, Adiponectin 
(Acdc), Adipsin (Adn), and Resistin (Retn), and the UPR marker XBP1 (Xbp1) are 
shown. The expression levels are an average of three independent experiments (p< 0.05). 
Full gene expression profiles can be obtained through www.diabetesgenome.org B. 3T3-
L1 cells were at full confluence (day –2), just prior to addition of hormonal cocktail (day 
0), and at indicated days of differentiation thereafter. Cell extracts were analyzed by 
western blotting with antibodies to the proteins indicated. Blots are representative of 
three independent experiments.  
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XBP1 has been shown to be required for expression and folding of IgM in plasma 
cells (154). To determine the functional role of XBP1 in adipocyte differentiation and 
function, XBP1 was depleted during the early stages of 3T3-L1 adipocyte differentiation. 
When cells were exposed to an interfering RNA oligonucleotide directed to XBP1 at day 
2 of differentiation, the mRNA levels of XBP1 and spliced XBP1 measured at day 5 were 
decreased to approximately 20% and 40% respectively (Figure 2.3A) and the protein was 
decreased about 50% (Figure 2.3B), compared to scrambled levels. To determine the 
effect of XBP1 depletion on adipocyte differentiation, lipid accumulation was examined. 
XBP1 depletion by siRNA had no effect on lipid accumulation based upon either visual 
examination of lipid droplets stained with Oil Red O (Figure 2.3C) or quantification of 
Oil Red O staining (Figure 2.3D). As an additional functional parameter of adipogenesis, 
we analyzed insulin stimulated glucose uptake, which depends on the appropriate 
expression of the insulin-signaling pathway as well as trafficking elements specific to the 
adipocyte (155). Although basal glucose uptake was decreased in response to XBP1 
depletion, insulin produced a robust stimulation of glucose uptake in XBP1 depleted cells 
(Figure 2.3E). Thus, XBP1 depletion did not affect the development of lipid 
accumulation and insulin responsiveness, two key parameters of adipocyte 
differentiation.  
 
 
 
 
  
47 
 
Figure 2.3: Effect of siRNA to XBP1 on mRNA expression. 
3T3-L1 cells were transfected by electroporation at day 2 of differentiation with either 
non-targeting scrambled (Scr) siRNA or siRNA targeting XBP1. Experiments were 
performed 72 hours later. A. The degree of knockdown was determined for mRNA 
expression by qRT-PCR. B. The degree of knockdown was determined for protein 
expression by western blot. C. Representative fields of Oil Red O stained cells. D. 
Quantification of Oil Red O staining by absorbance in a multimode plate reader. E. 
Glucose uptake expressed as a function of basal glucose uptake in cells treated with Scr 
siRNA. * indicates p<0.05 by paired two-tailed Student t-test. All values are means of a 
minimum of three independent experiments.  
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To further investigate any effects that XBP1 depletion had on the differentiating 
adipocyte, we examined the expression of several proteins involved in ER function or the 
UPR, including BiP and ERO1α, as well as transmembrane and secreted proteins that 
need to be processed by the ER, including adiponectin, glucose transporter 4 (GLUT4), 
and glucose transporter 1 (GLUT1), in addition to perilipin, mitochondrial HSP60, and β-
actin by western blot analysis. There was no apparent change in the expression levels of 
these proteins upon XBP1 depletion (Figure 2.4A). These results show the specificity of 
the silencing oligonucleotides to the XBP1 mRNA, and also indicate that the diminished 
level of XBP1 mRNA does not have a generalized effect on ER or mitochondrial 
chaperones (BiP, ERO1α, mHSP60) nor on adipocyte-specific protein expression 
(GLUT4 and perilipin). 
To test the hypothesis that the UPR is required to meet the increased demand in 
secretory capacity during differentiation, the effect of disruption of XBP1 expression on 
adiponectin secretion was analyzed. The rate of adiponectin accumulation in the media of 
cells exposed to either Scr or XBP1-directed siRNA was measured by western blot 
(Figure 2.4B). A 35% decrease in adiponectin secretion was measured in cells depleted of 
XBP1 (Figure 2.4C). Adiponectin forms trimers stabilized by disulfide bonds that can 
then form larger complexes of up to 16-18 peptides (8,9). These higher molecular weight 
complexes are secreted by adipocytes into the circulation. Since all oligomeric forms of 
adiponectin are decreased to the same extent, XBP1 depletion does not seem to 
preferentially affect the more complex oligomers (data not shown). This decrease was 
also not due to a generalized decrease in secretory function, as total 35S-methionine 
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labeled proteins detected in the media were not significantly decreased by XBP1 
depletion (data not shown). Thus, the induction of XBP1 during adipocyte differentiation 
appears to be mostly required for the adaptation of this cell for secretion of adiponectin. 
In this regard, XBP1 function in adipocytes is similar to that seen in B cells, where it 
promotes the synthesis, maturation, and secretion of IgM heavy chains, but not other 
secretory proteins, such as class I and class II MHC, and Ig light chains (154).  
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Figure 2.4: Effect of siRNA to XBP1 on adiponectin secretion. 
3T3-L1 cells were transfected by electroporation at day 2 of differentiation with either 
non-targeting scrambled (Scr) siRNA or siRNA targeting XBP1. Experiments were 
performed at day 5 of differentiation. A. Cell extracts were analyzed by western blotting 
with antibodies to the proteins indicated. B. Media was replaced and samples of the 
media were taken at times indicated and analyzed by western blotting with anti-
adiponectin antibodies. C. Quantification of the western blot analyses shown in B by 
densitometry. * indicates p<0.05 by paired two-tailed Student t-test. Blots are 
representative of 3 independent experiments, values are the means of three independent 
experiments. 
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 As described earlier, mitochondrial biogenesis occurs in parallel with increased 
protein secretion and the upregulation of the UPR during 3T3-L1 differentiation. We 
decided to test whether this increase in mitochondrial mass and function was necessary 
for the enhanced secretory capacity of the cell. We have previously shown that siRNA-
mediated depletion of Tfam, a nuclear-encoded transcription factor for mitochondrial 
DNA, does not impair the increase in mitochondrial mass seen during adipocyte 
differentiation, but does lead to impaired respiratory chain function (145). This 
impairment is due to reduced transcription of the respiratory chain subunits encoded by 
mitochondrial DNA. We used this model system of reduced mitochondrial function to 
closely examine UPR function and protein secretion. siRNA targeted depletion led to a 
decrease in Tfam mRNA expression and mtDNA content by 60% and 40% respectively 
(Figure 2.5A and B). This caused a decrease in oxygen consumption and ATP levels 
similar to what was published previously (data not shown and (145)). The depletion in 
Tfam did not alter lipid accumulation indicating that differentiation proceeded normally 
(Figure 2.5C). Additionally, there was no obvious change in mitochondrial structure as 
assessed by HSP60 immunostaining (Figure 2.5D). These data confirm what was seen 
previously, that Tfam depletion does not affect general adipocyte function or 
mitochondrial mass.  
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Figure 2.5: Tfam depletion does not inhibit induction of UPR. 
Cells were transfected with scrambled (Scr) or Tfam targeting (Tfam) siRNA at day 2 of 
differentiation. Experiments were performed on day 5 of differentiation. A. Level of 
Tfam mRNA determined by qRT-PCR. B. Level of mtDNA copy number. C. Lipid 
accumulation based upon Oil Red O staining (red) with Hoeschst stained nuclei (blue). D. 
Mitochondrial morphology determined by HSP60 immunostaining (red) with Hoeschst 
stained nuclei (blue). * indicates p<0.05 by paired two-tailed Student t-test. Images are 
representative of 3 independent experiments. Values are the means of a minimum of three 
independent experiments. 
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We then examined the effect Tfam depletion has on the UPR. We first examined 
the structure of the ER based upon immunocytochemistry with an anti-calreticulin 
antibody and found no obvious differences between scrambled and Tfam-directed siRNA 
treated cells (Figure 2.6A). Next we analyzed the effect of Tfam depletion on the 
expression of several UPR markers. The decrease in Tfam expression did not impair 
basal sXBP1 mRNA levels, nor the basal mRNA levels of the UPR sensors, PERK, 
ATF6, and IRE1α (Figure 2.6B). Analysis of proteins involved in the control of post-
translational processing in the ER revealed a decrease in mRNA levels for ERO1α, which 
re-oxidizes protein disulfide isomerase to support disulfide bond formation (156). ERO1α 
levels are sensitive to oxygen tension (157), suggesting that its decrease may reflect 
alterations in the redox state caused by impairment in the respiratory chain function of 
Tfam depleted cells. Similar to the affects seen on mRNA expression, Tfam depletion did 
not have a significant effect on protein levels of two key markers of the UPR, sXBP1 and 
BiP (Figure 2.6C). Taken together these data indicate that decreased respiratory chain 
function through Tfam depletion does not significantly impair the induction of the UPR 
induced by differentiation in 3T3-L1 cells. 
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Figure 2.6: Basal UPR upon Tfam depletion. 
Cells were transfected with scrambled (Scr) or Tfam targeting (Tfam) siRNA at day 2 of 
differentiation. Experiments were performed on day 5 of differentiation. A. ER 
morphology determined by calreticulin immunostaining (green) with Hoeschst stained 
nuclei (blue). B. Fold change of mRNAs for specific UPR proteins determined by qRT-
PCR upon depletion of Tfam relative to scrambled. C. Protein levels for UPR markers by 
western blotting. * indicates p<0.05 by paired two-tailed Student t-test. Images and blots 
are representative of 3 independent experiments. Values are the means of a minimum of 
three independent experiments. 
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 To determine whether impaired respiratory chain function would affect the 
induction of the UPR by increased misfolded protein load in fully differentiated cells, we 
examined the effects of tunicamycin, which blocks N-linked glycosylation causing the 
accumulation of unfolded proteins. IRE1 activation was monitored through the splicing 
of XBP1 mRNA. Tfam depletion had no effect on the integrated magnitude of 
tunicamycin-induced XBP1 splicing over a 24-hour period (Figure 2.7A). The induction 
of BiP mRNA was used as a marker to assess the regulation of UPR chaperones. Again, 
there was no effect on the tunicamycin-induced increase in BiP mRNA upon Tfam 
depletion (Figure 2.7B). These experiments suggest that respiratory chain activity and 
oxidative phosphorylation are not rate limiting for UPR induction in response to 
enhanced secretory load in 3T3-L1 adipocytes. These results are also consistent with 
previous reports of a lack of requirement for electron transport for BiP induction in 
response to thapsigargin-induced ER stress (158). 
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Figure 2.7: Tfam depletion does not inhibit induction of UPR. 
Cells were transfected with scrambled (Scr) or Tfam targeting (Tfam) siRNA at day 2 of 
differentiation. Experiments were performed on day 5 of differentiation. A. Time course 
of IRE1 activation by tunicamycin, measured by qRT-PCR of spliced XBP1 (sXBP1). B. 
Time course of BiP accumulation upon tunicamycin treatment determined by qRT-PCR 
of BiP mRNA. All values shown are means of a minimum of three independent 
experiments. 
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 These results raise the question of the mechanisms by which nucleotides can exert 
such profound effects on endoplasmic reticulum function in previous studies. To better 
understand the relationship between energy levels and UPR function, we acutely 
manipulated ATP levels using FCCP or oligomycin, which impair oxidative 
phosphorylation by dissipating the proton gradient or by directly inhibiting the 
mitochondrial ATP synthase respectively. As was expected, FCCP increases oxygen 
consumption in 3T3-L1 adipocytes to the maximum respiratory capacity while 
oligomycin induces an almost complete block in cellular respiration (Figure 2.8A). At 
these concentrations, incubation with oligomycin and FCCP induced only a partial 
decrease in ATP levels, 25% and 50% respectively (Figure 2.8B), comparable to the 
approximate 50% decrease in ATP synthesis seen in Tfam depleted cells (145). Therefore 
these inhibitors are affecting mitochondrial oxidative respiration and ATP synthesis as 
expected. To assess these manipulations on the UPR, we examined IRE1 activation. 
Treatment with the mitochondrial inhibitors induced a 2-fold increase in XBP1 splicing 
(Figure 2.8C), similar to previously published accounts (128). Previously, Koh et al. have 
shown that incubation with CCCP, another mitochondrial uncoupler, or oligomycin 
causes impairment of adiponectin secretion (128), and here we confirm the effect of 
oligomycin and find that FCCP also has a similar effect (Figure 2.8D). In addition, DNP, 
another uncoupler of the proton gradient, can impair adiponectin secretion in a dose 
dependant manner (Figure 2.8E). Therefore, acute manipulation of mitochondrial driven 
ATP synthesis can affect ER function and secretion. 
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Figure 2.8: Chemical inhibitors of oxidative phosphorylation affect ER function. 
A. 3T3-L1 adipocytes at day 7 of differentiation were exposed to oligomycin (Olig) or 
FCCP and O2 consumption was measured. B. Cells were exposed to oligomycin (Olig) or 
FCCP for 2-4 hours and ATP levels in whole cell extracts was measured. Values are 
expressed as a function of the value in untreated cells (Con). C. Fold change of spliced 
XBP1 (sXBP1) mRNA levels was measured by qRT-PCR for 3T3-L1 adipocytes at day 7 
of differentiation treated with oligomycin (Olig) or FCCP for 2-4 hours compared to 
untreated (Con). D. Adiponectin secretion from cells treated with oligomycin (Olig) or 
FCCP as indicated. E. Adiponectin secretion from cells treated with DNP as indicated. * 
indicates p<0.05 by paired 2-tailed Student t-test. All values shown are means of a 
minimum of three independent experiments. 
  
59 
 To further test how impaired mitochondrial function would affect the UPR upon 
increased protein load, we treated 3T3-L1 cells with tunicamycin. Upon tunicamycin 
treatment, sXBP1 mRNA increases approximately 6 fold, however oligomycin and FCCP 
almost completely blocked this induction (Figure 2.9A). Interestingly, incubation with 2-
deoxyglucose (2DG), an inhibitor of glycolysis, had no effect on sXBP1 induction and 
actually trended higher than cells treated with tunicamycin alone (Figure 2.9A). To 
further examine the kinetics of this blockage, we treated cells with tunicamycin either in 
the presence of oligomycin at the beginning of treatment or with it added 5.5 hours after 
tunicamycin treatment began. As expected, tunicamycin-induced XBP1 splicing was 
completely blocked by oligomycin (Figure 2.9B). Moreover, addition of oligomycin to 
cells following tunicamycin treatment rapidly stops ongoing XBP1 splicing activity 
(Figure 2.9B). These results indicate that mitochondrial ATP production is critically 
required for the induction and maintenance of the UPR in response to an increased 
misfolded protein load.  
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Figure 2.9: IRE1 activation is highly sensitive to ATP levels. 
A. Fold change of tunicamycin induced spliced XBP1 (sXBP1) mRNA levels was 
measured by qRT-PCR for 3T3-L1 adipocytes at day 7 of differentiation treated with 
oligomycin (Olig), FCCP, or 2-deoxyglucose (2DG) for 2-4 hours compared to untreated 
(Con). B. Cells were treated with tunicamycin for times indicated. Some were treated 
with oligomycin (Olig) present from the start (t=0 hr) or added after 5.5 hours of 
incubation. Spliced XBP1 (sXBP1) was then measured by qRT-PCR at the times 
indicated. Values are expressed as a function of untreated levels. * indicates p< 0.05 by 
paired 2-tailed Student t-test. All values shown are means of a minimum of three 
independent experiments. 
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Conclusions 
 
In summary, we find that expansion of the ER through activation of the UPR 
pathway occurs during adipocyte differentiation, and is required for proper secretory 
function. A previous study found that the chemical chaperone 4-phenylbutyrate (4-PBA) 
inhibits both the activation of the UPR and differentiation in the 3T3-L1 cell line (127). 
We find that adipogenesis proceeds normally upon XBP1 knockdown, though secretory 
function is affected. This discrepancy could be due to the fact that XBP1 knockdown 
results in only a partial decrease in protein levels, or the other branches of the UPR may 
be promoting adipogenesis. Since the adequate secretion of adipokines is crucial in the 
control of whole body metabolism, defects in the adipocyte UPR, specifically in the 
IRE1/XBP1 pathway, could lead to alterations in energy utilization and whole body 
energy metabolism. Indeed, the requirement for the UPR in the control of whole body 
energy metabolism is evident in mice lacking the protein kinase PERK or harboring a 
replacement of eIF2α with a non-phosphorylatable mutant. This disruption of the 
translation control branch of the UPR results in neonatal or perinatal lethality due to 
disruption of carbohydrate metabolism (54,159). While defects in hepatic 
gluconeogenesis and β cell insulin production are the precipitating causes of death, the 
adipocyte UPR may also be involved in the failure to fulfill the organism’s metabolic 
needs under these conditions.  
 While it appears evident that the UPR plays a role in regulating the metabolic 
needs of an organism, we asked whether the metabolic status could also regulate the UPR 
on a cellular level. Protein synthesis and folding put an energetic strain on the cell due to 
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their requirement of approximately 15-20% of the total cellular ATP (160,161). In 
addition, UPR activity is sensitive to ATP levels since adenine nucleotides are able to 
activate IRE1 through induction of a conformational change promoted by trans-
autophosphorylation (25,28). Once properly folded, exiting the ER is also a nucleotide 
dependant step; ATP is required for the release of BiP from the folded proteins (162). 
Taken together, it appears that changes in adenine nucleotide levels could have a severe 
impact on ER function and protein folding on several levels.  
 To address the metabolic regulation of UPR induction we used two approaches in 
the 3T3-L1 cell line: 1) constitutive reduction of mitochondrial respiratory chain function 
through Tfam depletion during differentiation 2) acute inhibition of oxidative 
phosphorylation by chemical compounds. Impaired ATP production through Tfam 
depletion does not appear to affect basal expression of UPR markers or tunicamycin 
induced UPR activity. Therefore, there may be a mechanism compensating for this 
chronic state of diminished ATP. However, the acute depletion of ATP by chemical 
inhibitors of oxidative phosphorylation appears to be either too severe or occurs too 
quickly for compensation and therefore we see the dramatic effects on induction of the 
UPR. These combined results indicate that while there is a metabolic regulation of UPR 
function, it does not appear to simply be the cell’s total ATP levels. Moreover, there may 
be pools of nucleotides available for ER function and oxidative phosphorylation may not 
be the only metabolic pathway involved in their synthesis. Deficiencies in protein folding 
and impaired UPR have been shown to lead to apoptosis and multiple human pathologies, 
including neurodegeneration and metabolic disorders. Therefore, further understanding of 
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the regulation of the UPR by ATP and mitochondrial function as well as any mechanism 
by which the cell compensates for impaired mitochondrial function may be beneficial in 
treating these diseases. 
 
Experimental Procedures 
 
Primary Antibodies: Anti-ACRP30/adiponectin (Affinity Bioreagents, Inc.), anti-BiP 
(Transduction Laboratories), Anti-cytochrome C (BD Pharmingen), anti-CHOP (Santa 
Cruz), anti-calreticulin (Calbiochem), anti-GLUT1 (Abcam), anti-GLUT4 (Santa Cruz), 
anti-HSP60 (Assay Designs), anti-Perilipin (Fitzgerald Industries) and anti-mouse IgM 
(µ-chain specific) and anti-β-actin (Sigma). Anti-ERO1-Lα and XBP1 was kindly 
provided by Dr. Fumihiko Urano. 
 
Cell Culture: All cells were obtained from American Type Culture Collection and grown 
under 10% CO2. 3T3-L1 cells were cultured in complete media defined as: Dulbecco 
modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 
U of penicillin/mL, 100 µg of streptomycin/mL, and 50 µg of Normocin/mL 
(InvivoGen), which was replaced every 48 hours unless otherwise stated. 3T3-L1 cells 
were grown on 150 mm dishes. For differentiation, three days after reaching confluence 
(day 0) media was replaced with complete media containing 0.5 mM 3-isobutyl-1-
methylxanthine (Sigma), 0.25 µM dexamethasone (Sigma), and 1 µM insulin (Sigma). 72 
hours later, media was replaced with complete media.  
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Chemical Treatments: Cells were treated with 6 µM tunicamycin, 10 µg/mL oligomycin, 
or 5 µM FCCP for times indicated.  
 
XBP1 siRNA Transfection: siRNA for XBP1 was purchased from Dharmacon in a duplex 
form (sense sequence is 5'-GCUGGAAGCCAUUAAUGAAUU-3'). 3T3-L1 cells were 
grown and differentiated as described above. On day 2, medium was collected and cells 
were lifted with 1x trypsin with 1% collagenase and transfected with either 20 nmol 
XBP1 or scrambled siRNA into approximately 107 cells by electroporation. Cells were 
resuspended in the collected day 2 medium and re-plated; 24 hours later, the 
differentiation medium was replaced by complete medium. Experiments were performed 
72 hours post-transfection. 
 
Tfam siRNA Transfection: siRNA oligos against mouse Tfam mRNA was purchased 
from Dharmacon in a duplex form with 3'-dTdT protective overhangs (sense sequence is 
5'-GAAUGUGGAUCGUGCUAAAdTdT-3'). 3T3-L1 cells were grown and 
differentiated as described above. On day 2, medium was collected and cells were lifted 
with 1x trypsin with 1% collagenase and transfected with either 5 nmol Tfam or 
scrambled siRNA into approximately 107 cells by electroporation. Cells were 
resuspended in the collected day 2 medium and re-plated; 24 hours later, the 
differentiation medium was replaced by complete medium. Experiments were performed 
72 hours post-transfection. 
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Quantitative RT-PCR: Total RNA was extracted by using TRIzol reagent (Invitrogen). 
For quantitative mRNA analysis, 2 µg of the total RNA was reverse-transcribed by using 
an iScript complementary DNA (cDNA) Synthesis kit (Bio-Rad). Ten percent of each RT 
reaction was subjected to quantitative real-time PCR analysis using an iQ SYBR green 
supermix kit and Real-Time PCR detection system following the manufacturer’s 
instructions (MyiQ, Bio-Rad). Ferritin heavy chain (Fth) or β-actin was used as an 
internal housekeeping gene. Relative gene expression was calculated by the 2-ΔΔCT method 
(163). Briefly the threshold cycle number (Ct) of the target genes was subtracted from the 
Ct value of Fth or β-actin and raised 2 to the power of this difference.  
 
Mitochondrial DNA Measurement: Total DNA was extracted by DNeasy® tissue kit. 
Primer pairs corresponding to Nd1 (mitochondrial) and or β-actin (nuclear) were used to 
amplify a mitochondrial and nuclear DNA fragment, respectively. The 2-ΔΔCT method was 
used to analyze the relative mtDNA level. 
 
Affymetrix Gene Chip Analysis: Analysis was performed as previously described 
(102,149). Total RNA was prepared from three sets each of 3T3-L1 cells at day of 
differentiation indicated. Poly(A)+ mRNA was isolated from each set of total RNA by 
using an Oligotex mRNA kit (Qiagen) according to the manufacturer's instructions. 
Double-stranded cDNA synthesis was reverse transcribed from 5 µg of isolated mRNA 
by using the SuperScript choice system (Invitrogen) according to the manufacturer's 
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protocol in addition to using an oligo(dT) primer containing a T7 RNA polymerase 
promoter site. Biotin-labeled complementary RNA (cRNA) was transcribed by using a 
BioArray RNA transcript labeling kit (Enzo). Fragmented cRNA was hybridized to the 
murine genome U74 array (MG-U74A, MG-U74B, and MG-U74C) per Affymetrix 
protocols. The GeneChips were washed with a GeneChip Fluidics Station 400 and were 
scanned with an HP GeneArrayScanner (Affymetrix). Raw expression data was analyzed 
with the Bioconductor statistical environment (164) using RMA (165) and MAS5, a 
Bioconductor implementation of the MAS 5.0 algorithm (Affymetrix). The “fold change” 
for each gene was determined by dividing the mean of the average difference from three 
independent experiments. 
 
Immunoblot Analysis: Cell monolayers were washed twice with ice-cold phosphate-
buffered saline (PBS) and scraped into 1% sodium dodecyl sulfate (SDS) in PBS. Protein 
concentration was determined by a bicinchoninic acid (BCA) protein assay (Pierce), and 
equal amounts of protein were separated by SDS-polyacrylamide gel electrophoresis 
(PAGE) and transferred to nitrocellulose. Samples of the cell culture medium were taken 
just prior to media replacement every 24 hours, or as indicated in figure legends, spun 5 
minutes at 500xg, and equal volumes were separated by SDS-PAGE and transferred to 
nitrocellulose. The membranes were blocked with 5% nonfat-milk in Tris-buffered saline 
with 0.1% Tween and incubated with primary antibodies overnight. They were then 
incubated with anti-rabbit or anti-mouse IgG horseradish peroxidase conjugated 
antibodies (Promega) and detected using enhanced chemiluminescence (Perkin Elmer 
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Life Sciences, Inc.). Films were scanned at 300 dpi, and band intensities were quantified 
by using Photoshop software as follows. Images were inverted to render the bands white; 
bands were next selected by using the rectangular marquee tool and then delineated by 
using the color range tool until the whole band was selected. The histogram function was 
used to determine the number of pixels in the selection, which was multiplied by the 
average pixel intensity. 
 
ATP Assay: Cells were plated into a 96 well opaque plate and treated as indicated. ATP 
concentration was determined using the CellTiter-Glo luminescent assay (Promega) 
according to manufacturer’s instructions. Luminescence was read using a Tecan Safire2 
multimode microplate spectrophotometer. 
 
Brightfield Imaging: All images were obtained using a conventional wide-field 
microscope fitted with a 60x Nikon PlanApo objective.  
 
Oil Red O Staining and Quantification: Cells were washed twice in 1x PBS and fixed in 
4% formaldehyde for one hour. Cells were washed in dH2O three times before being 
stained with 5 mg/mL Oil Red O in 60% triethyl-phosphate for 30 minutes. Cells were 
washed in dH2O six times before proceeding with analysis. All images were obtained 
using a conventional wide-field microscope fitted with a 60x Nikon PlanApo objective. 
Oil Red O staining was quantified using a Tecan Safire2 multimode plate reader. Cells 
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stained with Oil Red O were read at an excitation wavelength of 530 nm and an emission 
wavelength of 580 nm. 
 
Fluorescent Imaging: Cells were seeded on coverslips, fixed in 4% formaldehyde for 15 
minutes at room temperature, permeabilized with 0.5% Triton X-100 plus 1% FBS in 
1xPBS, and stained with primary antibodies overnight at 4°C. Alexa Fluor® 488 or 594 
donkey anti-mouse or rabbit secondary antibodies were used to detect bound primary 
antibody. For staining of nuclei, cells were incubated with 1 µg/mL Hoechst 33258 
pentahydrate (bis-benzimide) for 10 minutes. All images were obtained using a 
conventional wide-field microscope fitted with a 100x Nikon PlanApo objective.  
 
2-Deoxyglucose Uptake Assay: Cells were plated in a 24-well dish. Cells were starved for 
2 hours in Krebs-Ringer HEPES (KRH) buffer (130 mM NaCl, 5 mM KCl, 1.3 mM 
CaCl2, 1.3 mM MgSO4, and 25 mM HEPES, pH 7.4) supplemented with 2 mM sodium 
pyruvate and 1% bovine serum albumin (BSA) prior to a 30 minute stimulation with 100 
nm insulin. Uptake was initiated by the addition of [3H]2-deoxy-D-glucose to a final 
assay concentration of 100 µM for 5 minutes at 37°C. Assays were terminated by three 
washes with ice-cold 1xPBS, and the cells were solubilized with 0.4 mL of 1% Triton X-
100, and 3H content was determined by scintillation counting. Nonspecific deoxyglucose 
uptake was measured in the presence of 20 µM cytochalasin B and subtracted from each 
sample to obtain specific uptake. 
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Oxygen Consumption: Cells were trypsinized and resuspended in KRH buffer 
supplemented with 1% fatty acid free BSA. Approximately 7.5x104 cells in 150 µL of 
KRH buffer were added to wells in a BD Oxygen Biosensor System plate (BD 
Biosciences) in triplicate. Chemical reagents were then added to the cells. Plates were 
sealed and fluorescence intensity was recorded for 120 minutes (2 minute intervals) at an 
excitation wavelength of 485 nm and emission wavelength of 630 nm on a Tecan Safire2 
multimode microplate spectrophotometer maintained at 37°C. 
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CHAPTER III 
 
ADENYLATE KINASE 2 LINKS MITOCHONDRIAL ENERGY 
METABOLISM TO THE INDUCTION OF THE UPR 
  
 
The following data includes unpublished results as well as data taken from: 
Burkart, A., Shi, X., Chouinard, M., and S. Corvera (2010) Adenylate Kinase 2 Links 
Mitochondrial Energy Metabolism to the Induction of the Unfolded Protein Response. 
Submitted. 
 
 
Isolation of mouse tissues was performed by My Chouinard. She also assisted in the 
generation and maintainence of the primary myoblast cultures. I performed the remaining 
experiments contained within this chapter.  
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Summary 
 
 The unfolded protein response (UPR) is a homeostatic signaling mechanism that 
balances the protein folding capacity of the endoplasmic reticulum (ER) with the cell's 
secretory protein load. ER protein folding capacity is dependent on the abundance of 
chaperones, which is increased in response to UPR signaling, and on a sufficient ATP 
supply for their activity. An essential branch of the UPR entails the splicing of XBP1 to 
form the XBP1 transcription factor. XBP1 has been shown to be required during 
adipocyte differentiation, enabling mature adipocytes to secrete adiponectin, and during 
differentiation of B cells into antibody-secreting plasma cells. Here we find that 
adenylate kinase 2 (AK2), a mitochondrial enzyme that regulates adenine nucleotide 
interconversion within the intermembrane space, is markedly induced during adipocyte 
and B cell differentiation. Depletion of AK2 by RNAi impairs adiponectin secretion in 
3T3-L1 adipocytes, IgM secretion in BCL1 cells, and the induction of the UPR during 
differentiation of both cell types. Interestingly, depletion of adenylate kinase 1 (AK1) a 
cytosolic enzyme in the muscle that also regulates nucleotide interconversion does not 
have the same effect upon UPR induction. These results reveal a new mechanism by 
which adenine nucleotides fulfill the energetic requirements for ER function, and suggest 
that specific mitochondrial defects may give rise to impaired UPR signaling. The 
requirement of AK2 for UPR induction may explain the pathogenesis of the profound 
hematopoietic defects of reticular dysgenesis, a disease associated with mutations of the 
AK2 gene in humans. 
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Background 
 
Obesity and its many associated co-morbidities are caused by an imbalance 
between food intake and energy expenditure (166-169). Addressing this problem requires 
an understanding of the mechanisms by which fuel consumption, energy production, and 
energy utilization are coordinated. In cells, energy production in the form of adenine 
nucleotides, ATP and ADP, is tightly coupled with energy utilization for motility or 
anabolic processes (170). Even in cells that have acute high-energy requirements, such as 
skeletal and cardiac myocytes and neurons, ATP synthesis is highly coordinated with 
ATP utilization, such that the steady state levels of ATP remain constant over a wide 
range of workloads. In these cells, carbohydrate or lipid fuels are channeled to oxidative 
phosphorylation in mitochondria, where ATP is primarily synthesized, and this process is 
enhanced dramatically in response to increased ATP utilization.  
Among the important molecular mechanisms by which energy flux is regulated in 
a single cell are enzymatic activities that utilize, are regulated by, or alter the levels of 
adenine nucleotides. For example, an increase in the AMP/ATP ratio ensuing from 
enhanced ATP utilization is sensed by AMP-activated protein kinase (AMPK), which 
then triggers an increase in fuel consumption that facilitates the restoration of 
homeostatic ATP levels (171-175). In addition, AMPK activation results in decreased 
energy expenditure by minimizing the activity of many anabolic pathways.  
An enzyme that influences adenine nucleotide levels is adenylate kinase (AK), 
which catalyzes the reversible phosphoryl transfer reaction AMP + ATP ⇔ 2ADP. The 
adenylate kinases are an ancient family of proteins (EC. 2.7.4.3), present from bacteria to 
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humans. A single isoform of adenylate kinase is present in bacteria and lower eukaryotes 
and is essential for life (108-110). AK has been thought to provide the principal 
homeostatic mechanism to maintain adenine nucleotide ratios under different conditions 
of ATP production and utilization. It has also been proposed that AK provides a 
mechanism to channel the high energy phosphate of ATP from sites of ATP production to 
sites of utilization through the operation of phosphotransfer networks (111). The human 
genome encodes for 9 genes bearing similarity to AK that differ in cellular and 
subcellular distribution.  
AK1 is localized to the cytosol and is found in skeletal muscle, brain, and 
erythrocytes (112,113). In skeletal muscle over 95% of the total adenylate kinase activity 
corresponds to AK1 (115). Given the importance of AK activity in prokaryotes, and the 
fact that AK1 is by far the predominant AK activity in muscle, it was rather surprising 
that mice lacking AK1 are ostensibly normal, capable of exerting enhanced contractile 
force, highly tolerant to fatigue, and able to maintain normal steady-state levels of ATP 
(114,115,117). These results suggest that compensatory mechanisms are elicited in these 
mice to adapt to the lack of this enzyme. Interestingly, muscles from AK1-/- mice had a 
higher rate of ATP synthesis in response to contraction, indicating more ATP had to be 
produced to maintain normal contractility. This suggests that the efficiency of ATP use 
was lower in AK1-/- mice compared to controls (114,115). These results are consistent 
with a proposed role of adenylate kinase for improving the efficiency of ATP utilization 
in cells through the operation of phosphotransfer networks (111), or other yet unknown 
mechanisms. 
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AK2 has not been as well characterized as AK1. Human AK2 is found in the 
mitochondrial intermembrane space of liver, kidney, spleen, and heart (112). There are 
two isoforms, AK2A and AK2B, of identical amino acid sequences except for at the C-
terminal region (113,119). Interestingly, there is large discrepancy between the 
expression of the mRNA and of the protein of AK2, indicating a significant post-
transcriptional regulation (120). AK2 has been shown to be required for Drosophila 
development (124). Recently, mutations in AK2 have been identified as the basis for a 
profound failure of lymphopoiesis in humans (125,126). 
We have previously reported that differentiation of 3T3-L1 preadipocytes is 
accompanied by a robust increase in mitochondrial biogenesis (102), which coincides 
with the initiation of adiponectin secretion. Additionally, it has been shown that the UPR 
is upregulated during 3T3-L1 adipocyte differentiation (127). These findings suggest the 
possibility that these two events are functionally linked, with mitochondrial function 
being required for UPR induction and to sustain adiponectin secretion in differentiated 
adipocytes. As we have shown in the previous chapter, mitochondrial oxidative 
phosphorylation is able to partially regulate induction of the UPR, however it appears that 
there could be other compensatory mechanisms as well. 
Here we report that in addition to a general increase in mitochondrial mass and 
oxidative phosphorylation (102), adipocyte differentiation is associated with a striking 
increase in the levels of AK2. In its role in regulating the interconversion of adenine 
nucleotides, it has the ability to compensate for impaired oxidative phosphorylation. 
Thus, we investigated the effects of AK2 depletion on the induction of the UPR. We find 
  
75 
that, while optimal oxidative phosphorylation appears unnecessary, AK2 is required for 
the induction of the UPR. To determine whether this was a universal role for AK family 
members, we tested whether a decrease of AK1 would also show the same results. 
Interestingly, although AK1 depletion produced significant metabolic alterations, the 
UPR was relatively unaffected. These results reveal a novel mechanism by which 
mitochondrial energy metabolism and ER homeostasis are linked, which may explain the 
profound hematopoietic defects associated both with UPR deficiency (30) and with 
genetic deficiency of AK2 (125,126). 
 
Results 
 
 Previous reports have shown that human AK2 is expressed in liver, kidney, 
spleen, and heart (112). Here we find that the protein expression in the mouse differs 
from the human studies, as it is highly enriched in white adipose tissue, liver, pancreas, 
and kidney (Figure 3.1A). We find that during 3T3-L1 differentiation, AK2 begins to 
express at around day 4 and continues to increase through day 8 (Figure 3.1B). This 
parallels the mitochondrial biogenesis that is occurring during this time frame, 
exemplified by cytochrome c expression (Figure 3.1B). Based upon 
immunocytochemistry, we find that AK2 is mainly localized in the mitochondria, co-
localizing with MitoTracker® Red staining (Figure 3.1C). While there appears to be AK2 
staining in the nucleus, it is unclear if it is physiologically relevant or a non-specific 
artifact of the staining.  
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Figure 3.1: AK2 expression in mouse tissues and 3T3-L1 adipocytes. 
A. Western blotting of mouse tissues with an antibody to mouse AK2. W, white adipose 
tissue; M, muscle; L, liver; B, brain; H, heart; P, pancreas; D, diaphragm; Lu, lung; K, 
kidney; Sp, spleen; St, stomach. B. 3T3-L1 cells were harvested just prior to the addition 
of hormonal cocktail (day 0), and at indicated days thereafter. Cell extracts were analyzed 
by western blotting with antibodies to the proteins indicated. C. Localization of AK2 by 
immunostaining (green) and mitochondria by MitoTracker® Red staining (red). Co-
localized areas are shown in yellow in the bottom panel. Data shown are representative of 
a minimum of three independent experiments. 
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To analyze the function of AK2 in 3T3-L1 adipocytes, AK2-directed RNAi 
oligonucleotides were introduced at day 2 of differentiation, to match the experimental 
conditions used in the analysis of Tfam in the previous chapter. At day 5 of 
differentiation, AK2 mRNA levels were decreased by 90%, and protein levels by an 
average of 60% (Figure 3.2A and B). This depletion of AK2 had no apparent effect on 
differentiation as estimated by lipid accumulation (Figure 3.2C). We also measured the 
mRNA levels of proteins involved in adipocyte differentiation such as C/EBPα, C/EBPβ, 
C/EBPδ, PPARα, and PPARγ, or reflective of differentiation such as AP2 and GLUT4, 
or secreted by adipocytes, including adiponectin, adipsin, and resistin. There was no 
significant change in many of the mRNAs we examined; however, the mRNA expression 
of GLUT1, which is responsible for basal glucose uptake, and CEBPα did decrease 
(Figure 3.2D). These data indicate that AK2 is not necessary for differentiation of 3T3-
L1 adipocytes. 
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Figure 3.2: Depletion of AK2 does not affect 3T3-L1 differentiation. 
Scrambled (Scr) or AK2 targeting (AK2) siRNA was transfected at day 2 of 
differentiation and experiments were performed at day 5. A. The mRNA change was 
determined by qRT-PCR. B. The change in protein was determined by western blot 
analysis. C. Lipid accumulation was determined by Oil Red O staining (red). Nuclei are 
depicted by Hoescht staining (blue). D. Fold change of mRNAs for adipocyte proteins 
determined by qRT-PCR upon depletion of AK2 relative to scrambled. * indicates 
p<0.05 by paired 2-tailed Student t-test. Data shown are means of a minimum of three 
independent experiments. 
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To further examine the role of AK2 in this model system, we tested whether AK2 
plays a role in maintaining the cell’s metabolic status. AK2 depletion had a measurable 
effect on energy homeostasis, reflected by a slight but significant decrease in basal 
oxygen consumption (Figure 3.3A). In addition, oxygen consumption with either glucose 
or palmitate provided as a substrate was decreased by AK2 depletion (Figure 3.3A). 
Notably, glucose was not able to stimulate oxygen consumption upon AK2 depletion. In 
addition, there was a 20% decrease in lactate levels upon AK2 depletion (Figure 3.3B). 
This may indicate that upon AK2 depletion glucose metabolism is decreased. These 
effects were accompanied by small changes in mRNA levels of a few mitochondrial 
components involved in oxidative phosphorylation and fatty acid β-oxidation, but overall 
the mRNA expression of mitochondrial enzymes was largely unaffected (Figure 3.3C). 
There was no obvious affect of AK2 depletion upon mitochondrial structure as assessed 
by the incorporation of MitoTracker® Red (Figure 3.3D). However, the small effects 
presented here resulted in a decrease in ATP levels of approximately 15%, with no 
significant changes in ADP or AMP (Figure 3.3E). Therefore, while AK2 depletion did 
not affect mitochondrial protein levels or structure, it did slightly alter the metabolic 
state. 
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Figure 3.3: Depletion of AK2 alters the metabolic status of day 5 3T3-L1 cells. 
Scrambled (Scr) or AK2 targeting (AK2) siRNA was transfected at day 2 of 
differentiation and experiments were performed at day 5. A. Rate of oxygen consumption 
expressed as fold change of the control scrambled cells. B. Basal lactate levels expressed 
as fold change of scrambled. C. Fold change of mRNAs for mitochondrial proteins 
determined by qRT-PCR upon depletion of AK2 relative to scrambled. D. Mitochondrial 
morphology by MitoTracker® Red staining. Nuclei are depicted by Hoescht staining 
(blue). E. Level of adenine nucleotides isolated from cell lysates by TCA extraction 
expressed as relative luminescent units (RLU). * indicates p<0.05 between Scr and AK2 
by paired 2-tailed Student t-test. # indicates p<0.05 between control and treated cells by 
paired 2-tailed Student t-test. Data shown are means of a minimum of three independent 
experiments. 
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We then sought to determine whether depletion of AK2 would affect the UPR or 
ER function. There was no noticeable change in calreticulin staining upon AK2 depletion 
indicating that the ER structure was unaffected (Figure 3.4A). We then examined the 
basal levels of key elements of the UPR. Strikingly, the mRNAs for all three ER stress 
sensors, IRE1α, PERK, and ATF6, were decreased by >50%, and total and spliced XBP1 
mRNAs were decreased by 80% in AK2-depleted cells (Figure 3.4B). The transcription 
factor CHOP, which is responsive to sustained UPR signaling, was also significantly 
decreased, and similar to what was observed in Tfam knockdown cells, the levels of 
ERO1α was reduced (Figure 3.4B compare to Figure 2.6B). Unlike the mRNA 
expression, IRE1α protein levels did not change and we were unable to view the 
phosphorylation state in order to determine activation (Figure 3.4C). However, the 
decreased level of spliced XBP1 indicates that IRE1 activity is inhibited. Although BiP 
mRNA did not change significantly, the protein level decreased indicating there is an 
effect on components downstream of XBP1 splicing. In addition, ERO1α protein 
expression was also decreased whereas the calcium binding protein calreticulin was 
unaffected. Despite unaltered levels of adiponectin seen in western blotting of cell 
extracts (Figure 3.4C), AK2 depletion and its concomitant perturbations in 
differentiation-induced UPR signaling correlated with a significant decrease in 
adiponectin secretion (Figure 3.4D). Thus, AK2 depletion during adipocyte 
differentiation leads to impaired induction of the UPR and the development of secretory 
function. 
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Figure 3.4: Depletion of AK2 reduces UPR induction and secretion. 
Scrambled (Scr) or AK2 targeting (AK2) siRNA was transfected at day 2 of 
differentiation and experiments were performed at day 5. A. ER morphology by 
calreticulin immunostaining. Nuclei are depicted by Hoescht staining (blue). B. The 
mRNA change of UPR markers was determined by qRT-PCR. C. The change in protein 
was determined by western blot analysis. D. Culture media was removed at days 4, 5, and 
6 of differentiation as indicated and secretion of adiponectin (Acrp30) over the previous 
24 hours was determined by western blot analysis. A representative blot is shown (top 
panel) as well as the average of all experiments (bottom panel). * indicates p<0.05 by 
paired 2-tailed Student t-test. Data shown are means of a minimum of three independent 
experiments. 
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To determine whether AK2 depletion affects the induction of the UPR in mature 
adipocytes we examined the effects of tunicamycin treatment. Cells at day 5 of 
differentiation, at which mitochondrial biogenesis is already maximal (102,145), were 
transfected with scrambled or AK2-directed oligonucleotides. At day 7, AK2 mRNA and 
protein levels were depleted by > 80% (Figure 3.5A and B). The ability of the adipocyte 
to accumulate and store lipid was unaffected as demonstrated by Oil Red O staining 
(Figure 3.5C). In addition, there was no obvious effect on the structure of the 
endoplasmic reticulum by AK2 depletion based upon calreticulin staining (Figure 3.5D 
top panels). Also, AK2 knockdown did not appear to alter mitochondria structure and 
membrane potential as demonstrated by MitoTracker® Red incorporation (Figure 3.5D 
bottom panels).  
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Figure 3.5: Depletion of AK2 does not affect general adipocyte function. 
Scrambled (Scr) or AK2 targeting (AK2) siRNA was transfected at day 5 of 
differentiation and experiments were performed at day 7. A. The mRNA change was 
determined by qRT-PCR B. The change in protein was determined by western blot 
analysis. C. Lipid accumulation depicted by Oil Red O staining (red). Nuclei are depicted 
by Hoescht staining (blue). D. ER morphology by calreticulin immunostaining (top 
panel) and mitochondrial morphology by MitoTracker® Red staining (bottom panel) * 
indicates p<0.05 by paired 2-tailed Student t-test. Data shown are means of a minimum 
of three independent experiments. 
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We next examined the effect of AK2 depletion on the metabolic status of these 
fully differentiated cells. Insulin sensitivity was unaffected based upon insulin stimulated 
2-deoxyglucose uptake, however basal uptake was increased (Figure 3.6A). There was no 
effect of AK2 depletion on basal lactate production though it did trend down (Figure 
3.7B). Functionally, the mitochondrial showed diminished basal oxygen consumption 
upon AK2 depletion (Figure 3.6C). Additionally, uncoupled respiration as well as 
substrate (glucose and palmitate) stimulated respiration was decreased by siRNA 
knockdown of AK2. Interestingly, similar to the day 2 knockdown cells, glucose did not 
stimulate an increase in respiration in AK2 depleted cells. Though basal glucose uptake is 
increased, it appears that the glycolytic metabolism of AK2 depleted cells is impaired. 
Similar to what was seen upon AK2 depletion early in differentiation, the result of these 
metabolic changes is a decrease in ATP levels (Figure 3.6D). Although ADP was again 
unaffected, the levels of AMP approximately doubled upon AK2 depletion (Figure 3.6D). 
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Figure 3.6: Depletion of AK2 alters the metabolic status of day 7 3T3-L1 cells. 
Scrambled (Scr) or AK2 targeting (AK2) siRNA was transfected at day 5 of 
differentiation and experiments were performed at day 7. A. 2-deoxyglucose uptake assay 
expressed as a percentage of maximal uptake. B. Basal lactate levels expressed as fold 
change of scrambled. C. Rate of oxygen (O2) consumption expressed as fold change of 
the control scrambled cells. D. Level of adenine nucleotides isolated from cell lysates by 
TCA extraction expressed as relative luminescent units (RLU). * indicates p<0.05 
between Scr and AK2 by paired 2-tailed Student t-test. # indicates p<0.05 between 
control and treated cells by paired 2-tailed Student t-test. Data shown are means of a 
minimum of three independent experiments. 
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Next we examined whether AK2 depletion in response to tunicamycin would 
have an effect once the secretory components had been allowed to reach their normal 
levels for mature adipocytes. Upon tunicamycin treatment of day 7 adipocytes, we found 
XBP1 splicing was delayed and reached a lower maximal level in AK2 depleted cells 
(Paired 2-tailed Student t-tests yielded a p = 0.00058, with means of 35.5 and 23.1 times 
basal values (t=0) for Scr and AK2 groups, respectively) (Figure 3.7A). This decrease 
was physiologically relevant, as BiP mRNA and protein accumulation were also 
significantly impaired (p = 0.0029, with means of 5.8 and 3.6 times basal values for Scr 
and AK2 groups, respectively) (Figure 3.7B). CHOP induction, a later, smaller response 
to tunicamycin treatment, was also diminished in AK2 depleted cells, indicating that the 
requirement for AK2 may extend to other branches of the UPR (p = 0.00028, with means 
of 3.4 and 2.2 times basal values for Scr and AK2 groups, respectively) (Figure 3.7C). In 
addition, the ability of the adipocytes to secrete adiponectin was impaired proportional to 
the decrease in AK2 expression (Figure 3.7D). Regression analysis on this data yielded 
an adjusted R2 of 0.326, and a significance of 0.012. These experiments suggest that AK2 
activity is necessary for the induction of the UPR in response to increased secretory 
protein load. 
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Figure 3.7: Depletion of AK2 decreases UPR induction and secretion. 
Scrambled (Scr) or AK2 targeting (AK2) siRNA was transfected at day 5 of 
differentiation and experiments were performed at day 7. A. Time course of tunicamycin 
induced spliced XBP1 (sXBP1) mRNA measured by qRT-PCR. B. Time course of BiP 
accumulation upon tunicamycin (Tuni) treatment measured by western blotting of BiP 
and β-actin (upper panel) and qRT-PCR of BiP mRNA (bottom panel). C. Time course of 
CHOP accumulation upon tunicamycin (Tuni) treatment measured by western blotting 
(upper panel) and qRT-PCR of CHOP mRNA (bottom panel). D. Cell lysates and culture 
media from multiple experiments were analyzed by western blot with antibodies to AK2 
and adiponectin (Acrp30). Band intensities were expressed as the ratio between AK2 and 
Scr and plotted against each other. Regression analysis yielded an adjusted R2 of 0.326, 
and a significance of 0.012. * indicates p<0.05 by paired 2-tailed Student t-test. All 
values shown are means of a minimum of three independent experiments. 
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Splicing of XBP1 has been shown to be required for terminal differentiation of B 
cells into antibody producing plasma cells (30,38). To investigate whether the role of 
AK2 in 3T3-L1 adipocytes could be generalized to other secretory cells, we first 
examined the expression levels of AK2 during B cell differentiation. Western blot 
analysis of extracts from BCL1 cells, a B cell lymphoma line, revealed a marked 
induction of AK2 protein upon LPS-induced differentiation (Figure 3.8A). Thus, like 
3T3-L1 adipocytes, BCL1 differentiation is accompanied by the induction of AK2 
protein. Interestingly, there is minimal change in AK2 mRNA levels suggesting that AK2 
induction may involve post-transcriptional regulation during this period (Figure 3.8B).  
siRNA mediated silencing of AK2 prior to LPS stimulation completely blocked 
AK2 protein (Figure 3.8C), and reduced AK2 mRNA expression to approximately 25% 
of the level of the scrambled cells (Figure 3.8D). This depletion in AK2 did not impair 
differentiation, as assessed by the unchanged levels of BCL6 (Figure 3.8D), nor did it 
result in detectable alterations in mRNA levels of mitochondrial proteins (Figure 3.8E). 
Oxygen consumption upon AK2 depletion was unchanged either under basal conditions 
or upon incubation with substrate (Figure 3.8F). Interestingly, the B cells nucleofected 
with scrambled siRNA responded to glucose with a small but significant increase in 
respiration, which was not seen upon AK2 depletion, while both responded to palmitate. 
There was no effect on lactate production under basal conditions (data not shown). 
Therefore similar to the 3T3-L1 cells, it appears that upon AK2 depletion, B cells have 
altered glucose metabolism. Additionally, depletion of AK2 did result in decreased 
cellular ATP levels, although ADP and AMP levels were unchanged (Figure 3.8G). 
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Therefore, AK2 does not seem to be required for differentiation of B cells into plasma 
cells but may affect the nucleotide equilibrium and cellular energetics of these cells. 
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Figure 3.8: AK2 expression during BCL1 differentiation and siRNA knockdown. 
A-B. AK2 expression in BCL1 cells during LPS induced differentiation at days indicated. 
A. Protein expression by western blot. B. mRNA expression by qRT-PCR. C-G. BCL1 
cells were nucleofected with either scrambled (Scr) or AK2 directed (AK2) siRNA then 
induced to differentiate 24 hours later by incubation with LPS. C. Western blot analysis 
for AK2 protein expression in scrambled (S) or AK2-directed (A) siRNA transfected 
cells. D. Fold change of mRNAs for AK2 and BCL6 determined by qRT-PCR upon 
depletion of AK2 relative to scrambled at day 4 of differentiation. E. Fold change of 
mRNAs for mitochondrial proteins determined by qRT-PCR upon depletion of AK2 
relative to scrambled at day 4 of differentiation. F. Rate of oxygen consumption 
expressed as fold change of the control scrambled cells. G. Level of adenine nucleotides 
isolated from cell lysates by TCA extraction expressed as relative luminescent units 
(RLU). * indicates p<0.05 by paired 2-tailed Student t-test. # indicates p<0.05 between 
control and treated cells by paired 2-tailed Student t-test. All values shown are means of a 
minimum of three independent experiments. 
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We then assessed the role of AK2 in the secretory function of the plasma cell. 
AK2 depleted cells displayed a profound decrease in IgM levels, seen in whole cell 
extracts, as well as in the amount of antibody secreted into the media (Figure 3.9A). This 
defect is likely to be due to an impaired induction of the UPR, as the mRNA levels 
IRE1α, sXBP1, and BiP were significantly decreased in AK2 knockdown cells (Figure 
3.9B). A pronounced impairment in the induction of BiP protein with differentiation was 
also seen in AK2 knockdown cells (Figure 3.9C, upper panel) while calreticulin 
expression was relatively unaffected (Figure 3.9C, lower panel). These experiments 
indicate that AK2 protein is required for the induction of the UPR during B cell 
differentiation, which is in turn required for secretory function of these cells. 
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Figure 3.9: AK2 depletion decreases UPR induction and IgM secretion. 
BCL1 cells were nucleofected with either scrambled (Scr or S) or AK2 directed (AK2 or 
A) siRNA then induced to differentiate 24 hours later by incubation with LPS. A. 
Western blot analysis for IgM protein expression in cell lysate (top panel) or culture 
media (middle panel) in transfected cells during BCL1 differentiation. Bottom panel 
shows the quantification of IgM secretion through analysis by densitrometry. B. Fold 
change of mRNAs for UPR proteins and IgM determined by qRT-PCR upon depletion of 
AK2 relative to scrambled. C. Western blot analysis with antibodies against BiP and 
calreticulin (calret) transfected cells during BCL1 differentiation. * indicates p<0.05 by 
paired 2-tailed Student t-test. All values shown are means of a minimum of three 
independent experiments. 
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 AK2 plays a profound role in regulating the UPR in both adipocytes and plasma 
cells. However, since other mitochondrial manipulations such as Tfam depletion did not 
have a similar affect on secretory ability as shown in the previous chapter, we asked 
whether other adenylate kinases could also regulate ER function. To test this, primary 
myotubes were depleted of AK1 to determine any metabolic changes or altered cellular 
response to tunicamycin induced ER stress. We first examined the tissue distribution of 
mouse AK1. We found AK1 in the mouse to be highly expressed in skeletal muscle and 
the diaphram (Figure 3.10A). To determine the functional role of AK1, we studied the 
effects of siRNA-mediated AK1 depletion in primary myocytes derived from satellite 
cells from 3-4 week old C57BL/6J mice. Myocytes obtained by this procedure produce a 
uniformly differentiated cell type regardless of the fiber-type, anatomic location, and 
embryonic origin of the donor muscles (176). Myoblasts were differentiated into 
myotubes (Figure 3.10B), and treated with either scrambled or AK1-targeted siRNA 
oligonucleotides. A decrease in AK1 mRNA of approximately 90% (Figure 3.10C) and 
of more than 80% in protein levels (Figure 3.10D) was seen with AK1 specific 
oligonucleotides compared with the scrambled siRNA controls.  
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Figure 3.10: AK1 depletion in primary myotubes. 
A. Western blot analysis of mouse tissues with an antibody to mouse AK1. W, white 
adipose tissue; M, muscle; L, liver; B, brain; H, heart; P, pancreas; D, diaphragm; Lu, 
lung; K, kidney; Sp, spleen; St, stomach. B. Phase images of primary myoblasts and 
myotubes. C. Expression of AK1 mRNA expression by qRT-PCR from cells transfected 
with scrambled or AK1 siRNA. D. Western blot analysis of AK1 protein from cells 
transfected with either scrambled or AK1 siRNA. * indicates p<0.05 by paired 2-tailed 
Student t-test. All values shown are means of a minimum of three independent 
experiments. 
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 To determine the functional role of AK1, we examined the metabolic changes 
elicited upon siRNA transfection. Myotubes depleted of AK1 showed increased basal 
glucose uptake, averaging a 1.3-fold increase over control myotubes exposed to 
scrambled siRNA (Figure 3.11A), and a significant increase in basal oxygen consumption 
(Paired 2-tailed Student t-tests yielded a p<0.001) (Figure 3.11B). These results indicate 
that AK1 depletion in cells elicits acute metabolic changes that increase fuel utilization. 
In addition, decreased AK1 levels led to lower cellular ATP levels (Figure 3.11C), while 
ADP and AMP trended higher but were not significantly altered. These changes in 
nucleotide levels led to increased levels of phosphorylated AMPK indicating increased 
activation (Figure 3.11D). These findings suggest that the cell is under energetic stress 
probably due to depleted energy stores and is responding through AMPK and altered 
metabolic activity to compensate for the lower ATP.  
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Figure 3.11: AK1 depletion affects primary myotube metabolism. 
Primary myotubes were transfected with either scrambled (Scr) or AK1-targeting (AK1) 
siRNA. A. 2-deoxyglucose uptake in cells transfected with either scrambled or AK1 
siRNA. B. Representative graph of oxygen consumption from cells transfected with 
either scrambled or AK1 siRNA C. Level of adenine nucleotides isolated from cell 
lysates by TCA extraction expressed as relative luminescent units (RLU). D. Western 
blot analysis on AMPK protein expression and activation illustrated by phosphorylation 
from cells transfected with either scrambled or AK1 siRNA and starved overnight in 
KRH buffer. Lower panel shows the ratio of phosphorylated AMPK to total AMPK based 
on densitometry of data from blots. * indicates p<0.05 by paired 2-tailed Student t-test. 
All values shown are means of a minimum of three independent experiments. 
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 We then examined whether this alteration in metabolic state would affect the 
ability of the cells to induce the UPR upon tunicamycin treatment. We found that under 
basal conditions, there was no change in the mRNA expression of key UPR markers upon 
AK1 depletion (Figure 3.12A). Therefore, the metabolic changes seen are not affecting 
the function of the ER or UPR during an unstressed state. To determine how the cell 
would respond upon increased protein load in the ER, myotubes were treated with 
tunicamycin to induce ER stress. Myotubes have a functional UPR upon tunicamycin 
treatment as illlustrated by the increased sXBP1 and BiP mRNA in scrambled siRNA 
transfected cells (Figure 3.12B). Since CHOP mRNA was also greatly increased, the cells 
may be unable to handle the increased stress and were proceeding with apoptosis. Upon 
AK1 depletion, there was no change in the induction of any of the UPR markers as 
determined by mRNA expression through qRT-PCR analysis. Therefore, unlike what we 
find in AK2 depleted cells, the nucleotide regulation by AK1 is not required for UPR 
function. 
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Figure 3.12: AK1 depletion in primary myotubes does not affect UPR induction. 
Primary myotubes were transfected with either scrambled (Scr) or AK1-targeting (AK1) 
siRNA. A. Basal expression of UPR markers determined by qRT-PCR. B. Cells were 
treated without (Con) or with tunicamycin (Tuni) for 3 hours. Expression of UPR 
markers was determined by qRT-PCR. # indicates p<0.05 between Con and Tuni by 
paired 2-tailed Student t-test. All values shown are means of a minimum of three 
independent experiments. 
 
  
100 
Conclusions 
 
 AK2 is a member of a conserved, ancient protein family involved in the 
interconversion of adenine nucleotides through the reversible reaction 
ATP+AMP⇔2ADP (120,177,178). Several isoforms of AK exist in humans, and they 
differ in subcellular localization and tissue distribution (179). The most studied of 
mammalian AKs is AK1, a cytoplasmic protein expressed specifically in muscle and 
heart. Studies in knockout mice have suggested that AK1 functions to maximize ATP 
utilization efficiency during muscle contraction, perhaps by distributing ATP from sites 
of production to sites of consumption via phosphotransfer reactions (111,114,115). Here 
we show that while AK1 depletion is able to alter the metabolic status of myotubes, it 
does not seem to affect induction of the UPR upon tunicamycin treatment. 
 In contrast to AK1, AK2 is localized to the mitochondrial intermembrane space, 
where it is imported by a co-translational mechanism that requires a membrane 
electrochemical potential (180). Previous studies of apoptosis in cultured Jurkat cells 
have found that AK2 can be released from mitochondria concomitantly with cytochrome 
c (181,182). This release occurs early in the apoptotic program, prior to changes in 
mitochondrial membrane potential (183). Additionally, a non-catalytic function for AK2 
in promoting apoptosis has been shown in cultured HeLa cells (184). However, its 
specific role in the regulation of adenine nucleotide metabolism in mammalian cells 
remained unexplored. AK2 could use increased ADP levels, produced by diminished or 
uncoupled respiratory chain activity, to generate ATP, serving to delay or mitigate energy 
depletion. At the same time, the AMP generated by this reaction can serve as a signal to 
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AMP-sensitive protein kinase to accelerate catabolic reactions to fuel the activity of the 
respiratory chain (185-187). Another function of AK2 can be proposed, where, under 
conditions of adequate respiratory chain activity and ATP production, AMP is recruited 
for the local production of ADP, serving both to maximize the pool of high-energy 
adenine nucleotides, and as a local signal that cellular energy levels are sufficient. In this 
way, AK2 has a unique capacity to buffer changes in adenine nucleotide levels and allow 
the cell to quickly adapt for decreased energy levels while also signaling for the cell to 
adapt to these changes.  
 One function of the cell that requires a large amount of energy is protein 
synthesis. Under conditions of low energy, the levels of AMP/ATP signal activation of 
AMPK that causes a decrease in protein translation through phosphorylation of eIF2α 
(188). This signal could also be directly interpreted by the ER, through the unique ability 
of IRE1 to bind adenine nucleotides (25,28). IRE1 would then respond accordingly, 
reflecting conditions that would allow a robust response to ER stress without 
compromising other vital energy intensive cellular functions. The physical proximity 
between mitochondria and ER membranes may facilitate local energetic signaling among 
these organelles, in a manner analogous to the communication of calcium signals (189). 
In this model, IRE1 may function as a checkpoint for cellular energy status, attenuating 
or promoting UPR signaling in response to cellular energy conditions.  
 Here we find that AK2 plays an important role in determining the extent and 
duration of ER stress signaling. The small (15%) decrease in ATP levels with a 
concurrent increase in AMP levels upon AK2 depletion has a significant impact upon the 
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UPR and ER function. Thus, a protein that may ensure the maintenance of mitochondrial 
energetic status in the presence of ER stress appears essential for an adequate cellular 
response to such stress. Energy status in turn can play a key role in determining the 
ultimate fate of a cell after ER stress (75). Due to the profound effect that AK2 depletion 
has on secretion of key extracellular proteins, in an organism, the consequences of AK2 
depletion may extend far beyond the cells directly affected. AK2 has been shown to be 
required for survival of bacteria, yeast, and Drosophila (108-110,124). However, higher 
organisms such as Zebrafish morphants expressing a non-functional AK2 survive though 
embryogenesis though they have a defect in the development of lymphoid cells (126). 
Additionally, it has been recently shown that mutations in the AK2 gene are the genetic 
basis for reticular dysgenesis, a rare form of human severe combined immunodeficiency 
(SCID) (126). These patients are almost completely devoid of mature lymphoid cells as 
well as granulocytes. Although the unfolded protein response has been well characterized 
in the differentiation of mature lymphoid cells, such as B cells and T cells (38,190), its 
potential role in the maturation of progenitor immune cells is not known. It has been 
shown that in mice lacking IRE1, the hematopoietic stem cells can reconstitute all 
lineages of blood cells including pro-B cells (30). However, the pro-B cells of these mice 
are deficient in VDJ recombination of Ig genes and unable to express B cell receptor 
(BCR), indicating a role for components of the UPR earlier in B lymphopoiesis. 
Therefore, the mechanism for which AK2 mutations are causing the human SCID disease 
may be through its effects on the activation of the unfolded protein response. 
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Experimental Procedures 
 
Primary Antibodies: Anti-ACRP30/adiponectin (Affinity Bioreagents, Inc.), anti-AMPK 
and anti-phospho-AMPK (Cell Signaling Technology), anti-BiP (Transduction 
Laboratories), Anti-cytochrome C (BD Pharmingen), anti-CHOP (Santa Cruz), anti-
calreticulin (Calbiochem), anti-GLUT1 (Abcam), anti-GLUT4 (Santa Cruz), anti-HSP60 
(Assay Designs), anti-Perilipin (Fitzgerald Industries) and anti-mouse IgM (µ-chain 
specific) and anti-β-actin (Sigma). Chicken IgY against AK1 was generated by 
immunization with full-length purified mouse AK1. Chicken IgY and Rabbit IgG against 
AK2 were generated by immunization with full-length purified mouse AK2. Anti-ERO1-
Lα and XBP1was kindly provided by Dr. Fumihiko Urano. 
 
Cell Culture: All cell lines were obtained from American Type Culture Collection and 
grown under 10% CO2. 3T3-L1 cells were cultured in complete media defined as: 
Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS), 100 U of penicillin/mL, 100 µg of streptomycin/mL, and 50 µg of Normocin/mL 
(InvivoGen), which was replaced every 48 hours unless otherwise stated. 3T3-L1 cells 
were grown on 150 mm dishes. Three days after reaching confluence (day 0), media was 
replaced with culture media containing 0.5 mM 3-isobutyl-1-methylxanthine (Sigma), 
0.25 µM dexamethasone (Sigma), and 1 µM insulin (Sigma). 72 hours later, media was 
replaced with culture media. BCL1 cells were cultured in RPMI 1640 media 
supplemented with 10 mM HEPES, 1 mM sodium pyruvate, 2.5 g/L D-glucose, 10% 
fetal bovine serum (FBS), 100 U of penicillin/mL, 100 µg of streptomycin/mL, and 55 
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µM B-mercaptoethanol. Cells were induced to differentiate by stimulating with 20 µg/mL 
Lipopolysaccharide (LPS).  
 
Chemical Treatments: Cells were treated with 6 µM tunicamycin, 10 µg/mL oligomycin, 
5 µM FCCP, 2.5 mM glucose, or 10 µM palmitate as indicated. 
 
Primary Cell Isolation and Culture: Satellite cells were obtained as previously described 
(191) with slight modifications. Whole leg muscles from 3-4 week old C57BL/6J mice 
were dissected and finely minced, and individual cells were separated using 2.4 U/mL 
dispase and 1% collagenase and then filtering through a 0.7 mm mesh strainer. Cells were 
plated onto collagen-coated dishes and fed daily with Ham’s (F-10) media supplemented 
with 20% FBS, 400 U of penicillin/mL, 400 mg of streptomycin/mL, 1% Normocin, and 
0.25 ng/mL bFGF. Cells were differentiated to myotubes by feeding with DMEM 
supplemented with 4% horse serum, 400 U of penicillin/mL, 400 mg of 
streptomycin/mL, and 1% Normocin for 4 days.  
 
siRNA Transfection of 3T3-L1 cells: siRNA oligos to mouse AK2 were obtained and used 
as a SMARTpool from Dharmacon. Experiments were performed 48 hours post-
transfection or as indicated in the figure legends. For day 2 transfections, medium was 
collected and cells were lifted with 1x trypsin with 1% collagenase and transfected with 
20 nmoles of either AK2 or scrambled siRNA into approximately 107 cells by 
electroporation. Cells were resuspended in the collected day 2 medium and re-plated; 24 
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hours later, the differentiation medium was replaced by complete medium and the 
medium was refreshed every 2 days afterward. For day 5 transfections, cells were lifted 
with 1x trypsin with 1% collagenase, and 20 nmoles of siRNA was introduced into 
approximately 107 cells in suspension by electroporation. Cells were re-plated and 48 
hours later experiments were performed. 
 
siRNA Nucleofection of BCL1 cells: siRNA oligos to mouse AK2 were obtained and used 
as a SMARTpool from Dharmacon. Cells were suspended and 0.5 nmoles of siRNA were 
introduced into approximately 2.5x106 cells. Nucleofection was performed using the 
Amaxa Nucleofector® Kit V and program G-015. Cells were re-plated, 24 hours later 
media was replace and cells were induced to differentiate. 
 
siRNA Transfection of Myotubes: siRNA oligos to mouse AK1 were obtained and used as 
a SMARTpool from Dharmacon. Differentiated primary myotubes were fed with DMEM 
supplemented with 4% horse serum, and immediately transfected with 5 nM of either 
scrambled or AK1 siRNA using HiPerFect transfection reagent per the manufacturer’s 
protocol (Qiagen). Experiments were performed 48 hours post-transfection. 
 
Quantitative RT-PCR: Total RNA was extracted by using TRIzol reagent (Invitrogen). 
For quantitative mRNA analysis, 2 µg of the total RNA was reverse-transcribed using an 
iScript cDNA Synthesis kit (Bio-Rad). Ten percent of each RT reaction was subjected to 
quantitative real-time PCR analysis using an iQ SYBR green supermix kit and Real-Time 
  
106 
PCR detection system following manufacturer’s instructions (MyiQ, Bio-Rad). Ferritin 
heavy chain (Fth) or β-actin were used as an internal housekeeping gene. Relative gene 
expression was calculated by the 2-ΔΔCT method (163). Briefly the threshold cycle number 
(Ct) of the target genes was subtracted from the Ct value of Fth or β-actin and raised 2 to 
the power of this difference.  
 
Immunoblot Analysis: Cell monolayers were washed twice with ice-cold phosphate-
buffered saline (PBS) and scraped into 1% sodium dodecyl sulfate (SDS) in PBS. Protein 
concentration was determined by BCA (Pierce), and equal amounts of protein were 
separated by SDS-PAGE and transferred to nitrocellulose. Samples of the cell culture 
medium were taken just prior to media replacement every 24 hours, or as indicated in 
figure legends, spun 5 minutes at 500xg, and equal volumes were separated by SDS-
PAGE and transferred to nitrocellulose. The membranes were blocked with 5% nonfat-
milk in Tris-buffered saline with 0.1% Tween and incubated with primary antibodies 
overnight. They were then incubated with anti-rabbit or anti-mouse IgG horseradish 
peroxidase conjugated antibodies (Promega) or anti-chicken IgY horseradish peroxidase 
conjugated antibodies (Sigma) and detected using enhanced chemiluminescence (Perkin 
Elmer Life Sciences, Inc.). Films were scanned at 300 dpi, and band intensities were 
quantified by using Photoshop software as follows. Images were inverted to render the 
bands white; bands were next selected by using the rectangular marquee tool and then 
delineated by using the color range tool until the whole band was selected. The histogram 
  
107 
function was used to determine the number of pixels in the selection, which was 
multiplied by the average pixel intensity. 
 
Adenine Nucleotide Assay: Levels of adenine nucleotides were measured by a coupled 
enzymatic assay (192). Cells were washed twice with 1x PBS and then scraped into 20 
mM HEPES with 3 mM MgCl2 pH 7.75. An equal volume of 10% TCA was added, 
lysate was incubated 3 minutes and then spun at 5000xg for 5 minutes Supernatant was 
transferred to a new tube and neutralized by diluting 1:5 with 1 M Tris pH 7.5. 10 µL of 
sample was added to 12 wells each of an opaque 96-well plate. 90 µl of 20 mM HEPES 
with 3 mM MgCl2 pH 7.75 was added to each well. To eight wells of each sample, 1.5 
mM phosphoenolpyruvate (PEP) and 2.3 U/mL pyruvate kinase (PK) were added to 
convert ADP to ATP. To 4 of those wells, 36 U/mL of adenylate kinase was added to 
determine AMP levels. The plate was incubated for 30 minutes then 100 µL of the 
CellTiter-Glo luminescent assay reagent (Promega) was added and incubated for an 
additional 15 minutes. Luminescence was measured using a Tecan Safire2 multimode 
microplate spectrophotometer. Relative ADP levels were determined by subtracting the 
wells with PEP/PK from those without. Relative AMP levels were determined by 
subtracting the wells with PEP/PK/AK from those with PEP/PK. 
 
Lactic Acid Assay: Levels of lactic acid were measured by a coupled enzymatic assay. 
Cells were washed twice with 1x PBS and then scraped into 20 mM HEPES with 3 mM 
MgCl2 pH 7.75. An equal volume of 10% TCA was added, lysate was incubated 3 
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minutes and then spun at 5000xg for 5 minutes Supernatant was transferred to a new tube 
and neutralized by diluting 1:5 with 1 M Tris pH 7.5. 40 µL of each sample was added to 
triplicate wells in a 96-well plate. 50 µl of 600 mM Hydrazine buffer with 1 M Glycine 
and 5.6 mM EDTA pH 9.5 was added to each well. 3 µL of 50 mM β-Nicotinamide 
Adenine Dinucleotide (β-NAD) was added to each well. Absorbance at 340 nm was 
measured using a Tecan Safire2 multimode microplate spectrophotometer. 10 Units of L-
lactate dehydrogenase were added to each well. Absorbance was read every minute until 
assay reached completion, approximately 90 minutes. Relative lactic acid levels were 
determined by subtracting the wells without enzyme from those with it.  
 
Brightfield Imaging: All images were obtained using a conventional wide-field 
microscope fitted with a 60x Nikon PlanApo objective.  
 
Oil Red O Staining: Cells were washed twice in 1x PBS and fixed in 4% formaldehyde 
for one hour. Cells were washed in dH2O three times before being stained with 5 mg/mL 
Oil Red O in 60% triethyl-phosphate for 30 minutes. Cells were washed in dH2O six 
times before proceeding with analysis. All images were obtained using a conventional 
wide-field microscope fitted with a 60x Nikon PlanApo objective. 
 
Fluorescent Imaging: Cells were seeded on glass coverslips. Cells were fixed in 4% 
formaldehyde for 15 minutes at room temperature, permeabilized with 0.5% Triton X-
100 and 1% FBS in 1x PBS, and stained with primary antibodies overnight at 4°C. Alexa 
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Fluor® 488 or 594 donkey anti-mouse or rabbit secondary antibodies were used to detect 
bound primary antibody. For MitoTracker® staining, cells were treated for 30 minutes 
with 100 nM MitoTracker® Red prior to fixation. For staining of nuclei, cells were 
incubated with 1 µg/mL Hoechst 33258 pentahydrate (bis-benzimide) for 10 minutes. All 
images were obtained using a conventional wide-field microscope fitted with a 100x 
Nikon PlanApo objective.  
 
2-Deoxyglucose Uptake Assay: Cells were plated in a 24-well dish. Cells were starved for 
2 hours in Krebs-Ringer HEPES (KRH) buffer (130 mM NaCl, 5 mM KCl, 1.3 mM 
CaCl2, 1.3 mM MgSO4, and 25 mM HEPES, pH 7.4) with 2 mM sodium pyruvate and 
1% BSA prior to a 30 minute stimulation with either 1 or 100 nm insulin. Uptake was 
initiated by the addition of [3H]2-deoxy-D-glucose to a final assay concentration of 100 
µM for 5 minutes at 37°C. Assays were terminated by three washes with ice-cold 1x 
PBS, and the cells were solubilized with 0.4 mL of 1% Triton X-100, and 3H content was 
determined by scintillation counting. Nonspecific deoxyglucose uptake was measured in 
the presence of 20 µM cytochalasin B and subtracted from each sample to obtain specific 
uptake. 
 
Oxygen Consumption: Cells were trypsinized and resuspended in KRH buffer 
supplemented with 1% fatty acid free BSA. Approximately 7.5x104 of 3T3-L1 cells, 
2x105 BCl1 cells, or 1x105 primary myotubes in 150 µL of KRH buffer were added per 
well in a BD Oxygen Biosensor System plate (BD Biosciences) in triplicate. Plates were 
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sealed and fluorescence intensity recorded for 120 minutes (2 minute intervals) at an 
excitation wavelength of 485 nm and emission wavelength of 630 nm on a Tecan Safire2 
multimode microplate spectrophotometer maintained at 37°C. 
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CHAPTER IV 
DISCUSSION 
 
 
Summary and Critique 
 
On a cellular level, the unfolded protein response has been shown to be necessary 
for the function of secretory cells such as pancreatic β cells and antibody secreting 
plasma cells. UPR activity, specifically XBP1 splicing, is increased and important during 
the differentiation of plasma cells, but also during the development of secretory organs, 
hepatogenesis, cardiac myogenesis, and bone development (36-38,193,194). Similar to 
previous studies, we also find increased UPR activity during 3T3-L1 adipogenesis 
identifying another cell type where the UPR plays an important developmental role 
(127,195). In this study, we find that the UPR is necessary for the secretory function of 
3T3-L1 adipocytes; upon XBP1 knockdown, adiponectin secretion is impaired. However, 
unlike previous studies which found adipogenesis was prevented by either treatment with 
chemical chaperones (127) or by siRNA mediated depletion of XBP1 (195), we do not 
see a block in differentiation. We transfected XBP1 siRNA at day 2 of differentiation 
resulting in only a partial knockdown and functional adipogenesis. This indicates that the 
adipocyte is able to function with either partial XBP1 expression or can compensate for 
its depletion. In addition, in XBP1-/- mice rescued with XBP1 expression in the liver, 
adipose depots are small but present indicating that adipogenesis can occur in vivo 
without XBP1 activity (36). Important to note, functional activity of the adipocytes upon 
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XBP1 deletion was not examined, so there could still be affects on this organ. Therefore, 
the regulation of the UPR, especially the IRE1 pathway, is important for proper adipocyte 
function but may not be necessary for adipogenesis. 
 From the initial discovery that UPR components respond to glucose deprivation, 
it has been proposed that the UPR can monitor nutrient levels and act accordingly. Since 
approximately 15-20% of the total cellular ATP is used for protein synthesis and folding 
(160,161), energetic regulation of the UPR is important to ensure that its activity will not 
put further stress on the cell. Adenine nucleotides, mainly ATP, have been suggested as 
key components in UPR activity. UPR signaling can be regulated by adenine nucleotide 
levels through the activation of IRE1 (25,28). ATP is also required for the function of ER 
chaperones during protein folding (162). Consequently, dysregulation of adenine 
nucleotide levels could affect ER function and protein folding on several levels. 
Signaling between the ER and mitochondria during calcium regulation and apoptosis has 
been previously demonstrated (131,132,189). Adenine nucleotides may act as another 
mechanism for inter-organelle communication. IRE1 may potentially function as a 
checkpoint for cellular energy status, attenuating or promoting UPR signaling in response 
to cellular energy conditions. In addition, several mouse models of UPR components 
demonstrate that the UPR plays a role in regulating the metabolic needs of an organism. 
Therefore, we sought to determine whether the metabolic status of the cell would regulate 
the UPR.  
 To address the metabolic regulation of UPR induction we looked at two methods 
of ATP production in the 3T3-L1 adipocyte: 1) mitochondrial oxidative phosphorylation 
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and 2) regeneration of ATP by adenylate kinase (AK). We first examined the effects of 
ATP synthesis by mitochondrial oxidative phosphorylation on the UPR. Tfam depletion 
reduces mtDNA and components of the electron transport chain resulting in impaired 
ATP production. However, this decrease in ATP does not appear to affect basal 
expression of UPR markers or tunicamycin induced UPR activity. However, under our 
conditions there may be a mechanism compensating for the chronic state of diminished 
ATP that resulted in the unaltered UPR activation we observed. We then used chemical 
inhibitors to generate an acute depletion of ATP. They were able to induce a small 
increase in the basal UPR signaling as determined by sXBP1 levels, similar to previous 
reports (128). It has also been shown that oligomycin induced mitochondrial dysfunction 
can activate an ER stress response due to impaired calcium regulation (196). The authors 
find that oligomycin treatment results in altered mitochondrial membrane potential and 
increased cytosolic calcium levels. This could explain the increase we show in sXBP1 
mRNA levels upon FCCP and oligomycin treatment. However, when the cells were put 
under stress through tunicamycin treatment, those with diminished ATP levels were 
unable to further activate the UPR. This inhibition of oxidative phosphorylation appears 
to be either too severe or occurs too quickly for compensation resulting in the striking 
effects on UPR induction. In addition, Tfam depletion, which also results in altered 
mitochondrial membrane potential (145), shows a trend for increased ER stress that could 
indicate that calcium regulation is slightly altered. Surprisingly, treatment with 2-
deoxyglucose does not have the same affect as FCCP and oligyomycin on sXBP1 levels 
induced by tunicamycin (Figure 2.9A). This difference could be due to the ability of cells 
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to use alternate carbon sources during aerobic conditions (197). In addition, 2-
deoxyglucose has been shown to alter protein glycosylation and induce the UPR (198), 
which could explain why we see a trend for increased sXBP1 mRNA levels. However, 
further analysis on the metabolic alterations caused by these different inhibitors could 
help determine why this difference occurs though energy levels should be depleted under 
all conditions. This analysis could include the measurement of adenine nucleotide levels, 
rates of flux of various metabolic pathways including glycolysis and oxidative 
phosphorylation, and levels of small molecules including ROS and electron donors, 
NADH and FADH2. Therefore, while there is mitochondrial regulation of UPR function, 
it does not appear to simply be the cell’s total ATP levels and other compensatory 
metabolic pathways may be involved. 
 Another mechanism to generate ATP is by the enzymatic activity of the adenylate 
kinases, a conserved protein family involved in the interconversion of adenine 
nucleotides through the reversible reaction ATP+AMP⇔2ADP (120,177,178). AK1 may 
function to maximize ATP utilization by distributing newly generated ATP to areas of 
ATP deficiency through a phosphotransfer cascade (111,114,115). Though AK2 has been 
proposed to be involved in apoptosis (181-184), other roles have not been explored. We 
find that depleting either AK1 in myotubes or AK2 in adipocytes and B cells results in 
metabolic alterations. While AK1 depletion appears to increase fuel metabolism and 
oxygen consumption, AK2 depletion results in decreased oxygen consumption and 
altered glucose metabolism. These differences could be due to their different subcellular 
localization. Knockdown of both enzymes results in a small (15%) decrease in ATP 
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levels with a concurrent trend towards increased AMP levels. AK1 may promote efficient 
energy usage in the cytosol and upon knockdown the decreased ATP levels activate 
AMPK resulting in increased catabolic pathways, as indicated by increased fuel usage 
and oxidative metabolism. On the other hand, AK2 may promote the availability of ADP 
to the ATP synthase, which upon AK2 depletion might become a rate-limiting step. If 
ADP were unavailable, oxidative phosphorylation would decrease resulting in lower 
oxygen consumption. During impaired oxidative phosphorylation, protons cannot pass 
back into the matrix. As a result, the gradient becomes too strong and the protein 
complexes of the electron transport chain are unable to operate. This prevents NADH, 
which is made during the transfer of electrons, from being oxidized. Since NAD+ is 
required for the function of both glycolysis and the Krebs cycle, these pathways may also 
be inhibited, which could explain the effects we see on glucose metabolism (199,200). 
Therefore, the activity of both of these adenylate kinase enzymes is critical for metabolic 
regulation in several cell types. 
 We then examined how these alterations in metabolic status would affect UPR 
activity. AK1 depletion did not alter the levels of key UPR markers, either under basal 
conditions or upon tunicamycin induced ER stress. We and others (127) have shown that 
adipogenesis is accompanied by an increase in proteins involved in the UPR. AK2 
depletion resulted in a dramatic reduction in this expression of UPR markers at both the 
mRNA and protein level. Of note, the mRNA levels of several key adipogenic markers 
show a non-significant decrease of about 30% (Figure 3.2D). This presents the question 
of whether the affect on the UPR by AK2 depletion is in fact actually a block in 
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differentiation that causes the UPR effect. We believe this is not the case for several 
reasons. First, we find that lipid accumulation is unchanged indicating that some aspects 
of adipogenesis are occurring normally. Second, we find mitochondrial biogenesis, which 
is also induced by adipocyte differentiation, is unchanged based upon mRNA levels 
(Figure 3.3C), protein levels (data not shown), and morphology shown by 
immunostaining (Figure 3.3D). Finally, we find that the mRNA levels of the UPR are 
reduced by 50-80%, much greater than any changes we see in adipocyte or mitochondrial 
markers, which would indicate that if the UPR effect was due to impaired adipogenesis, it 
would have to be more tightly regulated than even lipid accumulation. Though this is 
possible, it is highly unlikely, therefore we feel that the decreased levels of UPR markers 
at day 5 of differentiation is due to the depletion of AK2 early in adipogenesis. Also, we 
feel that the decrease in mRNAs of the UPR as well as the trend in decreased adipogenic 
mRNAs does not illustrate a general inhibition of transcription since the levels of other 
mRNAs are shown to be either unchanged or increased by quantitative RT-PCR. In 
addition, microarray analysis showed 1.9% of mRNAs were decreased and 1.5% were 
increased, indicating that general transcription was unaffected (data not shown). 
Therefore, we conclude that AK2 depletion specifically impairs the expression of UPR 
proteins during 3T3-L1 differentiation. Additional support for this conclusion comes 
from our finding that UPR induction during the differentiation of BCL1 cells is also 
specifically impaired by AK2 depletion while plasma cell differentiation as well as 
mitochondrial structure and gene expression is unaffected. 
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  In addition to the inhibition of UPR activation during differentiation, AK2 
depletion also resulted in diminished UPR activation under increased protein load due to 
impaired protein folding by tunicamycin treatment. We used tunicamycin because we 
believe that it is the most specific inhibitor of protein folding, due to its precise 
impairment of protein folding through impaired protein glycosylation (201). Other 
commonly used inhibitors include thapsigargin, Dithiothreitol (DTT), and Brefeldin A, 
but were not used due to the off target effects that can occur. Thapsigargin impairs the 
storage of calcium in the ER and by doing so raises cytosolic calcium levels (202), which 
can affect mitochondrial structure and function (203-205). DTT is a reducing agent that 
prevents proper protein folding, however it will reduce any available disulfide bond, 
which would affect the function of numerous cellular proteins (206). Brefeldin A blocks 
transport from the ER to the Golgi apparatus increasing the protein load in the ER 
thereby initiating the UPR (207). Disruption of the Golgi apparatus can have secondary 
effects on both lipid regulation (208,209) and lysosomes (210,211). For these reasons, we 
only assessed the role of AK2 in tunicamycin induced UPR activation. In this 
experiment, the cell had been allowed to differentiate normally and fully develop ER 
functionality. In addition, the induction of UPR proteins was allowed to progress 
normally. Therefore, we feel that this inhibition of AK2 is on the acute induction of the 
UPR in response to tunicamycin, rather than a global impairment of ER function. This 
again illustrates the specificity of AK2 depletion on UPR activity.  
 In addition, we show that the functionality of the ER was affected by AK2 
depletion, as secretion was impaired in both the 3T3-L1 and BCL1 cell lines. This was 
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demonstrated by decreased levels of adiponectin and IgM in the culture media. However, 
there are other possible mechanisms for this result. We believe that this is a post-
transcriptional event since both adiponectin and IgM mRNA levels are unchanged by 
decreased AK2 levels. To clearly demonstrate that AK2 depletion affects secretion, the 
rate of translation and protein turnover needs to be examined.  
 To begin with, in the 3T3-L1 cells, we see normal levels of adiponectin in the 
lysate but decreased levels in the media. We would expect that if adiponectin synthesis is 
normal and secretion is decreased, there would be increased levels in the lysate. There are 
two obvious reasons for this effect, either there is increased degradation or decreased 
synthesis. UPR activation includes induction of the ER degradation system, ERAD, so it 
would not be surprising that if adiponectin were not efficiently folded, it would be 
degraded. Another possibility is decreased translation of adiponectin, which would result 
in less expression. If the rate of secretion also decreased, the lysate levels would appear 
unchanged or lower. To conclusively determine the mechanism, we could analyze the 
incorporation of [35S]-methionine into newly synthesized adiponectin with or without 
incubation with cycloheximide, which blocks translation. Thus we can measure the rate 
of protein expression and turnover to conclusively determine the cause of decreased 
adiponectin levels in the media.  
 Separately, we find that AK2 depletion affects both the expression and secretion 
of IgM based upon decreased levels in the lysate and media. It has been shown before 
that XBP1 splicing is required for both the synthesis and secretion of IgM (154). 
However, a more thorough analysis using [35S]-methionine should provide a convincing 
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result about whether those same effects are occurring under our conditions. Therefore, we 
find that AK2, a protein that may stabilize mitochondrial and cellular energetics, appears 
essential for an adequate cellular response to ER stress and efficient regulation of major 
secretory proteins. 
 The different locations of AK1 and AK2 could explain the difference in the 
functional results upon the UPR. AKs have a unique ability to buffer changes in adenine 
nucleotide levels and allow the cell to quickly adapt to decreased energy levels. If AK1 is 
unable to efficiently transfer ATP through the cytosol to sites of usage, the cell may try to 
compensate via the altered metabolism that we observe. In the mitochondrial 
intermembrane space, AK2 may generate ATP when impaired mitochondrial activity 
results in increased ADP levels. Simultaneously, the AMP produced can activate AMPK 
to increase mitochondrial generated ATP (185-187). However, AK2 activity also can 
work in the opposite direction. Therefore, under conditions of sufficient ATP production, 
AK2 can convert AMP for the production of ADP, which would promote the generation 
of ATP through oxidative phosphorylation.  
 Changes in nucleotides can signal to IRE1 so the UPR can respond accordingly 
without compromising other important cellular functions. The ATP necessary for the 
UPR may come directly from the mitochondria or from specific pools of concentrated 
ATP in regions where the ER and mitochondria are closely located, similar to calcium 
regulation (131,132). Therefore, because of its location, AK2 may specifically regulate 
the nucleotides required for the ER. AK2 may act as a buffer for impaired mitochondrial 
function and provide nucleotides to the ER for proper protein folding and UPR signaling 
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(Figure 4.1). AK2 may have compensated for the impaired Tfam depletion, which is why 
there was no alteration in UPR activity. However, the effect of the mitochondrial 
inhibitors coupled with treatment with tunicamycin may have been too severe of a stress 
for AK2 to adequately compensate for resulting in impaired UPR activation.  
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Figure 4.1: Model for the interactions between AK2 and IRE1. 
AK2, localized to the mitochondrial intermembrane space, catalyzes the reversible 
interconversion of adenine nucleotides. In this location, AK2 can draw AMP into the 
high-energy nucleotide pool under conditions of high ATP production and ADP 
limitation. Conversely, under conditions of ADP accumulation, such as after FCCP-
mediated uncoupling or oligomycin-mediated ATP synthase inhibition, AK2 can catalyze 
the synthesis of ATP from ADP to support IRE1 activity and other essential functions. In 
addition, AK2 may be necessary for channeling ATP from its site of synthesis to sites of 
contact with the ER, facilitating an energy flux to IRE1. MOM: mitochondrial outer 
membrane; MIM: mitochondrial inner membrane; ER: endoplasmic reticulum. 
 
  
122 
 The model we have detailed is based upon our findings and the current knowledge 
concerning regulation of energy and the requirement of ATP by ER resident proteins. 
However, the existing tools available to us limit our conclusions. While we propose that 
AK2 may be promoting the generation of maintenance of a pool of ATP specifically for 
use by the ER, our data only suggests its possibility rather than conclusively show that it 
is in fact the mechanism. A detailed analysis of the subcellular localization of ATP pools, 
and how their levels change upon AK2 depletion would help support this theory. As 
mentioned before, BiP requires ATP for success in its protein folding capacity within the 
ER lumen (162). However, some studies indicate that it is only the binding, rather than 
the hydrolysis, of ATP that promotes BiP’s activity (212,213). The nucleotide binding 
domain of IRE1 is located in its cytosolic region (25). Therefore there are two distinct 
subcellular regions that require adenine nucleotides, the ER lumen and the cytosolic side 
of the ER membrane.   
 Theoretically, this subcellular requirement for ATP would result in four possible 
scenarios for ER stress and UPR activation. 1) Adequate levels of ATP in ER and cytosol 
would lead to normal protein folding, no ER stress, and therefore no activation of the 
UPR. 2) Decreased ATP in the ER with normal levels in the cytosol would cause 
impaired protein folding leading to ER stress and activation of the UPR, which should 
respond normally. 3) Normal ATP levels in the ER and decreased cytosolic levels should 
allow for normal protein folding so even though there could be impaired UPR activation, 
this is not a problem since there is no ER stress. 4) Decreased ER and cytosolic ATP 
levels would result in impaired protein folding leading to ER stress, however the UPR 
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may not be able to fully respond due to impaired IRE1 activation. Therefore, based on 
our studies, the effect on the UPR by AK2 depletion would most likely be due to 
conditions such as is found in scenario 4, although scenario 3 could also be occurring if 
there is some other mechanism of increased ER stress under these conditions.
 Notably, binding of ADP to this domain of IRE1 has been shown to promote 
greater activity than ATP binding (25). The normal levels of ATP and ADP in the cell are 
approximately 10mM and 1mM, respectively, but vary depending on cell type (214). 
Based on these concentrations, while ATP would most likely be the active molecule, 
ADP would also activate IRE1, especially under conditions of increased ADP to ATP 
ratios. Therefore, the result we see upon AK2 depletion could be a combination of 
decreased ATP and ADP levels. We observe decreases in total cellular ATP levels, 
however ADP levels appear to be unaffected. This could be due to our assay not being 
sensitive enough to measure any changes, or there could be changes in the subcellular 
location of these molecules rather than the global amount. 
 While we believe that the decrease in adiponectin and IgM secretion is due to 
impaired protein folding, there could be other possibilities for this result. Trafficking 
from ER to the Golgi Apparatus requires ATP (215), therefore, the decreased ATP could 
be preventing the exit of these proteins from the ER. In addition, motors required for 
exocytosis need to hydrolyze ATP to function (216,217). We disagree with these 
mechanisms since we would expect that retention of the proteins due to impaired 
trafficking at either stage would result in increased intracellular levels, which we do not 
observe. 
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 It has been shown that adenylate kinase 2 mutations lead to increased levels of 
reactive oxygen species (ROS) in isolated fibroblasts (126). In addition, oligomycin and 
low levels of FCCP can increase ROS production (218,219). However, oxidative stress 
due to increased levels of ROS has been shown to induce ER stress and the UPR 
(220,221), therefore the small increase we see in sXBP1 mRNA levels upon FCCP and 
oligomycin treatment could be due to ROS, however the dramatic impairment by these 
molecules on tunicamycin induced UPR is most likely due to another mechanism. In 
addition, although AK2 mutations result in increased levels of ROS, we saw no change in 
basal levels of ROS upon AK2 depletion (data not shown), and increases in ROS would 
not explain the impaired UPR activation.  
 Based upon the previous data, we propose the model that depletion of AK2 leads 
to a decreased in ATP levels (Figure 4.2). Decreased ATP impairs both protein folding 
and induction of the UPR (which also adds to the impaired protein folding) leading to the 
decrease in protein secretion we observe. However, there are still other potential models 
that could explain our results.  These would need to be addressed in order to confirm or 
dispute our conclusions. 
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Figure 4.2: Alternate models for AK2 effect on the UPR. 
Our model shows that the depletion of AK2 leads to decreased ATP, which impairs 
protein folding and the UPR resulting in decreased secretion. We acknowledge that there 
are at least three additional models that could explain our findings. First, AK2 depletion 
could result in altered products of oxidative phosphorylation (ATP or another factor) that 
could lead to the impaired protein folding, UPR, and secretion. Second, AK2 depletion 
may decrease either transcription or translation leading to decreased proteins in the ER, 
decreased secretion, and a lack of UPR activation. Finally, AK2 depletion may impair 
UPR accessory proteins, such as AIP1 or PTP-1B, leading to impaired IRE1/XBP1 
pathway and decreased secretion. 
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 We acknowledge that there are at least three additional models that could explain 
our findings. First, oxidative phosphorylation appears to be affected by AK2 depletion in 
our studies. Changes in the levels of ATP or another product from this mitochondrial 
pathway could lead to the impaired protein folding, UPR induction, and protein secretion 
that we observe. The similar effects we see on impairment of the UPR by FCCP and 
oligomycin treatment support this model.  However, Tfam depletion also impairs 
oxidative phosphorylation and yet does not affect the UPR, thereby refuting this idea. To 
test this model, careful analysis would have to be performed to quantify products of 
oxidative phosphorylation and then determine their effects on UPR activation. 
 Second, AK2 depletion resulted in decreased levels of several mRNAs and 
proteins. If AK2 depletion led to a direct impairment of either transcription or translation 
in these cells, the result would be a decrease in the load on the ER due to a decreased 
requirement for protein folding and secretion. As a result, the need for the UPR to 
promote protein folding would be decreased, as demonstrated by the decreased levels of 
UPR markers. This model is supported by the finding that cycloheximide, an inhibitor of 
protein translation, can reduce UPR activation (222,223). Our gene chip data shows no 
global change in transcription, however careful analysis of total protein synthesis would 
also need to be conducted to disprove this hypothesis. 
 Finally, AK2 depletion may impair UPR accessory proteins, such as AIP1 or 
PTP-1B, leading to an impaired IRE1/XBP1 pathway and decreased secretion. Besides 
via the direct inhibition of classic UPR proteins, very few studies have demonstrated 
decreased UPR activation. Recent papers, however, have shown that two proteins 
  
127 
promote the UPR and decreasing their levels leads to impaired UPR activation. Apoptosis 
signal-regulating kinase 1 (ASK1) has been shown to be involved in JNK mediated 
induction of apoptosis by IRE1 activation (224-226). Another protein, ASK1-interacting 
protein 1 (AIP1), however, has been shown to be important for a more global 
transduction of UPR signaling (227). In AIP1 knockout cells, IRE1 activation and XBP1 
splicing are impaired, as is ER stress mediated JNK activation. This regulation is 
potentially through the binding of AIP1 to IRE1, rather than an interaction through 
ASK1. Protein-tyrosine phosphatase 1B (PTP-1B) also has been shown to promote the 
IRE1 signaling cascade (228). PTP-1B knockout mouse embryonic fibroblasts (MEFs) 
show impaired XBP1 splicing, EDEM expression, JNK activation, and ER stress induced 
apoptosis. Therefore, either AIP1 or PTP-1B may be mediating the decreased UPR 
activation, though it is unlikely that AK2 can directly affect either of these proteins their 
levels should be measured. The lack of data on cellular alterations that impair the UPR 
supports the need to further understand the regulation by AK2 and its effect on cellular 
and whole body function. 
 
Clinical Implications 
 
 
 White adipose tissue was traditionally thought to only function as a lipid storage 
depot. It is now known that it regulates whole body metabolism by monitoring nutrient 
levels and responding through the secretion of adipokines that act on the central nervous 
system and peripheral tissues to control caloric intake and utilization (6,7). Because 
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adipokines regulate whole body metabolism, defects in adipokine secretion due to 
impaired UPR function could result in similar disease states. The importance of AK2 has 
been shown through its requirement for lymphoid cell development in Zebrafish and the 
survival of bacteria, yeast, and Drosophila (108-110,124,126). However, since it is also 
necessary for UPR function and secretion, the consequences of AK2 depletion may affect 
health of an organism. 
 While the role of the UPR is to promote the proper function of the ER, it has been 
shown to play a key role in human health and disease. Several conditions, including 
neurodegeneration, tumor growth, the immune response, and metabolic disease have been 
linked to improper or impaired UPR activation. A major focus had been on the pro-
apoptotic feature of the UPR and its relationship to disease. Recently, more direct links 
between UPR signaling and function/dysfunction has been shown to play a role in these 
maladies. The PERK/eIF2α branch has been shown to be important for glucose 
metabolism (54,229) and the UPR in adipose tissue seems to play a similar role since 
treatment of ob/ob mice with chemical chaperones relieves ER stress in adipose tissue 
and restores glucose homeostasis and insulin sensitivity (99). Therefore, the regulation of 
UPR activity by AK2 activity and manipulation of energetic levels could serve as 
important therapeutic targets. 
 Mutations in AK2 result in reticular dysgenesis, a rare form of human severe 
combined immunodeficiency (SCID) (126). These patients do not produce a functional 
immune system and are deficient in hematopoietic cells from both the myeloid and 
lymphoid lineages. Mitochondriopathy, based upon increased apoptosis and reactive 
  
129 
oxygen species as well as an altered mitochondrial membrane potential, was observed in 
fibroblasts from these patients. This has been proposed as the cause of the absence in 
hematopoietic cells, however it was not fully examined. The UPR has also been 
implicated in hematopoiesis, however only late stage B cell maturation appears to be 
affected by impaired IRE1/XBP1 signaling (30,230). The exact mechanism of AK2 
impairment in development of reticular dysgenesis has not been clearly identified and we 
show that AK2 depletion affects UPR activity; therefore, the role of the UPR in early 
hematopoiesis, especially in relation to this disease, should be investigated.  
  
Future Directions 
 
 The UPR has been linked to many diseases including defects in hematopoiesis 
and impaired immune function. Although the UPR has been well characterized in the 
differentiation of mature lymphoid cells, such as B cells and T cells (38,190), its potential 
role in the maturation of progenitor immune cells is not known. Since AK2 mutations 
have been shown to block hematopoiesis, a mouse model for AK2 function during 
development would aid in determining the root cause of the disease pathology seen in the 
SCID patients. Characterization of this mouse would help in determining whether the role 
of AK2 in UPR function is responsible for the human condition.  
 If the AK2 mouse model is viable and shows a similar phenotype to patients with 
reticular dysgenesis, it would be extremely useful for experiments involving 
reconstitution of immune cell lineages. The Rag2 mouse, often used for immune studies, 
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lacks lymphoid cells due to impaired VDJ rearrangement (231). On the other hand, the 
AK2 mouse would lack granulocytes and all cells from the lymphoid lineage resulting in 
no innate or adaptive immunity. This would allow it to be a more efficient model for the 
numerous research studies that require reconstitution of various aspects of the immune 
system. 
 In addition, further understanding of the regulation of the UPR by ATP and 
mitochondrial function as well as any mechanism by which the cell compensates for 
impaired mitochondrial function may be beneficial in treating several diseases linked to 
UPR function. Since ATP is the only adenine nucleotide that is consistently altered upon 
AK2 depletion, our results suggest that ATP levels are critical for UPR function. In 
addition, AK2 depletion results in a trend of the other adenine nucleotides towards 
increased levels, which may also be able to regulate the UPR. Our studies were only able 
to quantify total cellular levels of these molecules; however, measuring changes in the 
concentrations of local nucleotide pools may be a more accurate method. As of now, I 
know of no quantitative procedure to perform these experiments, but new in vivo 
fluorescent monitors for ATP may be useful as their specificity and responsiveness 
improves (232,233). The importance of AK2 expression during ER stress is supported by 
our preliminary data demonstrating its resistance to the block of translation induced by 
the UPR (Appendix I). Understanding the regulatory mechanisms for AK2 expression 
could help in determining how the cell adapts to cellular stress as well as offer greater 
insight into how to alter its expression and perhaps its activity. 
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 The post-transcriptional regulation of AK2 that has been observed by several 
laboratories including our own could be a key mechanism by which to alter AK2 
expression. Further analysis of the 5’ and 3’UTR of AK2 as well as examination of the 
sequence for alternative ribosome binding sites, including an IRES, could help in 
determining the method of regulation. In addition, analysis of the rate of translation could 
show that while the level of transcript is unchanged, the number of polyribosomes 
actively translating the mRNA might be altered. These studies could provide useful 
insight into how the cell regulates AK2 expression and therefore, how its expression 
could be modulated. 
 Decreasing AK2 activity seems to specifically alter ER function while general 
metabolism and other cellular functions appear to be largely unaffected by the resulting 
decrease in ATP levels. Therefore, AK2 may be an important target for disease 
therapeutics. Since inhibition of AK2 blocks UPR function, compounds targeting this 
enzyme would be useful as a treatment for infections by viral strains that increase the 
UPR to promote their replication.  
 Conversely, by increasing AK2 activity, the hypothesis would be that UPR 
function would improve. However, AK2 has been associated with increased apoptosis 
upon release from the mitochondria (182,184). In addition, we found that constitutive 
overexpression of AK2 resulted in cell death (data not shown). Therefore, experiments 
examining increased AK2 activity would require careful regulation of AK2 levels to 
ensure cell survival. If the activity of the UPR can be increased, such as in the studies 
involving prolonged IRE1 signaling (75), the cell may be given enough time to recover 
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preventing a cellular cascade into a disease state. While increasing AK2 may not be a 
practical method for improving UPR function, the data presented here demonstrate the 
importance of energetic regulation on UPR activity. Therefore, other means of increasing 
the availability of ATP for ER function should be examined, including improving 
mitochondrial function in pathologies such as diabetes and Alzheimer’s disease. This 
may improve protein folding and thereby slow or prevent the development of these 
diseases. 
 Though AK1 depletion did not affect UPR function, it did alter the metabolic 
status of the myotubes. Previous studies on the knockout mice have shown that they are 
relatively healthy with normal muscle contractility (114,115). They do display enhanced 
ATP synthesis indicating impaired energy efficiency. Preliminary studies in our lab 
demonstrate a resistance to high fat feeding indicating that the mice may burn more fuel 
for normal activity (Appendix II). Further studies are needed to characterize this 
phenotype and determine the mechanism for action. If inhibiting AK1 activity does 
decrease energy efficiency, drugs targeting this enzyme may be useful for weight loss and 
the treatment of obesity and diabetes. Of note, AK1 mutations have been associated with 
hemolytic anemia in a Japanese patient (234). Surprisingly, a sibling with the same 
genetic mutation did not show symptoms of the disease indicating compensation is 
possible. The possibility of a severe reaction to the lack of AK1 activity in the 
erythrocyte would need to be accounted for during any targeting of AK1 for therapeutic 
purposes. 
  
133 
 The data presented in this thesis supports the function of the UPR during normal 
cellular secretion. It expands on the role ATP plays in promoting UPR activation that has 
been suggested in other studies. We focused on the regulation of the UPR by energy 
levels and determined the specificity of catabolic systems in ER function. Here we find 
that while ATP from mitochondrial oxidative phosphorylation can affect UPR function 
and secretion, AK2 activity appears to play a more specialized role in this regulation. 
Further studies of the energetic crosstalk between the ER and mitochondria and the role 
of AK2 would improve the understanding of protein synthesis and secretion and could 
also promote the development of new drugs to treat the numerous diseases associated 
with abnormal UPR and/or mitochondrial function. 
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APPENDIX I 
 
A MITOCHONDRIAL RESPONSE TO THE UPR VIA 
TRANSLATIONAL CONTROL MECHANISMS 
 
 
 
The following data includes unpublished results. 
 
2-D PAGE analysis was performed by the Proteomic Fractionation Core Facility. John 
Leszyk performed the mass spectrometry analysis. I performed the remaining 
experiments contained within this appendix.  
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Summary 
 
 When the protein folding capacity of the ER is exceeded, it triggers signaling 
pathways that increase chaperone levels and diminish protein secretory load. Here we 
find that ER stress brings about remodeling of mitochondria through differential effects 
on translation of mitochondria specific proteins. While translation of most cellular 
proteins is attenuated, translation of a set of soluble mitochondrial proteins is either 
unaffected or increased in response to ER stress. One of these proteins is adenylate kinase 
2 (AK2), an enzyme localized to the mitochondrial intermembrane space that catalyzes 
the reversible reaction AMP+ATP⇔2ADP. An active cross-communication between ER 
function and mitochondrial energy homeostatic pathways could explain the link between 
ER stress and immune, neurodegenerative, endocrine and cardiovascular pathologies 
which are also associated with mitochondrial dysfunction. 
Background 
 
 As discussed previously, the ER must adapt to acute and chronic changes in 
secretory protein load. Three known signaling pathways are triggered by ER stress, the 
PERK, ATF6, and IRE1 pathways (138,140,235). Together they initiate an adaptive 
response that decreases protein secretory load and enhances chaperone biosynthesis, 
known as the UPR (Unfolded Protein Response). PERK is a transmembrane kinase that 
phosphorylates eIF2α, resulting in the suppression of general protein translation. ATF6 is 
proteolytically processed into an active transcription factor that induces genes involved in 
endoplasmic reticulum folding. IRE1 is an ER membrane-spanning, bi-functional 
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kinase/site-specific endoribonuclease that catalyzes XBP1 mRNA splicing, generating a 
stable mRNA product (sXBP1) from which the transcription factor XBP1 is translated. 
ER stress simultaneously induces pro-apoptotic signals such as JNK activation (224), and 
the ultimate fate of cells undergoing ER stress appears to depend on their ability to 
sustain adaptive UPR signaling while mitigating pro-apoptotic signaling (14,75,236). The 
strength of UPR signaling, particularly that of IRE1, influences cell fate in response to 
ER stress (75), but the mechanisms that determine the duration and magnitude of the 
UPR are not known. These mechanisms are important as, in a physiological context, 
unresolved ER stress is linked to multiple human pathologies (19,75). 
 An essential feature of the UPR is the increased synthesis of ER chaperones. ER 
chaperones bind and release folding intermediates in a manner coupled to ATP 
hydrolysis. Thus, adequate ER function must involve both a sufficient number of 
chaperones and an ATP supply that maximizes chaperone function. Consistent with the 
notion that adequate energy metabolism is important for normal ER function are 
observations that ischemia, which is associated with reduced nutrient delivery and 
decreased ATP production, affects several features of the ER stress response both in brain 
and in myocardium (237). In obesity, adipose tissue displays evidence of enhanced PERK 
activity (96), which may represent altered ER stress resulting from obesity related 
hypoxia (238). While these results are suggestive, the precise molecular links between 
ER physiological function and cellular energy metabolic status are unknown. 
 In order to better define the relationship between energy homeostasis and ER 
stress, we conducted experiments in 3T3-L1 adipocytes, which recapitulate many 
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characteristics of primary adipose cells, including triglyceride storage, glucose transport 
and insulin sensitivity. A specific, major function of adipocytes is to secrete adiponectin, 
a 247 amino acid polypetide that undergoes extensive folding to form a trimer stabilized 
through disulfide bonds (8,9). High molecular weight complexes of trimeric adiponectin 
are formed and secreted into the circulation, reaching concentrations of 10-20 ug/ml, 
suggesting that adiponectin secretion comprises a substantial load on the adipocyte ER. 
Interestingly, a robust increase in mitochondrial biogenesis occurs within this period 
(Figure 2-1B and (102)), making the differentiating adipocyte an excellent model system 
to study the potential interplay between energy homeostatic mechanisms and ER 
function.  
 
Results 
 
 As previously shown, adiponectin secretion by 3T3-L1 adipocytes begins at day 4 
of differentiation (Figure 2.1C), and the levels of key proteins of the UPR, including BiP 
ERO1α, increase in parallel (Figure 2.2B). Thus, differentiation is accompanied by a 
robust induction of the ER folding pathways, probably reflective of compensating UPR 
induction, and of mitochondrial biogenesis (Figure 2.1B and (102)).  
 In order to understand the UPR in 3T3-L1 adipocytes, we used tunicamycin, 
thapsigargin, and brefeldin A, all previously shown to induce ER stress in other cell 
types. One of the immediate responses to ER stress is the phosphorylation of the protein 
translation initiation factor eIF2α by PERK. Exposure of cells to all three of the 
chemicals resulted in global inhibition of translation, reflected as a decrease in [35S]-
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methionine labeling of proteins in whole cell extracts (Figure I.1A). However, in 
response to tunicamycin, which is a much more specific activator of ER stress, we noted 
a pronounced and consistent increase in [35S]-methionine labeling of a band of the 
apparent molecular weight of ~25 kDa as well as smaller increases in several other bands 
(Figure I.1A, arrows) seen over the background of the globally decreased [35S]-
methionine labeling. Increased labeling of this ~25 kDa band was detected within 30 
minutes of addition of tunicamycin, and was evident at very low levels of the inhibitor 
(Figure I.1B and C). Further fractionation of the crude extract revealed that this band co-
purified with mitochondria (Figure I.1D).  
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Figure I.1: Paradoxical enhancement of a (35S)-methionine band during the UPR. 
A. Duplicate wells of 3T3-L1 adipocytes were exposed to brefeldin A (BA), thapsigargin 
(Th) or tunicamycin (Tu) and pulsed with [35S]-methionine for 30 minutes. Cell lysates 
were analyzed by SDS-PAGE gels and phosphoimaging. Arrows indicate the enhanced 
incorporation of radioactivity into protein bands. B. Time course of the ~25 kDa band 
expression with tunicamycin (Tuni) treatment. C. Dose dependency of the ~25 kDa band 
expression with tunicamycin (Tuni) treatment. D. Co-purification of ~25 kDa band with 
the crude mitochondrial (Mito) fraction and not with the cytosolic (Cyto) fraction from 
control (Con) and tunicamycin (Tuni) treated cells. Results are from one representative 
experiment, which was confirmed 3 times. 
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 This finding prompted us to analyze the effects of tunicamycin on turnover of 
mitochondrial proteins in more detail. To ensure that the effects seen were due to changes 
in translation, and not transcriptional responses to ER stress that could alter 
mitochondrial composition (239), cells were treated for 60 minutes with actinomycin D 
to inhibit transcription prior to exposure to tunicamycin for 2 hours. Cells were then 
pulsed for 30 minutes with [35S]-methionine, and soluble proteins from purified 
mitochondria were analyzed by 2D gel electrophoresis. Gels were transferred to 
nitrocellulose filters, which were exposed to phosphorimager screen to estimate [35S]-
methionine incorporation (Figure I.2A and B, green color). The blots were then stained to 
visualize total protein amounts in specific spots (Figure I.2A and B, red color). The 
overlap of the two signals reflects the extent of [35S]-methionine incorporation relative to 
total protein, where yellow to green reflects higher and red to yellow lower incorporation 
rates. Three results are evident from this experiment; first, that the basal turnover rate of 
soluble mitochondrial proteins is very variable, with some high abundance proteins 
displaying very little [35S]-methionine incorporation (Figure I.2A, red spots), and proteins 
of low abundance displaying the largest incorporation of [35S]-methionine (Figure I.2A, 
green spots), revealing very rapid turnover. Second, that the predominant effect of 
tunicamycin is to decrease translation, reflected by decrease in [35S]-methionine 
incorporation into proteins of high turnover. And third, that several proteins escape 
translational repression in response to tunicamycin, reflected by increased [35S]-
methionine incorporation (green spots in Figure I.2B). 
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Figure I.2: Tunicamycin affects translation of soluble mitochondrial proteins. 
3T3-L1 adipocytes were treated with actinomycin D and then without (A) or with (B) 
tunicamycin (+Tuni) and labeled with [35S]-methionine. Mitochondria were purified, 
soluble proteins extracted with sodium carbonate, and separated on pH 4 to 7 isoelectric 
focusing strips followed by PAGE. Gels were transferred to nitrocellulose filters, which 
were exposed to reveal [35S]-methionine incorporation (35S, green signal) and stained to 
reveal total protein levels (Sypro, red signal. Results are from one representative 
experiment, which was confirmed 3 times. 
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 To better identify those proteins that escape translational repression, we compared 
the patterns of [35S]-methionine incorporation in control cells (Figure I.3A, blue) with 
those seen in tunicamycin-treated cells (Figure I.3A, red). Visual inspection of the 
overlapped filters reveals those proteins that are highly sensitive to translational 
inhibition (blue spots), and also those that escape inhibition (purple spots) or are 
enhanced in response to tunicamycin (red spots). A quantitative analysis of this 
experiment, in which the relative volume of each spot from the control or tunicamycin 
treated samples are compared (Figure I.3B and C), reveals that translation of 
approximately ~6 % of the spots detected is stimulated (increased by more than 2-fold) in 
response to the drug. To explore the functional relevance of this subset of proteins, we 
proceeded to identify by mass spectrometry a prominent series of spots with isoelectric 
points around pH 7, in the region between 25-30 kDa, which were stimulated in their 
[35S]-methionine incorporation in response to tunicamycin (Figure 1.3C, rectangle).  
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Figure I.3: Effects of tunicamycin of translation of soluble mitochondrial proteins. 
3T3-L1 adipocytes were treated with actinomycin D and then without or with 
tunicamycin and labeled with [35S]-methionine. Mitochondria were purified, soluble 
proteins extracted with sodium carbonate, and separated on pH 4 to 7 isoelectric focusing 
strips followed by PAGE. Gels were transferred to nitrocellulose filters, which were 
exposed to reveal [35S]-methionine incorporation A. Overlapped images of [35S]-
methionine incorporation from untreated (35S-control, blue signal) and tunicamycin 
treated (35S-Tuni, red signal) samples. B. Ratio of [35S]-methionine incorporation into 
278 spots identified in samples from tunicamycin-treated cells relative to controls. C. 
Outlines of identified spots, where blue outlines represent decreased and red outlines 
increased [35S]-methionine incorporation in response to tunicamycin. Rectangle indicates 
region subjected to further analysis by mass spectrometry. Results are from one 
representative experiment, which was confirmed 3 times. 
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 These results suggest that the translation of mRNAs encoding for at least some 
mitochondrial proteins is controlled in response to ER stress in ways that prevent 
translational inhibition, and/or enhances translation. Furthermore, this response may be 
relevant for the overall cellular response to such stress. To further explore this 
hypothesis, we proceeded to identify those proteins that fail to respond to tunicamycin 
with decreased [35S]-methionine incorporation, and characterize their function in relation 
to ER stress. These proteins were identified by comparison of the ratio of SyproRuby 
staining and [35S]-methionine incorporation under control (Figure I.4A, top panel) and 
tunicamycin-treated (Figure I.4A, bottom panel) conditions. Amongst the most salient of 
these (more yellow or red in Figure I-4 bottom panel compared to top panel) were a series 
of protein spots with isoelectric points around pH 7, in the region between 25-30 kDa. 
These were excised from gels run in parallel, and analyzed by Mass spectrometry (Figure 
I.4A). From these, peptides corresponding to two proteins, adenylate kinase 2 (gi: 
34328230) and a hypothetical protein of unknown function (gi: 31560255) that 
corresponds to a mitochondrial protein (101) were reproducibly detected.  
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Figure I.4: Identification of proteins that escape translational suppression. 
A. 3T3-L1 adipocytes were treated with actinomycin D and then tunicamycin followed 
by labeling with [35S]-methionine. Soluble mitochondrial proteins were separated in 
parallel 2D gels, one was stained (green signal) and one transferred to nitrocellulose for 
subsequent exposure to reveal [35S]-methionine incorporation (red signal). The 
overlapped images were used to identify spots corresponding to proteins displaying 
unchanged or enhanced [35S]-methionine incorporation in response to tunicamycin (red or 
yellow spots). Blue circles indicate the regions subjected to excision and mass 
spectrometry, and the corresponding gene identifier numbers of the proteins identified. B. 
Western blot of AK2 performed on the nitrocellulose filter, demonstrating 
correspondence with the identified protein. C. Immunoprecipitation with AK2 specific (I) 
or non-immune (NI) rabbit antibodies from cells treated as above without (-) or with (+) 
tunicamycin and labeled with [35S]-methionine, followed by western blot analysis and 
exposure to phosphorimager screens.  
 
  
158 
 Western blot analysis confirmed that AK2 indeed corresponded to several of the 
spots of interest (Figure I.4B), and immunoprecipitation experiments with antibodies to 
AK2 confirmed that AK2 escapes translational attenuation during ER stress (Figure 
1.4C). The heterogeneous mobility of yeast adenylate kinase on isoelectric focusing gels 
has been previously noted (240), but the biochemical basis for this altered mobility is 
unclear.  
 The other protein identified, gi: 31560255, is a hypothetical mammalian protein 
identified in a mitochondrial proteomic screen (101). It is a homolog to the C. elegans 
protein RMD-1, which has been shown to associate with microtubules (241). Depletion 
of this protein impairs mitotic chromosome segregation. Western blot analysis with an 
antibody generated against this protein showed co-localization with one of the identified 
spots (Figure I.5). Further analysis is required to determine whether this protein escapes 
the translational block induced by tunicamycin. In addition, further confirmation of its 
mitochondrial localization as well as the function of this protein may provide insight into 
why it is alternatively regulated. 
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Figure I.5: Co-localization of gi: 31560255 with translationally upregulated spot. 
3T3-L1 adipocytes were treated with actinomycin D and then without (A) or with (B) 
tunicamycin followed by labeling with [35S]-methionine. Soluble mitochondrial proteins 
were separated in parallel 2D gels, one was stained (red signal) and one transferred to 
nitrocellulose for subsequent exposure to reveal [35S]-methionine incorporation (green 
signal). The overlapped images were used to identify spots corresponding to proteins 
displaying unchanged or enhanced [35S]-methionine incorporation in response to 
tunicamycin (green or yellow spots). Western blot analysis of gi: 31560255 was 
performed on the nitrocellulose filter, demonstrating co-localization of the identified 
protein (blue spots) with the spot subjected to excision (arrow). 
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Conclusions 
 
 AK2 is a member of an ancient family of proteins (EC. 2.7.4.3), present from 
bacteria to humans, that catalyze the reversible reaction ATP+AMP⇔2ADP. The 
function of AK is classically described to be the maintenance of a constant concentration 
and fixed ratio of adenine nucleotides, and the single isoform of adenylate kinase present 
in bacteria and lower eukaryotes is essential for life, underscoring the crucial biological 
relevance of adenine nucleotide interconversion (108-110). The findings reported here 
demonstrate that AK2 protein levels can be acutely regulated by posttranscriptional 
control mechanisms, revealing a new level of regulation for these essential kinases. While 
these results are consistent with previous findings that show that the levels of AK2 
protein are not predictable from mRNA levels (120), they are first to directly demonstrate 
translational control in an acute setting. More work is needed to determine which if any 
of the many known molecular mechanisms that control translation operate on AKs. In 
addition more work is required to determine whether the regulation of AKs is a universal 
feature of cells that undergo chronic ER stress, and to determine whether it plays a role in 
cellular adaptation. In addition, several proteins that separated with a soluble 
mitochondrial fraction were shown to escape the translational attenuation elicited by 
tunicamycin. The identity and function of these proteins may provide insight into the 
cellular response to ER stress. The results shown here suggest that this translational 
regulation and the affected proteins will be important new targets of investigation. 
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Experimental Procedures 
 
Reagents: Chicken IgY against AK2 was generated by immunization with full-length 
purified mouse AK2. Rabbit IgG against the protein encoded by gi: 31560255 was 
generated by immunization with a C-terminal peptide. 
 
Cell Culture: All cells were obtained from American Type Culture Collection and grown 
under 10% CO2 and cultured in Dulbecco modified Eagle medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 100 U of penicillin/ml, and 100 µg of 
streptomycin/ml which was replaced every 48 hours unless otherwise stated. 3T3-L1 cells 
were grown on 150-mm dishes. Three days after reaching confluence (day 0), media was 
replaced with culture media containing a differentiation cocktail consisting of 0.5 mM 3-
isobutyl-1-methylxanthine (Sigma), 0.25 µM dexamethasone (Sigma), and 1 µM insulin 
(Sigma). 72 hours later (day 3) media was replaced with culture media, which was 
replaced every 48 hours. Experiments were performed with day 7 cells. Other treatments 
were as follows: 17 µM brefeldin A for 2 hours, 2 µM Thapsigargin, 6 µM tunicamycin 
for 2 hours or as indicated, and 2 µg/mL actinomycin D for 1 hour prior to tunicamycin 
treatment. 
 
[35S]-Methionine Incorporation: Cells were fed 24 hours prior to the experiment, and 
were treated as described in each figure legend. Cells were then pulsed with 50 µCi/mL 
35S Methionine/Cysteine for 30 minutes, rinsed twice in phosphate-buffered saline and 
once in isolation buffer (250 mM sucrose, 0.5 mM EGTA, 5 mM HEPES; pH 7.4), and 
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homogenized by 7 passages through a 27-gauge needle. Homogenates were centrifuged at 
500xg for 10 minutes. The postnuclear supernatant was centrifuged at 18,000xg for 25 
minutes. An aliquot of the supernatant (cytosolic fraction) was taken for analysis. The 
pellet was resuspended in 20% sucrose in isolation buffer and centrifuged at 18,000xg for 
30 minutes. The pellet was resuspended in 60% sucrose (in 10 mM Tris with 0.05 mM 
EDTA) for further processing. The suspension was overlaid with a 53% sucrose layer (in 
10 mM Tris with 0.05 mM EDTA) and a 44% sucrose layer (in 10 mM Tris with 0.05 
mM EDTA). The sucrose step gradient was centrifuged at 141,000xg for 2 hours. The 
purified mitochondria settled at the 44-53% sucrose interface. The mitochondrial layer 
was removed, diluted in isolation buffer, and centrifuged at 18,000xg for 30 minutes. The 
mitochondrial pellet was suspended in 200 µl of 100 mM sodium carbonate pH 11, 
vortexed and centrifuged at 288,000xg for 10 minutes. The solubilized proteins were 
prepared for 2D analysis. 
 
2D Gel Analysis: Samples were acetone-precipitated and solubilized in 40 mM Tris, 7 M 
urea, 2 M thiourea, and 2% CHAPS, reduced with tributylphosphine, and alkylated with 
10 mM acrylamide for 90 minutes at room temperature. After a second round of acetone 
precipitation, the pellet was solubilized in 7 M urea, 2 M thiourea, and 2% CHAPS 
(resuspension buffer), and the buffer was run through a 10 kDa cutoff Amicon Ultra 
device with at least 2 volumes of the resuspension buffer to reduce the conductivity of the 
sample. Seventy-five micrograms of protein were subjected to isoelectric focusing (IEF) 
on 11 cm pH 4 to 7 immobilized pH gradient strips (Proteome Systems, Sydney, NSW, 
  
163 
Australia). After IEF, immobilized pH gradient strips were equilibrated in 6 M urea, 2% 
sodium dodecyl sulfate (SDS), 50 mM Tris-acetate buffer, pH 7.0, and 0.01% 
bromphenol blue and subjected to SDS-PAGE on 6 to 15% Gel Chips (Proteome 
Systems). Gels were electroblotted onto nitrocellulose, or fixed and stained in SYPRO 
Ruby (Invitrogen). Blots were exposed to phosphorimager screens followed by SYPRO 
Ruby staining. Spot detection, matching, background subtraction, and normalization 
analysis of all images was performed using Progenesis Discovery software (Nonlinear 
Dynamics Inc., Newcastle upon Tyne, UK).  
 
Mass Spectrometry: Spots excised from polyacrylamide gels were digested in-gel with 
trypsin. Analysis was performed on a Kratos Axima QIT (Shimadzu Instruments) matrix-
assisted-laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometer. 
Peptides were analyzed in positive ion mode in mid-mass range (700-3000 Da). The 
instrument was externally calibrated with Angiotensin II (MH+ of 1046.54), P14R (MH+ 
of 1533.86) and ACTH clip 18-39 (MH+ of 2465.20). Precursors were selected based on 
signal intensity at a mass resolution width of 250 for CID fragmentation (MS/MS) using 
Argon as the collision gas. All spectra were peak processed with Mascot Distiller (Matrix 
Sciences, Ltd.) prior to database searching. Database searches were performed in house 
with the Mascot search engine (Matrix Sciences, Ltd.). For MS searches the Peptide Mass 
Fingerprint program was used with a peptide mass tolerance of 50 ppm. For MS/MS 
searches (CID spectra) the MS/MS Ion Search program was used with a Precursor 
tolerance of 50 ppm and a fragment tolerance of 0.5 Da. 
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Immunoblot Analysis: The membranes were blocked with 5% nonfat-milk in Tris-
buffered saline (TBS) with 0.1% Tween and incubated with primary antibodies 
overnight. They were then incubated with anti-chicken IgY or anti-rabbit IgG horseradish 
peroxidase conjugated antibodies (Sigma) and detected using enhanced 
chemiluminescence (Perkin Elmer Life Sciences, Inc.).  
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APPENDIX II 
 
ENHANCED OXIDATIVE METABOLISM AND RESISTANCE TO 
OBESITY IN RESPONSE TO ADENYLATE KINASE 1 DEPLETION  
 
The following data includes unpublished results and Affymetrix gene chip data taken 
from: 
 
Nilsson EC, Long YC, Martinsson S, Glund S, Garcia-Roves P, Svensson LT, Andersson 
L, Zierath JR & Mahlapuu M (2006) Opposite transcriptional regulation in skeletal 
muscle of AMP-activated protein kinase gamma3 R225Q transgenic versus knock-out 
mice. J Biol Chem 281, 7244–7252. 
 
 
Femke Streijger fed the animals and aided in the dissections. I performed microarray 
analysis experiments on wild type and AK1-/- muscle. The core facility performed the 
genechip hybridization and Juerg Straubhaar performed the statistical analysis on the 
resulting data. I performed the remaining experiments contained within this appendix.  
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Summary 
 
 
 Energy expenditure in live organisms is determined by the amount of work 
performed and by the efficiencies with which ATP is produced and used for such work. 
Imbalances in nutrient availability and energy expenditure lead to obesity and associated 
co-morbidities. Thus, understanding the molecular mechanisms that control energy 
expenditure is important. The enzyme adenylate kinase 1 (AK1) has been found to 
influence the efficiency of ATP utilization during muscle contraction. In Chapter 3, we 
found that deletion of AK1 in primary myotubes results in enhanced glucose transport 
and oxygen consumption, suggesting that increased oxidative metabolism is elicited as a 
compensatory response to inefficient ATP utilization resulting from AK1 depletion. Here 
we find this effect is relevant in vivo, as AK1-/- mice are resistant to fat accumulation 
induced by a high fat diet. Moreover, expression of genes of oxidative metabolism and 
ATP synthesis is increased in muscles from AK1-/- mice, and genes involved in ribosome 
synthesis are decreased. Similarities with other perturbations that enhance oxidative 
metabolism, such as a mutation in the muscle-specific γ3 subunit of AMP-activated 
protein kinase, are seen throughout the expressed genome of AK1-/- mouse muscle. These 
results indicate that AK1 can play an important role in controlling muscle and whole 
body energy homeostasis, and point to the AK family of enzymes as novel potential sites 
of both dysfunction and therapeutic intervention in metabolic disease.  
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Background 
 
 
 Obesity and its many associated co-morbidities are caused by an imbalance 
between food intake and energy expenditure (166-169). Addressing this problem requires 
an understanding of the mechanisms by which fuel consumption, energy production, and 
energy utilization are coordinated. In single cells energy production in the form of 
adenine nucleotides ATP and ADP is tightly coupled with energy utilization for motility 
or anabolic processes (242). Even in cells that have acute high-energy requirements, such 
as skeletal and cardiac myocytes and neurons, ATP synthesis is highly coordinated with 
ATP utilization, such that the steady state levels of ATP remain constant over a wide 
range of workloads. In these cells, carbohydrate or lipid fuels are channeled to 
mitochondria for oxidative phosphorylation, where ATP is primarily synthesized, and this 
process is enhanced dramatically in response to increased ATP utilization.  
 Among the important molecular mechanisms by which energy flux is regulated in 
single cells are enzymatic activities that utilize, are regulated by, or alter the levels of 
adenine nucleotides. For example, an increase in the AMP/ATP ratio ensuing from 
enhanced ATP utilization is sensed by AMP-activated protein kinase (AMPK), which 
then triggers an increase in fuel consumption that facilitates the restoration of ATP levels 
(171-175). In addition, AMPK activation results in decreased energy expenditure by 
minimizing the activity of anabolic pathways.  
 An enzyme that influences adenine nucleotide levels is adenylate kinase (AK), 
which catalyzes the reversible phosphoryl transfer reaction AMP + ATP ⇔ 2ADP. AK is 
present in organisms from bacteria to humans, and its single isoform in lower eukayotes 
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is essential for survival. The human genome encodes for 9 genes bearing similarity to AK 
that differ in cellular and subcellular distribution. AK1 is responsible for over 95% of AK 
activity in skeletal muscle (243). AK has been thought to provide the principal 
homeostatic mechanism to maintain proper levels of adenine nucleotide under various 
metabolic states. It has also been proposed that via phosphotransfer networks, AK 
channels ATP from sites of ATP production to sites of utilization (111). 
 Given the importance of AK activity, and the fact that AK1 is by far the 
predominant AK activity in muscle, it was rather surprising that mice lacking AK1 are 
seemingly normal (114,115,117). They are able to maintain normal levels of ATP and 
show similar muscular capability as wild type mice. They do display enhanced ATP 
synthesis during muscle contraction, indicating more ATP was generated to maintain 
normal contractility (114,115). These results suggest that compensatory mechanisms are 
elicited in these mice to adapt to the lack of this enzyme. These results are consistent with 
a proposed role of adenylate kinase to of improve the efficiency of ATP utilization in 
cells through the operation of phosphotransfer networks (111), or other yet unknown 
mechanisms. 
 To better define the compensatory mechanisms by which AK1 deficiency leads to 
increased ATP production, and whether the effects of AK1 depletion in muscle are 
sufficient to impact whole body metabolism, we have analyzed the phenotype of AK1-/- 
mice on a high fat diet. Here, we find that AK1-/- mice are protected from fat 
accumulation. This protection is likely to be due to enhanced oxidative metabolism in 
vivo, as genes in the pathways of oxidative metabolism are increased in muscles from 
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these mice. Interestingly, changes throughout the expressed genome of muscles from 
AK1-/- mice are highly concordant with those induced by a dominant mutation in the γ3 
subunit of AMP kinase (Prkag3R225Q mice), a condition in which fuel utilization and work 
performance are maximized (244,245), and discordant with mice lacking the γ3 gene. 
Thus, alterations in AK1 have a highly significant rapid effect on energy metabolism, and 
the compensatory changes elicited by changes in AK1 levels resemble those produced by 
changes in AMPK, a central regulator of energy balance (171-175). This work points to 
the adenylate kinases as novel potential sites of dysfunction and/or intervention in obesity 
and other metabolic diseases. 
 
Results 
 
 We have shown that AK1 depletion rapidly enhances basal glucose uptake and 
oxygen consumption in differentiated primary myotubes, suggesting that AK1 depletion 
enhances oxidative metabolism to increase ATP production (Figure 3.11). To determine 
whether the metabolic changes elicited by AK1 depletion at the cellular level would 
translate into changes in whole body fuel metabolism, AK1-/- mice were fed either normal 
diet or high fat diet for 18 weeks. The average body weight of AK1-/- mice on a normal 
diet was higher than that of wild type controls (Figure II.1A, left panel), but the size of 
the epididymal fat pads were comparable (Figure II.1A, right panel). This tendency 
towards a more lean whole body mass was more apparent upon high fat feeding, where 
the total body weight of AK1-/- mice and their wild type littermates were not significantly 
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different (Figure II.1B, left panel), but the degree of adiposity in the AK1-/- mice was 
significantly lower than that of the wild type littermates (Figure II.1B, right panel).  
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Figure II.1: Response of the AK1-/- mice to high fat feeding. 
A. Whole body weight (left) and isolated epididymal adipose tissue weight (right) in 
grams (n=9) of AK1-/- mice and wild type controls (WT) fed normal diet (ND). B. Whole 
body weight (left) and isolated epididymal adipose tissue weight (right) in grams (n=9) of 
WT and AK1-/- fed a high fat diet for 18 weeks (HFD).  
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 Consistent with the observed differences in adiposity, the serum leptin levels of 
the wild type mice increased about 6-fold while those of the AK1-/- mice only increased 
around 3-fold in response to the high fat diet (Figure II.2A). The attenuation of fat depot 
expansion appears to be due to decreased lipid accumulation per cell, as the average lipid 
droplet size of isolated adipocytes from wild type mice was significantly larger than that 
from AK1-/- mice when animals were exposed to a high fat diet (Figure II.2B and C). 
While further phenotyping needs to be performed to determine the basis for the 
differences in lean body mass between the AK1-/- and wild type animals, our results are 
consistent with a protection from lipid accumulation in response to changes in muscle 
oxidative metabolism elicited by AK1 depletion. 
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Figure II.2: Response of the AK1-/- mouse adipose to high fat feeding. 
A. Leptin values in serum from WT and AK1-/- animals fed ND or HFD for 18 weeks 
(n=9). B. Isolated adipocytes from WT and AK1-/- stained with anti-perilipin antibody. C. 
Cell diameter in millimeters (n=14). * indicates p<0.05 between WT and AK1-/- by paired 
2-tailed Student t-test. # indicates p<0.05 between WT ND and WT HFD by paired 2-
tailed Student t-test. + indicates p<0.050 between AK1-/- ND and AK1-/- HFD by paired 
2-tailed Student t-test. 
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 To further test the hypothesis that AK1 depletion leads to enhanced muscle 
oxidative metabolism in vivo, we analyzed the global changes in gene expression that 
accompany AK1 deletion, and compared them with alterations induced by changes in 
AMP-sensitive protein kinase (AMPK), which is a central regulator of energy 
metabolism (107,171,172,246-248).  
 Of the 45037 probes present in the MOE430-2 Affymetrix GeneChip, 865 were 
significantly (p<0.05) upregulated by more than 10% in muscles from AK1-/- mice 
compared to controls (range 1.1 – 7.8 fold). Of these, 245 probes had annotations in 
KEGG (Kyoto Encyclopedia of Genes and Genomes) (249), and were significantly 
annotated to 36 pathways, shown in Table II.1. The most significantly represented 
metabolic pathways were that of oxidative phosphorylation, ATP synthesis, and 
glycolysis/gluconeogenesis. These changes are consistent with an increase in steady-state 
fuel utilization in response to AK1 deficiency, and with the previously reported increase 
in glycolytic flux in muscles from AK1-/- mice (114,115). Significant downregulation of 
1619 probes also occurred in the AK1-/- muscle. Of these, 276 probes were annotated to 
44 KEGG pathways, the most salient being the ribosomal pathway (Table II.1). 
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TABLE 1 
INCREASED in AK1-/- DECREASED in AK1-/- 
KEGG Pathway P value KEGG Pathway P value 
Oxidative phosphorylation 6.28E-16 Ribosome < 2.22e-16 
ECM-receptor interaction 6.17E-11 MAPK signaling pathway 3.62E-14 
Focal adhesion 2.62E-10 Wnt signaling pathway 3.77E-14 
ATP synthesis 6.25E-07 Cell cycle 1.43E-11 
Glycolysis / 
Gluconeogenesis 
1.82E-06 Phosphatidylinositol 
signaling system 
1.81E-10 
MAPK signaling pathway 3.65E-05 Huntington's disease 2.19E-10 
Carbon fixation 0.00013477 Calcium signaling pathway 1.69E-08 
Pentose phosphate pathway 0.00020791 Insulin signaling pathway 1.70E-08 
Starch and sucrose 
metabolism 
0.00021868 Basal transcription factors 6.67E-08 
Valine, leucine and 
isoleucine degradation 
0.00046573 Inositol phosphate 
metabolism 
6.80E-08 
Fatty acid metabolism 0.00049936 TGF-beta signaling pathway 3.25E-07 
gamma-
Hexachlorocyclohexane 
degradation 
0.00062564 Benzoate degradation via 
CoA ligation 
4.30E-06 
TGF-beta signaling pathway 0.00080461 Neurodegenerative Disorders 8.41E-06 
Cell adhesion molecules 
(CAMs) 
0.00103084 Adipocytokine signaling 
pathway 
1.17E-05 
Adherens junction 0.00173257 Adherens junction 3.56E-05 
Glutathione metabolism 0.00195161 Notch signaling pathway 8.59E-05 
Butanoate metabolism 0.00410956 DNA polymerase 9.52E-05 
Nitrogen metabolism 0.00566353 Nicotinate and nicotinamide 
metabolism 
0.00033866 
Tight junction 0.006045 Alzheimer's disease 0.00044752 
Nucleotide sugars 
metabolism 
0.00639769 Toll-like receptor signaling 
pathway 
0.00053714 
Pentose and glucuronate 
interconversions 
0.00718602 Glutathione metabolism 0.00113208 
Gap junction 0.00775716 Valine, leucine and isoleucine 
degradation 
0.00141952 
Cyanoamino acid 
metabolism 
0.0105907 Jak-STAT signaling pathway 0.00156384 
Hematopoietic cell lineage 0.01137075 Tryptophan metabolism 0.00169053 
Adipocytokine signaling 
pathway 
0.01256125 Aminoacyl-tRNA synthetases 0.00237739 
Ubiquinone biosynthesis 0.01778983 Glycine, serine and threonine 
metabolism 
0.00346765 
Riboflavin metabolism 0.01963987 Gap junction 0.00347963 
Glycine, serine and 
threonine metabolism 
0.02820949 B cell receptor signaling 
pathway 
0.0053048 
Valine, leucine and 
isoleucine biosynthesis 
0.02975211 Glycerophospholipid 
metabolism 
0.00554265 
Glycerophospholipid 
metabolism 
0.03433134 Purine metabolism 0.00704883 
Regulation of actin 0.0383473 Protein export 0.00857957 
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cytoskeleton 
Purine metabolism 0.03934515 Butanoate metabolism 0.01112014 
Lysine degradation 0.03975178 Focal adhesion 0.01369923 
Cytokine-cytokine receptor 
interaction 
0.04076289 Parkinson's disease 0.0141911 
Toll-like receptor signaling 
pathway 
0.04263423 Regulation of actin 
cytoskeleton 
0.01481001 
Pyruvate metabolism 0.0474699 Urea cycle and metabolism of 
amino groups 
0.01528664 
  Apoptosis 0.01710462 
  Porphyrin and chlorophyll 
metabolism 
0.01761754 
  Alkaloid biosynthesis II 0.01761754 
  Circadian rhythm 0.02146565 
  Valine, leucine and isoleucine 
biosynthesis 
0.02370443 
  Androgen and estrogen 
metabolism 
0.02725566 
  T cell receptor signaling 
pathway 
0.03377148 
 
 
  
 
Table II.1: Pathways analysis in response to AK1 knockout. 
 
Affymetrix GeneChip databases were obtained as described in Materials and Methods. 
Analysis was performed using annotations in KEGG to determine significantly enriched 
pathways. Pathways listed are significantly populated by genes that increase or decrease 
in response to AK1 knockout. 
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 Transgenic expression of a mutation in the muscle-specific, gamma regulatory 
subunit of AMPK (TgPrkag3225Q) (244,245,250-252) elicits increased fat oxidation in 
muscle. Analysis of published Affymetrix databases of muscle from TgPrkag3225Q mice 
(253) revealed 299 probes that were significantly (p< 0.05) upregulated by more than 
10% compared to non-transgenic controls (range: 1.1 - 2.36 fold). Of these, 97 probes 
had annotations in KEGG, to 19 pathways, of which the most significantly represented 
were that of oxidative phosphorylation and starch metabolism (Table II.2), consistent 
with the reported alterations in glycogen deposition and fat oxidation in muscles from 
these mice (244,245). Significant downregulation of 348 probes also occurred in 
TgPrkag3225Q muscle. These were annotated to 11 KEGG pathways, which, like in the 
AK1-/- muscle included the ribosomal and diverse signal transduction pathways (Table 
II.2). 
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TABLE 2 
INCREASED in TgPrkag3225Q DECREASED in TgPrkag3225Q 
KEGG Pathway P value KEGG Pathway P value 
Oxidative phosphorylation 1.59E-07 Ribosome < 2.22e-16 
Starch and sucrose metabolism 1.08E-06 DNA polymerase 6.25E-05 
Nucleotide sugars metabolism 3.83E-06 TGF-beta signaling pathway 0.00011669 
Pentose and glucuronate 
interconversions 
4.75E-06 Glutathione metabolism 0.0010422 
Galactose metabolism 3.27E-05 Notch signaling pathway 0.00885056 
Novobiocin biosynthesis 3.65E-05 MAPK signaling pathway 0.00994324 
Carbon fixation 0.00015475 Arginine and proline metabolism 0.01484344 
Alkaloid biosynthesis I 0.00016692 Wnt signaling pathway 0.01855903 
ATP synthesis 0.00019103 Prion disease 0.02278944 
Synthesis and degradation of ketone 
bodies 
0.00036008 Urea cycle and metabolism of 
amino groups 
0.03587762 
Arginine and proline metabolism 0.00049755 Selenoamino acid metabolism 0.04327788 
Phenylalanine metabolism 0.00136156   
Phenylalanine, tyrosine and tryptophan 
biosynthesis 
0.00163826   
Cysteine metabolism 0.0020962   
Fructose and mannose metabolism 0.00531628   
Alanine and aspartate metabolism 0.00805732   
Tyrosine metabolism 0.01017063   
Glutamate metabolism 0.01484851   
Glutathione metabolism 0.02009483   
 
 
Table II.2: Pathways analysis in response to transgenic expression of Prkag3225Q. 
 
Affymetrix GeneChip databases were obtained as described in Materials and Methods. 
Analysis was performed using annotations in KEGG to determine significantly enriched 
pathways. Pathways listed are significantly populated by genes that increase or decrease 
in response to transgenic expression of Prkag3225Q. 
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 When the changes induced by TgPrkag3225Q were compared to those induced by 
AK1 knockout, a highly significant correlation (Pearson correlation 0.36; P=2.963E-14) 
was observed throughout the 1963 probes that were significantly altered (increased or 
decreased) by either perturbation (Figure II.3A). A significant correlation was maintained 
(Pearson correlation 0.79; P= 0.005) even when only those 225 probes that were altered 
by both perturbations were compared (Figure II.3B). Of the 91 probes that were increased 
by both TgPrkag3225Q and AK1-/-, 42 were annotated to 8 KEGG pathways, the most 
significant of which were oxidative phosphorylation and ATP synthesis (Table II.3). 116 
probes were decreased in both TgPrkag3225Q and AK1-/-, of which 39 were annotated to 2 
KEGG pathways, the ribosomal and notch signaling pathways (Table II.3). Probes 
reciprocally regulated in TgPrkag3225Q and AK1-/- were not annotated to any significant 
KEGG pathway. Thus, the overall genetic signature produced by TgPrkag3225Q is highly 
similar to that produced by the lack of AK1, and includes increased expression of genes 
of oxidative metabolism, and decreased expression of ribosome synthesis genes. 
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Figure II.3: Gene expression induced by AK1-/- or increased AMPK activation. 
Gene expression analysis from mice with the AK1 deletion (AK1-/-), transgenic 
expression of Prkag3225Q (TgPrkag3225Q ). Affymetrix GeneChip databases were obtained 
as described in Materials and Methods. A: Correlation between the 1963 genes that were 
significantly altered either in AK1-/- or in TgPrkag3225Q. B: Correlation between the 255 
genes significantly altered in both AK1-/- and TgPrkag3225Q. The correlation values and 
statistical significance are described in the text. 
 
  
181 
TABLE 3 
INCREASED in TgPrkag3225Q AND AK1-/- DECREASED in TgPrkag3225Q AND AK1-/- 
KEGG Pathway P value KEGG Pathway P value 
Oxidative phosphorylation 6.63E-07 Ribosome 2.47E-16 
ATP synthesis 0.00024334 Notch signaling pathway 0.001192 
Nucleotide sugars metabolism 0.00058089   
Pentose and glucuronate 
interconversions 
0.00065688   
Starch and sucrose metabolism 0.0019398   
Galactose metabolism 0.00823947   
Pyruvate metabolism 0.02107063   
Carbon fixation 0.04715053   
 
 
Table II.3: Co-regulation by AK1 knockout and AMPK activation. 
 
Affymetrix GeneChip databases were obtained as described in Materials and Methods. 
Analysis was performed using annotations in KEGG to determine significantly enriched 
pathways. Pathways listed are significantly populated by genes similarly regulated by 
both AK1 knockout and transgenic expression of Prkag3225Q. 
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 To further define the specificity of the changes induced by TgPrkag3225Q and 
AK1-/-, we also compared them with gene expression changes induced by the absence of 
the AMPK gamma 3 subunit (Prkag3-/-), conditions in which oxidative metabolism would 
be expected to be impaired. Consistent with this notion, these mice displayed significant 
downregulation of 407 probes of which 109 were annotated to 21 KEGG pathways, the 
most significant of which were oxidative phosphorylation and the citric acid cycle (Table 
II.4). Significant upregulation of 579 probes was also seen, of which 158 were annotated 
to 14 pathways, which did not include major ATP-generating metabolic pathways (Table 
II.4).  
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TABLE 4  
INCREASED IN AMPKg3 -/ -   DECREASED IN  AMPKg3 -/ -   
KEGG Pathway  P val u e  KEGG Pathway  P val u e  
Ribosome  < 2.22e-16 Oxidative phosphorylati o n  3.76E-07 
MAPK signaling pathway  0.0018499 Citrate cycle (TCA cycle )  6.90E-05 
Neurodegenerative Disorders 0.0053206 Nucleotide sugars metaboli s m  0.00012584 
Insulin signaling pathwa y  0.0079063 Pentose and glucuronate 
interconversions 
0.00014855 
Parkinson's diseas e  0.0082755 Galactose metabolis m  0.00050073 
Aminosugars metabolis m  0.0083659 Arginine and proline metabolism  0.00067533 
Valine, leucine and isoleucine 
degradati o n  
0.0184083 Starch and sucrose metaboli s m  0.00156465 
Phenylalanine, tyrosine and 
tryptophan biosynthesi s  
0.0290124 ATP synthesi s  0.00206983 
Glycerophospholipid metabolism  0.0311116 Carbon fixati o n  0.00219274 
Ethylbenzene degradat ion  0.0364429 Novobiocin biosynthesi s  0.00246121 
N-Glycan degradati o n  0.0417588 Cyanoamino acid metabolism  0.00516133 
Benzoate degradation via CoA 
ligati o n  
0.0436785 Alkaloid biosynthesis I 0.00626312 
Prion diseas e  0.0445194 Phenylalanine metabolism  0.01500918 
Protein export 0.047346 Glyoxylate and dicarboxylate 
metaboli s m  
0.02431501 
  Phenylalanine, tyrosine and 
tryptophan biosynthesi s  
0.02644191 
  Tryptophan metaboli s m  0.02981624 
  Cysteine metabolism  0.03091156 
  Methane metabolism  0.03565699 
  Glycolysis / Gluconeogenesi s  0.03739465 
  Glycine, serine and threonine 
metaboli s m  
0.04539238 
  Cytokine-cytokine receptor 
interact ion  
0.04574703 
  One carbon pool by folate  0.04591963 
 
 
 
Table II.4: Pathways analysis in response to Prkag3 knockout. 
 
Affymetrix GeneChip databases were obtained as described in Materials and Methods. 
Analysis was performed using annotations in KEGG to determine significantly enriched 
pathways. Pathways listed are significantly populated by genes that increase or decrease 
in response to Prkag3 knockout (Prkag3-/-). 
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 When the changes induced in Prkag3-/- mice were compared to those induced in 
the TgPrkag3225Q, a significant negative correlation (Pearson correlation -0.509; 
P=3.090E-09) was seen throughout the 2025 probes that were altered by either 
perturbation (Figure II.4A). Of the 356 probes that were both upregulated in 
TgPrkag3225Q and downregulated in Prkag3-/-, 110 were annotated to 24 KEGG pathways, 
the most significant of which was oxidative phosphorylation (Table II.5). A similar 
reciprocal correlation was seen in the comparison between Prkag3-/- and AK1-/- mice 
(Pearson correlation -0.398; P=3.553E-62) throughout 2049 probes (Figure II.4B). Of the 
470 probes upregulated in the AK1-/- muscle and downregulated in the Prkag3-/- muscle, 
163 were annotated to 25 KEGG pathways, of which the most significant was also 
oxidative phosphorylation (Table II.5). Together these results support the hypothesis that 
AK1 deficiency induces an increase in muscle fuel oxidation to compensate for 
inefficient ATP utilization. 
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Figure II.4: Gene expression induced by AK1 deletion or altered AMPK activation. 
Gene expression analysis from mice with the AK1 deletion (AK1-/-), transgenic 
expression of Prkag3225Q (TgPrkag3225Q ) and Prkag3 deletion (Prkag3-/-). Affymetrix 
GeneChip databases were obtained as described in Materials and Methods. A. Correlation 
between the 2025 genes significantly altered either in TgPrkag3225Q or Prkag3-/-. B. 
Correlation between the 2049 genes significantly altered either in AK1-/- or Prkag3-/-. The 
correlation values and statistical significance are described in the text. 
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TABLE 5  
INCREASED in TgPrkag3225Q AND DECREASED in 
AMPKg3 -/ -  
INCREASED in AK1 -/- AND DECREASED in 
AMPKg3 -/ -  
KEGG Pathway  P val u e  KEGG Pathway  P val u e  
Oxidative phosphorylati o n  1.55E-08 Oxidative phosphorylati o n  1.51E-15 
Starch and sucrose metaboli s m  2.66E-06 ECM-receptor interacti o n  2.66E-08 
Nucleotide sugars metaboli s m  6.82E-06 ATP synthesi s  1.63E-05 
Pentose and glucuronate 
interconversions 
8.44E-06 Carbon fixati o n  6.09E-05 
ATP synthesi s  4.26E-05 Starch and sucrose metaboli s m  8.93E-05 
Novobiocin biosynthesi s  5.17E-05 Glycolysis / Gluconeogenesi s  0.0001746 
Galactose metabolis m  6.34E-05 Adipocytokine signaling 
pathway 
0.00030173 
Alkaloid biosynthesis I 0.00023585 Nucleotide sugars metaboli s m  0.00030445 
Arginine and proline metabolism  0.00084883 Pentose and glucuronate 
interconversions 
0.00035859 
Phenylalanine metabolism  0.00209409 Fatty acid metaboli s m  0.00135669 
Phenylalanine, tyrosine and tryptophan 
biosynthesi s  
0.00228838 Novobiocin biosynthesi s  0.00385855 
Carbon fixati o n  0.0026333 Focal adhesion  0.00480606 
Cysteine metabolism  0.0029225 Cysteine metabolism  0.00483472 
Cyanoamino acid metabolism  0.00569057 Pyruvate metabolism  0.00646492 
Fructose and mannose metaboli s m  0.00865596 Glutathione metaboli s m  0.00749087 
Alanine and aspartate metabolism  0.01107617 Galactose metabolis m  0.00953447 
Synthesis and degradation of ketone 
bodies 
0.01116507 Alkaloid biosynthesis I 0.00974511 
Tyrosine metabolis m  0.01510871 Citrate cycle (TCA cycle )  0.01191082 
Pyruvate metabolism  0.01703923 Arginine and proline metabolism  0.01191082 
Glutamate metaboli s m  0.02022357 Hematopoietic cell lineage  0.01964042 
Glutathione metaboli s m  0.02721871 Phenylalanine metabolism  0.02735982 
Hematopoietic cell lineage  0.03266883 Valine, leucine and isoleucine 
degradati o n  
0.03279888 
Methane metabolism  0.03906596 Phenylalanine, tyrosine and 
tryptophan biosynthesi s  
0.04023578 
Glycolysis / Gluconeogenesi s  0.04367849 Nitrogen metabolism  0.04023578 
  Purine metabolism  0.04468538 
  
Table II.5: Reciprocal regulation upon AK1 deletion and altered AMPK activation. 
 
Affymetrix GeneChip databases were obtained as described in Materials and Methods. 
Analysis was performed using annotations in KEGG to determine significantly enriched 
pathways. Pathways listed are significantly populated by genes reciprocally regulated by 
Prkag3 knockout, and either AK1 knockout or transgenic expression of Prkag3225Q. 
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Conclusions 
 
 
 The adenylate kinase reaction, ATP + AMP⇔2ADP is a component of cellular 
phosphotransfer networks (111,254,255), and its absence has been shown to result in a 
decreased efficiency of ATP utilization in muscle (114,115). The results shown in this 
thesis reveal the importance of adenylate kinase in controlling the rate of oxidative 
metabolism in muscle, evidenced by the increase in glucose and oxygen consumption 
seen in isolated muscle cells depleted of AK1 (Figure 3.11), by the expression of genes 
involved in fuel oxidation in muscles from AK1-/- mice (Table II.1), and by the protection 
from fat accumulation seen in these mice (Figure II.1). This increase in metabolic 
pathways of fuel utilization and oxidative phosphorylation is likely to be required to 
compensate for the inefficiency of ATP utilization caused by the absence of AK1. This 
compensatory mechanism can explain the enhanced ability of AK1-/- muscles to sustain 
high ATP levels upon isometric contraction (117,256).  
 The mechanism by which AK1 depletion leads to the observed compensatory 
increase in fuel oxidation is not known. The only known role of AK is the reversible 
phosphoryl transfer reaction between ATP, AMP and ADP. If this is indeed the sole 
function of AK, alterations in cell function in response to changes in AK levels or activity 
are likely to result from chronic changes in adenine nucleotide ratios. These may in turn 
directly affect mitochondrial functions, for example by modulating the effects of calcium 
on mitochondrial membrane potential (257), or indirectly through the activities of 
enzymes sensitive to adenine nucleotide ratios. The only observed alteration in adenine 
nucleotide levels found in the AK1-/- muscle is a significant increase in total AMP, but 
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further work is required to define the source and metabolic significance of this elevation 
(117,256).  
 It is interesting that, in addition to a significant increase in genes of the oxidative 
phosphorylation pathway, muscles from AK1-/- mice also display decreases in more than 
20 genes encoding for ribosomal proteins, in RNA polymerase 1 and in RNA polymerase 
2 binding proteins. Ribosomal protein biosynthesis is suppressed under different cellular 
stress conditions, (258) possibly as an energy economizing response. These results 
suggest that adaptation to AK1 deficiency involves both enhanced ATP production from 
fuel oxidation, and suppressed ATP utilization. Ribosomal RNA synthesis in response to 
nutrient and energy conditions is controlled by the mammalian target of rapamycin 
(mTOR), suggesting that the changes in nucleotide levels elicited by AK1 deficiency are 
sensed by this kinase. Many signaling mechanisms could result in decreased mTOR 
activity and ribosome biogenesis, including changes in reactive oxygen species, thymoma 
viral proto-oncogene/protein kinase B (Akt/PKB) signaling, and AMPK signaling 
(259,260), and further work will be required to identify which of those mechanisms is 
sensitive to AK1 depletion.  
 The possibility that AMPK signaling might be involved in mediating some of the 
effects of AK1 deletion is suggested by the evidence for both enhancement of fuel 
oxidation and suppression of energy consumption in AK1-/- mice muscle, a response 
known to be coordinated by AMPK signaling. In addition, compensatory increases in 
mitochondrial density seen in mice lacking AK1 (114) are also consistent with activation 
of AMPK (261,262). The concordance between the gene expression patterns seen in 
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muscles from AK1-/- mice and TgPrkag3225Q mice, as well as the discordance with 
Prkag3-/- mice are also consistent with this possibility. However, in previous reports, 
muscles from AK1-/- mice subjected to moderate isometric contraction contained less 
phospho-AMPK compared to controls (256). If this indeed reflects a chronic impairment 
in AMPK activation in muscles from AK1-/- mice, it will be very important to determine 
the nature of an AK1-regulated, non-AMPK dependent mechanisms that enhances energy 
production and conserves energy use. 
 The hypothesis that AK1 enhances the efficiency of ATP utilization, thereby 
decreasing the need for fuel oxidation raises the interesting possibility that differences in 
the level or activity of AK1 may contribute to determining individual basal metabolic 
rates and susceptibility to weight gain (263). Indeed, increased levels of AK1 have been 
reported in skeletal muscle from morbidly obese patients (118), although whether this 
correlation is causal cannot be established from these studies. Nevertheless the results 
shown here suggest that inhibition of AK1 could enhance fuel utilization and ameliorate 
obesity in these patients.  
 Our experiments in isolated muscle cells indicate that increased oxidative 
metabolism is an autonomous cellular response to AK1 deficiency, and support the 
concept that enhanced muscle metabolism is the basis for the resistance of AK1-/- mice to 
fat accumulation. However, because AK1 is also present in brain (264) and pancreatic 
beta cells, albeit at much lower levels that in skeletal muscle, we cannot rule out the 
possibility that an effect of AK1 knockout in these other tissues might also contribute to 
the phenotype of the AK1 null mouse. Further experiments involving more in-depth 
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metabolic phenotyping of a fully backcrossed AK1-/- mouse, as well as tissue-specific 
knockdown of AK1 will be necessary to determine the contribution of each tissue to the 
AK1-/- phenotype. 
 In summary, we demonstrate that alterations in energy efficiency due to AK1 
disruption can enhance muscle oxidative metabolism and affect whole body fuel 
metabolism. The effects of AK1 depletion are comparable to those seen upon 
perturbation of AMPK, a master regulator of energy balance, underscoring the 
importance of the AK reaction. Further research on the adenylate kinases is necessary to 
evaluate their role on important aspects of human energy balance.  
 
Experimental Procedures 
 
Animals: All procedures were carried out following either the guidelines from the 
University of Massachusetts Medical School Institution Animal Care and Use Committee 
(UMMA-IACUC) or the guidelines for the Care and Use of Laboratory Animals of the 
Dutch Council and were approved by the Institutional Animal Care and Use Committee 
at the University of Nijmegen. A cohort of gene-targeted mice carrying a HygroBR 
replacement mutation in the exon 3–5 region of the AK1 gene was generated and 
maintained as previously described (114). Male homozygous AK1-deficient and wild 
type littermates (both with 50–50% C57BL/6 x 129/Ola mixed inbred background) were 
used throughout experiments. Mice were housed 3 per cage, and half of the mice were 
fed a standard mouse chow (Sniff) and the rest were fed a high fat diet (Hope Farms) ad 
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libitum. This diet regimen was used for eighteen weeks. Gastrocnemius muscle was 
isolated and snap frozen in liquid nitrogen.  
 
Affymetrix GeneChip Expression Analysis: Analysis was performed as previously 
described (102,149). Briefly, total RNA was prepared from three sets each of 
gastrocnemius muscle from AK1-/- mice and AK1+/+ littermates. Affymetrix protocols 
were followed for the preparation of cRNA from total RNA, which was hybridized 
according to Affymetrix instructions to a MOE430-2 Chips. The GeneChips were washed 
with a GeneChip Fluidics Station 400 and were scanned with an HP GeneArrayScanner 
(Affymetrix). Raw expression data, as well as the CEL files published by Nilsson et al. 
(251) were analyzed with the Bioconductor statistical environment (164) using RMA 
(165) and MAS5, a Bioconductor implementation of the MAS 5.0 algorithm 
(Affymetrix). The “fold change” for each gene was determined by dividing the mean of 
the average difference from three independent experiments. Correlations between gene 
expression sets were evaluated using the Pearson product moment correlation coefficient.  
 
Serum Analysis: Leptin levels were determined using an ELISA kit following the 
protocol exactly (Linco Research Inc). 
 
Primary Adipose Cell Isolation: Epididymal fat pads were weighed, minced into 0.3 cm3 
pieces, and incubated for 30-45 minutes at 37°C in an orbital shaker shaking at 100 rpm 
in 1 mg/mL collagenase in Krebs-Ringer HEPES (KRH) buffer (130 mM NaCl, 5 mM 
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KCl, 1.3 mM CaCl2, 1.3 mM MgSO4, and 25 mM HEPES) supplemented with 2 mM 
pyruvate and 2.5% BSA, pH 7.4. The digested samples were squeezed through chiffon 
material, and the isolated cells were washed three times in KRH buffer containing 2.5% 
BSA prior to immunofluorescence analysis using anti-perilipin antibodies. 
 
 
 
 
 
 
 
 
 
 
 
